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ABSTRACT
The discovery of nitric oxide as a ubiquitous biochemical messenger makes
understanding of its signaling properties imperative.

The finding that nitric oxide is

enzymatically liberated from physiological S-nitrosothiols by protein disulfide isomerase
(PDI) proximal to cell membranes suggests 1) that *NO release is influenced by enzyme
redox status and 2) that *NO traverses biological membranes to elicit cellular signals.
This study was undertaken to determine 1) how vascular redox conditions
influence membrane-associated PDI activities and 2) whether membrane cholesterol
influences •NO-dependent signals. This study further benefited from application of a
therapeutic agent to mitigate redox changes in platelet functions mediated by PDI.
Objective 1 was achieved using cells derived from an animal model of the pre
diabetic state.

Upon induction of a pre-diabetic state, cellular ROS generation was

enhanced and redox-dependent changes in platelet functions mediated by PDI were
detected. Importantly, these changes 1) could be mimicked in platelets by treatment with
exogenous ROS and 2) could be remediated by administration of a hypocholesterolemic
agent.
Similarly, platelets derived human diabetic subjects exhibited altered metabolism.
The effects of varying redox conditions on psPDI-redox status, -activity and aggregation
were characterized. Our studies demonstrate the redox susceptibility of psPDI resulting
in inhibition of denitrosation and disulfide reductase activities.

Redox-dependent

increases in rates of aggregation, however, could not be attributed to psPDI active site
status based on the redox-independence of aggregation rates upon removal and controlled
replacement of psPDI.

iv
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Lastly, diffusion and reactivity of *NO generated or released proximal to the membrane
determines subsequent »NO-dependent signals.

The role of hydrophobic domains in

accelerated »NO autooxidation is recognized; however the role of cellular lipid
composition in fine-tuning *NO signals requires further attention. Model systems and
cells bearing a genetic defect that manifests as membrane sterol accumulation were used
to investigate the role of cholesterol in modulating 'NO-based signals. Studies show that
1) cholesterol alters the diffusion properties of *NO in model systems, 2) cellular sterol
accumulation diminished the response of guanylate cyclase to exogenous -NO and could
be mimicked by acute cholesterol loading and that 3) cellular metabolism of exogenous
•NO, measured by DAF nitrosation is also altered in a cholesterol-dependent manner.
Collectively, this study suggests that cholesterol influences the transmission of »NOdependent signals.

v
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PART I

CHAPTER 1

GENERAL INTRODUCTION
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1.1 Nitric Oxide
1.1.1

Introduction
In the 1980’s and early 1990’s, education of students on the properties and

chemistry of nitric oxide focused on its existence as a deleterious component of
automobile exhaust and air pollution. The evolution of a brown haze of nitrogen dioxide
as air was introduced into a syringe of pure nitric oxide was a memorable pedagogical
tool. However, it failed to convey the discovery of the seemingly ubiquitous nature and
broad bioactivity of this remarkable free radical.
Since the identification of »NO as the endothelium-derived relaxation factor
(ERDF) by Moncada [Plamer et al., 1987] and Ignarro [Ignarro, et al., 1987], there has
been a virtual explosion of interest in the properties and physiological interactions of
nitric oxide. In retrospect we can now appreciate the fact that nitric oxide plays a role in
nearly every major aspect of human physiology including immune responses [Marietta et
al., 1988], neurotransmission [Garthwaite et al., 1988], erectile dysfunction [Toda et al.,
2005], platelet aggregation [Bassenge et al., 1991], myocardial function [Champion et
al., 2003], respiration [Mason et a l, 2006], reproduction [Lapointe et al., 2006], cytoprotection [Wang et al., 2002a] and -toxicity [Pacher et al., 2007] , angiogenesis
[Roberts et al., 2007] and cellular proliferation [Contestabile et al., 2004]. Thus, this
section will discuss various facets of »NO chemistry, beginning with its biosynthesis,
followed by the physical and chemical properties which govern its ability to transmit
biological signals, insights from cellular reactivity experiments and close with a brief
overview of the paradigm of *NO signaling.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.1.2

Biosynthesis

Elucidation of the biosynthetic path of nitric oxide formation is reported to have resulted
from the convergence of three separate lines of investigation [Ignarro et a l, 2000]. Clues
to the agents responsible for formation of •NO came from 1) studies on the mechanism of
agonist-induced relaxation of isolated blood vessels [Furchgott et al., 1980, Griffith et al.,
1984, Furchgott et al., 1984], 2) studies of nervous transmission in the central nervous
system [Garthwaite et al., 1988, Garthwaite et al., 1987] and 3) the disposition of nitrate
from humans and animal models of infection and macrophage cytotoxicity [Marietta et
a l, 1988, Iyengar et al., 1987, Hibbs et al., 1987]. In concert, these studies confirmed
that *NO was endogenously produced in multiple tissues and cells in response to
physiological agents, synthesized enzymatically from L-arginine and excreted in oxidized
form as either nitrite (NO 2 ) or nitrate (NO 3 ). Several groups simultaneously noted the
NADPH-dependence of production of nitrogen oxides from L-arginine [Marietta et al.,
1988, Knowles et al., 1989], thus paving the way for affinity isolation of the neuronal
nitric oxide synthase (nNOS) from rat cerebellum

and demonstration of its Ca2+ /

calmodulin dependence [Bredt et a l, 1990]. Shown in Fig. 1.1.1 is the overall reaction
in which L-arginine undergoes a five-electron oxidation to L-citrulline with consumption
of two moles of oxygen and 1.5 moles of NAD(P)H and generating one mole of *NO.
Mechanistic studies have shown that 1 mole of NADPH is consumed in the conversion of
L-arginine to N 0)-hydroxy-L-arginine and 0.5 moles are consumed in the conversion of
N“-hydroxy-L-arginine to L-citrulline [Stuehr et al., 1991b],

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

h 2n

HN

/ ^ N K '2

HN

/ — N -O H
H
0.5 mol
NADPH

1 mol NADPH

o2

h 3n

O

h 3n

O
L-arginine

Figure 1.1.1

o2

o

+

o

h 3n

O

O
NG-hydroxy-L-arginine

■N = 0

L-citrulline

Generation of «NO from L-arginine

It has since been shown that nitric oxide synthase exists as neuronal (nNOS /
NOS1), endothelial (eNOS / NOS3) and inducible (iNOS / NOS2) isoforms related by
various prosthetic requirements (tetrahydrobiopterin, flavin mononucleotide, haem, flavin
adenine dinucleotide, Zn) and mechanism but distinguished by structure [Li et al., 2005],
localization [Dudzinski et al., 2007] and the factors which govern their activity [Govers
et a l, 2001, Papapetropoulos et al., 1999, Hattori et al., 1994].

Each of the three NOS

isoforms bear binding sites for NADPH, FAD, FMN and calmodulin (CaM) and require
homodimerization for activity [Kone, et al., 2000]. However, only nNOS and eNOS are
allosterically controlled by the Ca2+-dependent association of CaM, and as shown in
Figure 1.1.2 below, bear unique consensus sequences in the N-terminal domain (PDZ for
nNOS [Kone, et al., 2000] and acylation for eNOS [Kone, et al., 2000]) which are
thought to facilitate subcellular localization [Sessa et al., 1993, Garcia-Cardena et al.,
1996b, Brenman et al., 1997].

4
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PDZ domain (nNOS)
Fatty acylation site (eNOS)

N-terminal
sequence
H4B-binding site
Haem axial cysteine ligand
Arg-binding glutamate

Oxygenase
domain

]-CaM domain
FMN domain
Reductase
domain

^FAD domain

^NADPH domain
coo-

Figure 1.1.2 - Generalized NOS domain structure
Adapted from [Hemmens et a l, 1999]
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Both nNOS and eNOS are constitutively expressed [Moncada et al., 2006, Bredt
et al., 1999], whereas iNOS is inducibly expressed in response to various cytokines
produced by lymphocytes upon detection of a pathogen [Stuehr et al., 1991a, Lowenstein
et al., 1992].
eNOS and nNOS can be stimulated by increases in intracellular calcium [Fleming
et al., 1997] to produce submicromolar quantities of »NO and at this level are thought to
interact primarily with metal centres and other radicals evoking normal regulatory
mechanisms under physiological conditions. However, the widespread prevalence of in
vivo protein S-nitrosothiols under normal conditions [Bryan et al., 2004] suggests
mechanisms by which either low levels of »NO produced are activated or thiyl radicals
are formed to facilitate protein S-nitrosation/nitrosylation. This particular topic will be
discussed further at a later point in the thesis.
Alternately, iNOS isoforms, induced by an array of inflammatory cytokines (such
as IL-1, IL- 6 , TN F-a) are capable of generating localized jxM levels of *NO and are
considered to contribute largely to nitrosative and oxidative stress in pathophysiological
scenarios [Bredt et al., 1999].
Notably, studies also indicate that »NO can be formed from both nitrite (NCV)
[Lundberg et al., 2005, Huang et al., 2005, Grubina et al., 2007] and nitrate (NO 3')
[Lundberg et al., 2004] and thus require consideration in any comprehensive
understanding of the dynamics of nitrosation / nitrosylation.
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1.1.3

Reactivity, regulation and physiological targets
The study of nitric oxide as a signaling molecule presents many challenges to an

investigator due to the unique factors that regulate its bioactivity.

As a diffusible,

paramagnetic free radical with a half-life on the order of seconds [Viinikka et al., 1996],
features such as its spatial generation, diffusion characteristics, reactivity with other
species and stability of resultant *NO adducts play a critical role in its physiological and
pathophysiological activity. In a cellular milieu, the biological activity of *NO is highly
dependent upon variations in both the chemical and physical environments encountered
during its lifetime.

Thus, a thorough consideration of both the chemical reactions in

which it participates and its physical properties under an array of potential cellular
conditions are key to understanding how this short-lived free radical can convey
information in vivo.
Herein are described the major aspects of nitric oxide chemistry in a biological
milieu with particular emphasis on its regulation, role and physiological targets in the
vasculature.

1.1.4

Spatial and temporal regulation
As a short-lived free radical, both the cellular locale of nitric oxide production and

the temporal nature of its generation bear significant influence on the range of its
biological function and those species with which it is subsequently capable of interacting,
thus representing an additional level of regulation of «NO signaling.
Recent reports have indicated that the subcellular localization of various NOS
isoforms in cardiac tissue dictate the species with which »NO will interact and hence its

7
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overall effect on cardiac structure and function [Barouch et al., 2002]. Isoform-specific
NOS knockouts are reported to exhibit distinct phenotypes affecting Ca++ flux at either
the sarcoplasmic reticulum (nNOS) or the plasma membrane (eNOS), thus supporting the
notion that regulation of *NO-dependent signals is affected by the compartmentalization
of *NO-generating systems. Importantly, this study shows that the locale of *NO
synthesis contributes to fine tuning of its signals within distinct microdomains of the cell
acting as an autocrine rather than paracrine effector.

This, of course is ostensibly in

conflict with the notion that *NO at physiological levels diffuses widely (ie tens to
hundreds of jim) and that diffusion rates are sufficiently fast that, on average, »NO will
diffuse out of the cell faster than reacting within [Lancaster et al., 1996]. However, rapid
reactions that occur due to colocalization (or even coupling) of »NO generating systems
with that of species exhibiting high reactivity toward NO, may restrict its action to
subcellular compartments.
In extension, eNOS has been shown to interact with caveolin potently inhibiting
the production of nitric oxide [Feron et al., 1996] by binding to the same region as CaM.
Upon stimulation with either acetylcholine (Ach) or platelet activating factor (PAF),
eNOS was further shown to dissociate from caveolae to different cellular locales, thus
determining its distinct activities as either a vasodilatory- or permeability-enhancing
moiety [Sanchez et al., 2006].
In a recent publication, the Loscalzo group employed a modified version of the
biotin switch assay [Jaffrey et al., 2001] to visualize intracellular protein S-nitrosation
[Yang et al., 2005]. Their results indicate that protein S-nitrosation in endothelial cells
1) occurs under the conditions of endogenous •NO synthesis (stimulated by the addition

8

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

of calcium ionophore and L-arginine), 2) appears to be localized to mitochondria and
peri-mitochondrial space and 3) is diminished by the use of inhibitors of the electron
transport chain, superoxide scavengers (Mn(III)TMPyp), N 2O 3 scavengers (azide) and
superoxide/peroxynitrite scavengers (FeTmPyp).

This study thus implicates both

nitrosation and oxidative nitrosylation events in protein S-nitrosation [Yang et a l, 2005],
Although these studies collectively support the idea that the cellular locale of
•NO generation profoundly influences the subsequent signals it mediates, few studies
have addressed the role of lipid composition and hydrophobic compartments in
modulating cellular *NO signals. Alternately, proteomics studies aimed at identifying
motifs which facilitate protein S-nitrosation support the notion that hydrophobic domains
may contribute to post-translational modification of protein thiols with *NO [Greco et
al., 2006],

1.1.5

Physical properties
As a dynamic, highly mobile entity, much effort has been applied to creating a

conceptual framework that describes the spatial movement of *NO [Lancaster et al.,
1994, Lancaster et al., 1997].

This framework requires that we consider both the

solubility and diffusional movement of *NO in different biological environments to
understand the factors influencing its subsequent reactions.

In order to inform our

understanding of the motion and reactivity of nitric oxide, we will also consider the
properties of oxygen given both its importance in auto-oxidation of nitric oxide and
similarity in physical properties (molecular weight, paramagnetism, solubility etc.).
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1.1.5.1 Solubility
Nitric oxide is known to have a solubility of 1.94 ± 0.03 x 10‘6 mol m L 1 atm "1 at
25°C [Zacharia et al., 2005] in pure water which decreases to 1.75 ± 0.02 x 10‘6 mol mL "1
atm "1 in PBS at the same temperature; however, as a hydrophobic radical,

»NO is

reported to be 6-9 times more soluble in organic rather than aqueous solvents [Malinski,
T., et al. 1993, Shaw, A. et al. 1997]. Alternately, partition coefficients of 4.4 [Moller et
al., 2005] and 200 [Rafikova et al., 2004] have been reported for *NO in lipoproteins and
perfluorocarbons, respectively. One notes that the lipophilicity of »NO bears important
implications for its ultimate reactivity and signaling properties.
Subczynski

has

measured

the

partition

coefficient

(Kp) of oxygen

in

dimyristoylphosphatidylcholine (DMPC) vesicles by monitoring the resolution of the
super-hyperfine coupling of a spin-labeled probe [Subczynski et a l, 1983]. It was found
that the lipid environment greatly influences the partition coefficient of oxygen, reducing
it from a value of ~3 above the transition temperature of the phospholipid to less than 0.2
below the pre-transition temperature (in the crystalline state), indicating exclusion of
oxygen.

Importantly, these results corroborate the notion that the physical state of

membrane can substantially affect the physical processes of small gaseous radicals.
The partitioning of *NO and O 2 into lipoprotein and phospholipid vesicles was
investigated by Moller et al. employing an equilibrium shift assay to determine
coefficients of Kp = 3.8±0.8 and 4.8±0.5 for »NO in LDL

and egg yolk

phosphatidylcholine (EYPC) vesicles, respectively [Moller et al., 2005].

Partition

coefficients for O 2 were determined similarly and found to be 3.2+0.4 and 4.2+0.4 in
LDL and egg yolk phosphatidylcholine (EYPC) vesicles, respectively.

10
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That both nitric oxide and dioxygen partition into hydrophobic environements is of
particular importance

when one considers

the prevalence of lipoproteins

and

biomembranes in the vasculature. Seminal studies conducted within the Lancaster lab
noted the accelerated autooxidation of »NO in hydrophobic environments and the
dependence of this ‘lens effect’ on the aggregate structure of lipid environments [Liu et
a l, 1998a].
The partitioning of both *NO and O 2 were represented in combined form in order to
model and quantitatively describe the acceleration of autooxidation as follows:
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Figure 1.1.3

HQm

Two-Compartment model of NO auto-oxidation

An acceleration factor (X) was thus calculated as rate of reaction between •NO
and O2 in hydrophobic environments using the expression X = (k 3/k_3)(k i/L 1)2(k 2 /k2) [Liu
et al., 1998], Notably, the authors concluded that -90% of the autooxidation of *NO
would take place in the membrane as opposed to the cytosol. However, despite a 10%
decrease in the acceleration factor (taking into consideration hydrophobic volumes (vhkh))
from synthetic liposomes (322±2) to hepatocyte membranes (291 ±3), that ‘presence of
proteins and other components in biological membranes does not appreciably alter the

11
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rate of disappearance away from that predicted only on the basis of the hydrophobic
partitioning’. In light of the fact that subtle changes in »NO signaling can substantially
alter secondary signals (such as the generation of cGMP), it is precisely this assumption
at which we hoped to look more closely.

1.1.5.2 Diffusion
•NO diffusion coefficients have been measured in various lipid environments at
37°C including synthetic liposomes (1.7 X 1() 5 cm 2 s'1) [Denicola et al., 1996b], RBC
plasma membrane-derived liposomes (0.5 X 10~5 cm 2 s'1) [Denicola et al., 1996b],
lipoproteins (3.9 x 10'6 cm 2 s'1) [Moller et al.,2005], (2 x 10'5 cm 2 s'1) [Denicola et al.,
2002] and in situ in the aorta wall (3.3 X 10'5 cm 2 s'1) [Malinski et al., 1993].
Similarly, diffusion coefficients were measured for oxygen and reported as 4.1 X
10'5 cm 2 s' 1 in dipalmitoyl lecithin vesicles, 6.7 X 10'5 cm 2 s' 1 dimyristoyl lecithin
vesicles, 4.3 X 10'5 cm 2 s' 1 in 3:1 dimyristoyl lecithin cholesterol vesicles and 3.2 X 10'5
2 1
cm s' in erythrocyte plasma membranes [Fischkoff et al., 1975].
Using measured diffusion coefficients, it is thus possible to calculate the transit
time for a diffusible species through a defined distance according to the EinsteinSmoluchowski equation [Einstein et al., 1905, Lancaster et al.,2000].

(1)

<x2> = 2Dt

12
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Once generated from a source, its ability to convey messages is dependent upon
its movement from that source and its interaction with a target. The movement of a free
radical can be expressed as a diffusion constant (D) using Stokes law in which,

(2)

D = kT/4OT|r

[Lancaster et al., 2000]

where k is the Boltzmann constant, T the absolute temperature, r| the viscosity of the
medium and r the radius of the diffusing species. Alternately, it has been shown that the
inverse relationship between viscosity and the diffusion constant holds only for solute
molecules which are large in comparison to solvent [Evans et al., 1981] and thus can be
ignored in the case of -NO (and of O 2).
Fick's first law of diffusion states that the rate of diffusion (or flux) is proportional
to the concentration gradient of a diffusing species such that:

(3)

J = -D (dC/dx)

[Porterfield etal., 2001]

where J is the rate of diffusion per unit area of diffusion, C is the concentration, x is the
position from a point of generation and D, the diffusion coefficient. The negative sign is
needed if we assume the concentration decreases as x increases. A consequence of this is
that as •NO is being consumed intracellularly that the flux would increase as a result of
an increase in the magnitude of the gradients.
Alternately, as a comparative model authors have invoked steady-state conditions

13
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(in which *N0 is stable) to model the spherical diffusion of *NO and estimate the radius
it would diffuse by the expression:

(4)

C(r) = C0Ro/r

[Porterfield etal., 2001]

where C(r) is the concentration at a radius r, C 0 the initial concentration of diffusing
species and Rq is a finite radius value. As we see, as r increases, the concentration of the
diffusing species goes to zero and Q = C 0 when R0 = r.
Although useful for comparison,

»NO does not diffuse spherically (ie

unidirectionally in all directions) but moves in all directions equally and randomly
subject to local thermal fluctuations [Einstein et al., 1905, Lancaster, et a l, 1997], As we
know *NO is reactive and disappears in a manner that has been estimated by first order
decay such that:

(5)

Ct/C 0 = exp(kt)

[Porterfield etal., 2001]

where Ct is the concentration of «NO at time t and C 0 is the concentration at time zero.
Combining this with Einstein’s equation in (1) and the equation modeling spherical
diffusion of *NO in (4), the authors estimated the flux of *NO at various distances for
comparison to measured fluxes of *NO. Authors concluded that *NO flux was reduced
by -50% at -2 0 pm from a source of »NO.

These results are in the range of those

suggested by Lancaster (150 -300 pm) [Lancaster et al., 1994, Lancaster et al., 1997] and
suggest that not only will #NO act primarily as a paracrine effector but that it will traverse
a number of cellular membranes before reacting.

14
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Studies on the reaction of nitric oxide with erythrocyte-housed haemoglobin have
spurred a great deal of debate in an attempt to explain the large disparity in the rates of
reaction between *NO and free and RBC-encapsulated haemoglobin [Han et al., 2002].
Several theories have been advanced to explain this including 1) that the erythrocyte
membrane poses an intrinsic barrier to *NO diffusion and permeability [Huang et al.,
2001, El-Farra et al., 2003, Vaughn et al., 2001, Vaughn et al., 2000], 2) that the
unstirred layer surrounding the RBC membrane poses a barrier to diffusion [Liu et al.,
1998, Liu et al., 2002b, Azarov et al., 2005], 3) that underlying submembranous
cytoskeleton mediates »NO bioavailability [Han et al., 2005, Huang et al., 2001, ElFarra etal., 2003, Vaughn etal., 2000, Huang etal., 2001] or that an oxygen-dependent
intrinsic property of the membrane contributes to the barrier effect [Azarov et al., 2005,
Huang et al., 2007]. The ongoing debate serves to underscore the complexity of the
problem at hand.

1.1.5.3 Permeability
Permeability of a species is determined as the product of the partition coefficient
and the diffusion coefficient divided by thickness of the membrane (1) such that P =
(KpD)/l [Dzikovskiet al., 2003, Malinski et al., 1993b].

This permeability term is

proportional to spin-relaxation enhancements of a paramagnetic species and thus has
been exploited by Subczynski et al. to measure »NO permeability through model lipid
bilayers by electron paramagnetic resonance (EPR) spectroscopy

in one of the only

known papers to address this feature of »NO. In this paper, it was concluded that the
presence of 30% cholesterol in fluid-phase bilayers comprised of egg yolk phosphatidyl

15
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choline did not pose a permeability barrier to the transmembrane diffusion of NO
[Subczynski et a l, 1996].
In contrast, earlier studies conducted by Subczynski found that the oxygen
permeability coefficients in the presence and absence of 50 mol % cholesterol are 22.7
and 125.2 cm/s, respectively, for dimyristoylphosphatidyl choline ([Myr2]PtdCho)
membranes, and 54.7 and 114.2 cm/s, respectively, for dioleoylphosphatidyl choline
([01e2]PtdCho) membranes. It was thus concluded that in the absence of cholesterol,
bilayer membranes did not pose a barrier to transport.

However, in the presence of

cholesterol that oxygen permeability decreases by a factor of 5 and 2.5 for [Myr2]PtdCho
and [01e2]PtdCho membranes respectively [Subczynski et a l, 1989, Subczynski et a l,
1991],
By extension, cellular studies have correlated the magnitude of cellular oxygen
gradients (difference between extra- and intracellular oxygen concentration) with the
levels of PM cholesterol [Khan et al., 2003].

These studies measured intracellular

oxygen levels in cells bearing defects in cholesterol metabolism by electron paramagnetic
resonance (EPR)-based oximetry and found oxygen gradients could be enhanced by the
addition of PM cholesterol or nearly abolished by its removal. It is unknown how this
would affect the reaction of nano- to micromolar fluxes of *NO and the resultant »NO
based signaling. However, recent reports investigating the mechanism by which cells
liberate nitric oxide equivalents from S-nitrosothiols and take up resultant «NO provides
evidence which supports the formation of N 2O 3 in the membrane [Ramachandran et al.,

2001],
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1.1.6

Reaction with radicals
An interesting aspect of nitric oxide chemistry is the relative unreactive nature of

•NO to most biological molecules, excluding other free radicals and metal-centres. It has
been demonstrated that «NO will not nitrosate low molecular weight thiols such as
cysteine and glutathione in the absence of oxygen and must be 'activated' in order to
participate in S-nitrosation reactions; thus, a primary route of *NO 'activation' is via
reaction with molecular oxygen.

The reaction of *NO with oxygen in an aqueous

environment is as follows:

(6 ) 4 «NO + 0 2 + 2H20

4 N 0 2‘ + 4H+ (k= 2X 106 M 'V 1 at 25°C)
[Ford et a l, 1993]

and the rate of disappearance of »NO has been determined to be second order with respect
to [»NO] and third order overall.
This assertion bears several implications; firstly, that this reaction will
predominate at higher fluxes of *NO; secondly, that at low oxygen concentrations,
oxygen will act to limit the reaction; and thirdly that •NO and 0 2, both being hydrophobic
gases, will concentrate within the hydrophobic interior of the biological compartments,
thus facilitating reaction. Indeed, it has been suggested by Liu et a l, that the auto
oxidation of nitric oxide is confined (> 90%) to hydrophobic compartments [Liu et al.,
1998a]. This overall reaction is comprised of several intermediate reactions, represented
as follows:

17
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(7) 2 *N0 + 0 2 -> 2 «N02

[Stamler etal., 1992]

•NO 2 is then capable of reacting with another molecule of nitric oxide to form nitrous
anhydride or with another molecule of itself to form dinitrogen tetroxide:

(8)

N 0 + « N 0 2 - » N 20 3 (k = 1.1 X 109M '1s"1) [Fukuto, etal., 2000]

(9)

*N02 + *N02

N20 4 (k = 4.5 X 108 M 1s ')[Fukuto, et al., 2000]

Although it is generally held that m N20 4 is not a physiologically relevant species,
in light of the low levels of »N02 at any given time, both N20 3 and N20 4 are potent
nitrosating agents capable of transferring an »NO moiety to nucleophilic species
including thiols and amines given by the rate equation:

(10)

rate = k[Nuc][N20 3]

(11)

rate = k[Nuc][N20 4]

However, in any aqueous reaction, both species are subject to hydrolysis (shown
in the following reactions) and depending on rates, may compete with nitrosation.

(12)

N20 3 + H20

2 N 0 2 + 2H+ (k = 1 X 103 s'1)
[Gobert etal., 1999]

(13)

N20 4 + H20

N 0 2 + N 0 3‘ + 2H+ (k = 1 X 103 s"1)
[Fukuto, et al., 2000]
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N 2O 3 is

also

formed by

the

reaction

of protonated

nitrite

in

acidic

microenvironments (such as peroxisomes and lysosomes). The reaction is essentially a
dehydration reaction in which two molecules of nitrous acid lose water and generate the
nitrosating species:

(14) H+ + N 0 2

H N 02

(15) 2H N 0 2 -> N 20 3 + H20

[Fukuto, et al., 2000]
[Fukuto, et a l, 2000]

As indicated, »NO auto-oxidation proceeds via a reaction having second order
dependence on nitric oxide.

Thus, this reaction would proceed primarily under

circumstances of increased localized concentration of nitric oxide.

Given the

stoichiometric limitations of this reaction, other reaction pathways for the consumption /
activation of nitric oxide may play a significant role in its chemical transformation.
Importantly, *NO reacts with superoxide at diffusion-limited rates forming peroxynitrite
(OONO):

(16) »NO + 0 2‘' -^OONO"

(k = 6.7 X 109 M ^sec'1) [Huie, et al., 1999]

The physiological relevance of this reaction is supported by evidence that nitric oxide
synthases can, under conditions of arginine scarcity, produce superoxide as well as nitric
oxide [Vasquez-Vivar et al., 1998]. Once protonated, peroxynitrite forms peroxynitrous
acid which can undergo homolytic decomposition forming hydroxyl radical and nitrogen
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dioxide [Merenyi et a l, 1998], however the likelihood of this reaction has been
questioned [Koppenol et al., 1998]. Alternately, protonated peroxynitrite can then
decompose via a rearrangement forming nitrate [Chen et al., 1998] but can also
decompose to form nitrite with concomitant release of oxygen [Pfeiffer et al., 1997].
In light of the high levels and omnipresence of carbon dioxide (CO 2), the reaction
between OONO and CO 2 forming nitrosoperoxocarbonate (OONOCO 2 ) is thought to be
of critical importance:
(17)

OONO + C 0 2

OONOCO 2

(k = 5.8 X 104 M -1 s-1)
[Chen et al., 1973]

Nitrosoperoxocarbonate possess a half-life of ~ 1 jxs [Merenyi et al., 1997] and
decomposes according to two pathways:
(18)

OONOCO 2'

«N0 2 + C 0 3’

[Lymar et al., 1996]

(19)

OONOCO 2

NO 2 + C O 3'

[Lymar et al., 1996]

Species formed in (18) are both potent, one-electron oxidants (E°.no2 = 1.04V) [Stanbury
et al., 1989] and E° co 3*- = 1-78 V [Bonini et al., 2001]) and are thought to contribute
significantly to nitration events.
Nitric oxide is capable of reaction with lipid (L«), lipid-oxo (LO*) and lipidperoxyl (L O O ) radicals at diffusion-limited rates [O’Donnell et al., 2001]. It is this
ability to terminate the propagation of lipid radical reactions that is attributed
responsibility for the anti-oxidant potential of nitric oxide [Hayashi et al., 1995, Yates et
al., 1992]. Conversely, nitric oxide auto-oxidation products such as nitrogen dioxide and
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peroxynitrite are potent oxidizing agents capable of initiating lipid oxidation [Radi et al.,
1994].
It is becoming apparent that there are a wide array of nitrated lipid products
formed in reactions mentioned above [O'Donnell et al., 1999], some of which have been
isolated from in vivo sources [Baker et al., 2005],

That these lipids are capable of

inducing signaling event similar to that of nitric oxide [Cui et al., 2006] underscores the
importance of nitric oxide reactions in lipid environments.

1.1.7

Reaction with thiols
S-nitrosothiols represent a pool of nitric oxide donors that effectively stabilize the

relatively short-lived free radical, extending the lifetime of the active »NO species [Tsikas
et al., 1999], Any small molecule or protein that bears a free thiol moiety can, in
principle, be S-nitrosated; however, as has been demonstrated, endogenous nitrosation of
protein thiols appears more often selective [Greco et al., 2006, Hess et al., 2005],
Formation and degradation of S-nitrosothiols is a dynamic process that is influenced
largely by the prevailing redox environment, oxygen and metal ion availability and thiol
reactivity [Miersch et al., 2005].
Considering the limited direct reaction between »NO and thiols, nitrosothiol
formation is generally preceded by reaction with other species and thus an understanding
of protein S-nitrosation is predicated upon knowledge of the chemistry of nitric oxide and
its redox congeners with oxygen, metal ions and reactive oxygen species.
As stated above the reaction of •NO with oxygen generates the potent nitrosating
species N 2O 3. The rate constants for the nitrosation of low molecular weight thiols by

21

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

N 2O3 [Keshive et al., 1996] have been determined for reactions generating low molecular
S-nitrosothiols via the general reaction scheme:

(17) N2O3 + RSH

RSNO + N 02' + H+

[Keshive et al., 1996]

A rate constant of k = 6.6 X 107 M 'V 1 was provided for glutathione, however it is
expected that protein microenvironments, whether hydrophobic/hydrophilic, acidic/basic
would greatly influence the rate of formation of nitrosated protein thiols.

Dinitrogen

tetroxide is similarly capable of nitrosating thiols (or other nucleophilic species)
according to the reaction:

[Fukuto, et al., 2000]

(18) N 2O 4 + RSH -» RSNO + N 0 3 + H+

In light of the relatively high concentrations of *NO required for auto-oxidation
reactions, Gow et al have provided evidence suggesting an alternate mechanism that
would operate at physiological *NO concentrations.

This mechanism, shown below,

proceeds through sequential reactions in NO reacts directly with a reduced thiol forming
a radical intermediate which donates an electron to an electron acceptor, thus producing
nitrosothiols:

(19)

RSH + »NO

RSN«-OH

(20)

RSN*-OH + NAD+

R SN =0 + NADH

[Gow et al., 1997]
[Gow et al., 1997]
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One implication of this mechanism is that reaction will proceed under anaerobic
conditions, however only in the presence of an electron acceptor such as NAD+. Studies
have shown that *NO is capable of interacting directly with thiols under anaerobic
conditions in which »NO oxidizes thiols to the corresponding disulfide with concomitant
generation of N20 via a RS-N-OH intermediate as seen in the following reaction:

(21)

2 RSH + 2 «NO -> RSSR + N20 + H20

[Pryor et al., 1982]

The nitric oxide moiety of S-nitrosothiols exchanges readily with other thiols,
preferentially over nitrogen or carbon, via nucleophilic attack of the S-NO nitrogen by
thiolate anion:

(22) RjSH + R2SNO

RiSNO + R2SH

[Barnett et a l, 1994]

Thus, reactivity of thiols correlates well with increased acidity of the thiol group [Wang
et al., 2001] and would thus have significant effect on the transnitrosation of protein
thiols from small molecular weight nitrosothiols, given the influence of protein
microenvironment.

Spectral

studies

conducted

to

investigate

the

kinetics

of

transnitrosation between low molecular weight thiols, such as glutathione and cysteine,
and SNO donors such as S-nitrosoacetylpenicillamine (SNAP), revealed that rates of
transnitrosation were faster than decomposition yielding SNO at physiological pH
[Amelle et al., 1995]. The ease with which transfer of the NO-moiety occurs increases
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the likelihood that thiol-based storage pools of nitric oxide are involved in regulation of
protein function by S-nitrosation reactions.
Peroxynitrite (OONO ) is also capable of nitrosating thiols by a mechanism that is
believed to occur via direct thiol nitrosation coupled to the elimination of HOO [van der
Vliet et al., 1998] seen below and corroborated by the experimental observation of
concomitant peroxide generation:

(23)

GS + ONOOH -^GSNO + HOO

(keys = 5.9 X103 M 1 s'1, kesH = 1.5 X103 M'1 s 1 [van der Vliet et al., 1998]

OONO' also reacts with carbon dioxide [Denicola et al., 1996a] and protein-bound metal
centres [Thomson et al. 1995, Floris et al. 1993] at reaction rates 1-3 orders of magnitude
higher than with thiols and thus likely competitors for reaction.
Research efforts have now linked nitrosation of specific proteins to cellular
regions in which one would expect to see concomitant generation of superoxide and nitric
oxide and thus OONO'.

They have shown that treatment with superoxide dismutase

mimetics alter the extent of nitrosation [Yang et al., 2005] thus underscoring the role of
OONO" in protein S-nitrosation.

Iron-based metal-nitrosyl complexes can nitrosate

thiols through a redox reaction in which a ferric-nitrosyl is reduced to its ferrous state
with concomitant transfer of nitrosonium to a free thiol:

(24)

Fe3+(haem) + «N O -> Fe2+ -(NO+)(haem) + RSH
RSNO + Fe2+(haem) + H+

[Wade et al., 1990]
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S-nitrosothiols are generally considered to be stable compounds when protected from
light and in the presence of metal-ion chelators [Singh et a l, 1996]. However, photolytic
decomposition of the SNO bond is known to occur upon exposure to either 340 or 540
nm wavelength light effecting bond homolysis, thus yielding both thiyl and nitric oxide
radicals [Sexton et al., 1994].

S-nitrosothiols are also susceptible to metal-mediated

decomposition by mercury [Goldman et al., 1998], iron [Vanin et al., 1997, Vanin et al.,
2004] or copper [Singh et al., 1996]. Perhaps the best studied mode of decomposition is
the copper-mediated mechanism:
(25)

RSNO + Cu+ + H+^ RSH + -NO

(26)

2RSH + Cu2+

(k = 9.4±2.0 X 107 M 'V 1)
[Burg et al., 2000]

RSSR + Cu+

[Burg et al., 2000]

In the case of copper, both Cu2+ and Cu+ are both effective in decomposing Snitrosothiols; however the monovalent cation has been shown to be far more efficient that
the bivalent cation providing the basis for a redox-cycling mechanism in which Cu2+ can
be reduced by physiological reducing agents including GSH and ascorbate, thus
accelerating decomposition of RSNOs [Singh et al., 1996].

Computational studies

investigating interactions of Cu+ to the S and N centres of the SNO bond and found that
binding to the S-centre both lengthened (and weakened) the S-N bond and strengthened
the NO bond consistent with its role in catalyzing decomposition [Baciu et al., 2005].

1.1.8 Reaction with transition metals
The coordination of »NO by metals forming metal-nitrosyl complexes has been
well studied and haemoproteins (guanylate cyclase, haemoglobin, cytochrome c oxidase
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and cytochrome P450) constitute some of the best characterized systems. As a metal
ligand, »NO is capable of assuming either electrophilic (by donating an electron to the
metal) or nucleophilic (by accepting an electron from the metal) character [Collman et
al., 1987]. The geometry of the metal-nitrosyl complex can form either bent or linear
modes. In general, donation of an electron from *NO to an electropositive centre thus
forming NO+ is associated with a linear bond geometry.

In contrast, donation of an

electron from the metal centre to nitric oxide forming NO" is associated with a bent
geometry. This geometry / electronic status of metal-bound *NO may be able to predict
its subsequent chemistry with either nucleophilic or electrophilic species.
•NO is known to react with oxyhaemoglobin yielding nitrate and methaemoglobin
with a second order rate constant of 89 +/- 3 x 106 M"1 s"1 for oxyhaemoglobin according
to the reaction:

(25)

H b-Fe(II)-02 + -NO ^

Hb-Fe(III) + N 0 3" [Doyle et al., 1981]

Additionally, »NO is known to react with both met- and deoxy-forms of haemoglobin, as
shown:

(26)

Hb-Fe(III) + «NO -> Hb-Fe(III)-OH2 + N 0 2" [Eich et al., 1996]

(27)

Hb-Fe(II) + *NO ^ Hb-Fe(II)-NO

[Eich et al., 1996]

As indicated, iron-nitrosyl compounds thus formed are thought to be capable of
transferring nitrosonium equivalents to available thiols as shown in reaction (24) and,
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although contentious, is considered by some to be and important reaction in auto-catalytic
S-nitrosation of Cys093 in human haemoglobin [Jia et al., 1996, Stamler et al., 1997].
Of equal importance in vascular cells is the metal-mediated reaction of nitric
oxide with guanylate cyclase generating the key second messenger - cGMP [Arnold et
al., 1977]. Interaction of «NO with guanylate cyclase increases the affinity of the enzyme
for its substrate - guanosine triphosphate (GTP) ~3-fold and increases the Vmax ~ 100 to
200-fold [Stone et a l, 1996], It does so by formation of a metal-nitrosyl complex with
the haem-centre, inducing a conformational change in the metalloporphyrin moiety which
exposes the catalytic site [Zhao et al., 1998],
cGMP-dependent ion

channels,

kinases

Transient increases in cGMP activate

and phosphodiesterases

which

mediate

physiological effects of the *NO signal such as platelet inhibition [Moncada et al., 2006],
smooth muscle relaxation [Moncada et al., 2006] and regulation of neurotransmission
[Krumenacker e ta l, 2004] and ion flux [Lee et al., 2001].
Ceruloplasmin, a multi-copper containing oxidase protein found abundantly in
plasma, has been shown to efficiently catalyze the S-nitrosation of low molecular weight
thiol compounds such as glutathione and N-acetyl cysteine and may thus be important in
establishing stabilized nitric oxide pools. Experiments suggest that S-nitrosothiol adducts
are formed through reaction between a free thiol and nitrosonium ion generated upon the
one electron oxidation of nitric oxide by protein-bound copper [Inoue et al., 1999].
•NO can also react with free transition metal ions of which copper and iron are
perhaps the best studied. Experiments have shown rapid reaction of »NO with protein
thiols in both bovine serum albumin and human hemoglobin upon oxidation by Cu2+
[Stubauer et al., 1999], forming near stoichiometric amounts of protein S-N O in either
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oxygenated or deoxygenated solution. This reaction is thought to proceed via a metalnitrosyl intermediate, rather than via nitrosonium directly in that addition of Cu2+ was not
found to cause to rapid loss of *NO.

(28)

1.1.9

Cu2+ + ‘NO

Cu1+-NO+ + RSH

RSNO

[Stubauer et al., 1999]

Nitric oxide donors
The reactivity of nitric oxide in a biological milieu suggests that there are

mechanisms by which it is stabilized in vivo to preserve its biological functions. Indeed
there exist a number of physiologically stable «NO adducts that can donate authentic *NO
or its redox congeners.

Practical application of «NO donors as therapeutics in the

mitigation of disease and as diagnostics and research tools have spurred the development
of a number of synthetic donors including organic nitrites and nitrates [Wang et al.,
2002b], sodium nitroprusside [Thatcher et al., 2005], diazeniumdiolates (NONOates)
[Megson et al., 2002], S-nitrosothiols [Al-Sa'doni et al., 2000], novel NO-hybrid drugs
[Miller et al., 2007] and NO-binding zeolites [Miller et al., 2007] which vary in their
physical properties, rates of decomposition and products generated.

Although a

comprehensive discussion of available *NO donors is beyond the scope of this thesis, a
brief discussion of the properties of donors used in subsequent investigations is provided.
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1.1.9.1 S-nitrosothiols
S-nitrosated thiols functionally extend the lifetime and bioactivity of *NO from
time scales of seconds to minutes, hours and perhaps longer depending upon its
environment [Hogg

et al., 2000]. Physiological S-nitrosothiol-based »NO donors are

derived from low molecular weight thiols such as glutathione. This S-nitrosated species
bears a characteristic SNO absorption band between 330 - 370 nm with s = 980 L
m of'cm "1 [Xian et al., 2000]. »NO (or a redox congener) is subsequently released from
these species via the action of thiols [Hu et al., 2006], metals [Hogg et al., 2000] or
enzymes capable of cleaving the SNO bond [Sliskovic et al., 2005], evidenced by the loss
of absorbance at the absorption maxima. Other nitrosothiols are also easily prepared and
useful for investigation including S-nitrosocysteine, S-nitrosohomocysteine and Snitrosopenicillamine, each of which possesses unique decomposition profiles [Grossi et
al., 2002] and susceptibility to metal-mediated decomposition [Noble et al., 2000].

1.1.9.2 Diazeniumdiolates
Another useful class of NO-donors are the diazeniumdiolates (commonly known
as NONOates) that bear the general structure of X-[N(0)NO]( ) . Two commonly used
examples

(Sodium

(Z)-l-(N,N-Diethylamino)diazen-l-ium-l,2-diolate

(DEA/NO)

[Davies et al., 2001] and Disodium l-[(2-Carboxylato)pyrrolidin-l-yl]diazen-l-ium-l,2diolate (Proli-NO) [Waterhouse et al., 2006]) are shown below:
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Figure 1.1.4

DEA/NO

Proli/NO

ti /2 = 2 minutes

ti /2 = 2 seconds

Structures of two commonly used diazeniumdiolates

This class of compounds decomposes spontaneously (ie without metabolism or
redox activation) by hydrolysis generating «NO, nitrite ion as well as original and Nnitrosated base [Keefer et al., 2005]. These species decompose according to first-order
kinetics with half-lives in the range of minutes to hours, dependent upon their structure,
thus making very useful tools for the controlled delivery of *NO in the study of nitric
oxide signaling.

1.1.10 Use of diaminofluoresceins in the detection of redox activated nitric oxide
The diaminofluoresceins are a class of fluorophores that have been used to detect
the products of nitric oxide oxidation products, participating in reactions that result in the
formation of the highly fluorescent triazolofluoresceins [Nakatsubo et al., 1998, Kojima
et al., 1998]. The triazolofluoresceins can be formed by nitrosative reactions in which a
species capable of transferring a nitrosonium moiety (such as N2O3) nitrosates an
aromatic nitrogen as shown below:
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Fig 1.1.5A Nitrosation of diaminofluorescein by N2O 3
Alternately, triazolofluorescein can be formed by oxidative nitrosylation in which
one of the aromatic nitrogens undergoes one-electron oxidation (by species such as »N02
or CO3* ) followed by reaction with radical nitric oxide as shown below.

Fig 1.1.5B Oxidative nitrosylation of diaminofluorescein by »N0 2

1.1.11 Nitric Oxide Signaling
The paradigm of cellular signaling pathways mediated by »NO and its redox
congeners (NOx) generally envisions transduction of signals through reaction with
protein-bound metals, protein thiols and more recently via lipid species [O’donnell et al.,
1999]. Through these interactions, reports indicate that NOx are capable of influencing
diverse cellular events that regulate transcription [Ckless et al., 2007], protein-folding
[Uehara et al., 2006], contractility [Cartwright et al., 2007], cell death [Mitchell et al.,
2005], proliferation [Moreno-Lopez et al., 2004] and many more.
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Although the cellular signals transmitted by metal-nitrosyl complexes have been
well studied, signals based upon nitrosation have lagged due to methodological hurdles.
Recent technological advances have enabled the study of thiol nitrosation and revealed
this as another post-translational means of chemically modifying and functionally altering
proteins. Changes in protein function, which persist on a physiologically relevant time
scale, effectively transmit biological signals and thus provide a framework for elucidating
signaling networks.
In order to characterize the relative contribution of nitrosation (addition of NO+ to
nucleophilic species) versus nitrosylation (radical-radical reaction with or coordination of
•NO) reactions on a global scale, Feelisch measured S-nitrosation, N-nitrosation and
metal-nitrosyl formation in rat plasma, red blood cells, heart, lung, aorta, liver, kidney
and brain tissues [Bryan et al., 2004], Their study demonstrated that nitrosation products
were found at levels comparable to nitrosylation products and that the majority of
nitrosation products were associated with the protein fraction. The results of their study
reveal that protein S-nitrosation is a ubiquitous occurrence that rivals the competing
process of metal nitrosylation, despite appearances of being kinetically disfavored.
Although the authors concluded that the prevalence of comparable levels of
nitrate and nitrite argues in favour of an oxidative nitrosylation mechanism (by
peroxynitrite) rather than nitrosation (by nitrous anhydride), the observation that nitric
oxide can be formed by nitrite [Lundberg et al., 2005] complicates interpretation of data.
An alternate explanation for this observation may lie in the observations that
hydrophobic environments (cellular membranes, lipoproteins and protein microdomains)
promote the 1) auto-oxidation of nitric oxide [Liu et al., 1998a] by sequestering lipophilic
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oxygen and nitrogen and 2) nitrosation of protein residues [Nedospasov et al., 2000,
Rafikova et al., 2004]. Although our understanding of ‘NO reactivity in hydrophobic
environments has benefited greatly from these insights, the complex behaviour of lipids
and their ability to influence cellular physiology warrants closer consideration of how
•NO signaling is potentially altered by membrane lipid composition.
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1.2
1.2.1

Cholesterol
Introduction
Biochemical processes that contribute to the metabolism of cholesterol in health

and disease have occupied the scientific imagination for the last century.

From the

distant determination of its molecular structure [Crowfoot et al., 1943] to the elucidation
of regulatory mechanisms governing cholesterol synthesis and trafficking [Brown et al.,
1997], to its more recent role in membrane organization and dynamics [Brown et al.,
1998, Simons et al., 2000], modem life sciences continue to probe various aspects of this
vitally important sterol and its biosynthetic intermediates. Cholesterol contributes to both
human health and the pathogenesis of disease through its role as a structural lipid with
substantial influence over the properties of biological membranes and as a precursor
molecule for bile acid and steroid hormone synthesis. Intermediates in the biosynthetic
pathway of cholesterol also play a pivotal role in human health and disease independent
of their role in cholesterol production through their ability to exert effects on a variety of
cell-signaling pathways.
This section will provide an overview of various features of cholesterol
biosynthesis, cellular homeostasis and transport, as well as its influence on membrane
properties and the pathological consequences of its accumulation with emphasis on
aspects relevant to the studies within this thesis.

1.2.2

Biosynthesis
Early studies into its biosynthesis revealed that cholesterol is assembled from 2

carbon acetate precursors earning Konrad Bloch the 1964 Nobel Prize in Chemistry. In
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the years to follow, it was discovered that the assembly of cholesterol is orchestrated by a
complex array of soluble and membrane-bound enzymes and that this process is tightly
regulated by transcriptional [Moore et al., 1991, Reynolds et al., 1984] and translational
mechanisms [Peffley et al., 1985], feedback inhibition and hormonal regulation [Ness et
al., 2000], post-translational modification [Hinson etal., 1997] and regulated degradation
of synthetic enzymes [Shimomura etal., 1997].
Under

normal

circumstances

most

extra-hepatic

tissues

derive

required

cholesterol by de novo synthesis from acetyl coenzyme A and acetoacetyl coenzyme A in
a series of steps involving various enzymes and intermediates as depicted in Figure 1.2.1.
adapted from [Liscum et al., 2001].
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A key step of the pathway is catalyzed by the enzyme 3-hydroxy-3-methylglutaryl
Co-A reductase (HMG-CoA reductase) and as the rate limiting step, has been the focus of
intense attention from scientists, clinicians and pharmaceutical companies alike. This
enzyme is localized as a tetramer to the ER membrane, its C-terminal catalytic domain
situated on the cytosolic rather than luminal face of the ER [Liscum et al., 2001]. Here,
HMG-CoA reductase converts 3-hydroxymethylglutaryl-CoA to mevalonate. In addition
to the catalytic domain, HMG-CoA reductase possesses a sterol-sensing domain
comprised of membrane-spanning helices 2 to 5, which confer cholesterol-sensitivity
(changes in enzyme function sensitive to [cholesterol]) upon the enzyme thus limiting
biosynthesis during times of cholesterol availability. It is of interest to note that this
domain is similarly possessed by several other key enzymes of the cholesterol
biosynthetic and trafficking pathways (including NPC1 [Carstea et al., 1997], sterol
responsive element binding protein (SREBP) cleavage activating protein (SCAP) [Hua et
al., 1996] and 7-dehydrocholesterol A7-reductase [Bae et al., 1999]), suggesting that it
has been evolutionarily conserved for multiple cholesterol-dependent functions.
The product of this reaction - mevalonate is then converted via decarboxylation,
dehydration and isomerization to isopententenyl-diphosphate, geranyl-diphosphate and
ultimately to famesyl-diphosphate in a series of reactions. These species, in addition to
serving as substrates for the subsequent and final committed steps of cholesterol
biosynthesis, have also been shown to act as important bioactive intermediates which
fulfill critical cellular roles independent of cholesterol synthesis.

To illustrate,

investigators have shown that complete inhibition of cholesterol synthesis at the ratelimiting step induced cell death [Mosley et al., 1983]. This could not be mitigated by the
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addition of exogenous cholesterol alone but required mevalonate as well, thus
emphasizing the biological necessity of the subsequently produced intermediates.
It has since been demonstrated that non-sterol isoprenoids can post-translationally
modify

proteins

through

isoprenylation

(the

addition

of farnesyl,

geranyl

or

geranylgeranyl moieties). These modifications can facilitate the targeting of modified
proteins to biomembranes and other proteins [Resh et a l, 2006, Gelb et al., 2006] and are
critical components of functional enzymes [Magee et a l, 1999]. Notably, isoprenoids
represent an important link between the cholesterol biosynthetic machinery and
generation of deleterious reactive oxygen species (ROS) by NAD(P)H oxidase in a
pathological setting [Bedard et al., 2007]. These areas are functionally related through
the isoprenylation of R acl (a G-protein involved in the activation of NAD(P)H oxidase),
and have thus become key areas in the study of both the molecular basis of signaling and
disease, as well as an attractive target for therapeutic intervention. As such, this topic
will be discussed in greater detail under the aegis of cholesterol-lowering therapies.
In summary, the biosynthetic pathway of cholesterol not only gives rise to this
vitally important sterol but also generates a variety of crucial, non-sterol intermediates
bearing important biological roles in human health and disease. Understanding how to
modulate this pathway and the consequences of modulation on cellular function is
imperative in the development of pharmacological agents that mitigate the effects of
cholesterol dysregulation and associated pathologies.

38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.2.3

Cholesterol Homeostasis
Cellular cholesterol levels are maintained by a complex system of mechanisms

involving synthesis, uptake, storage and efflux [Maxfield et a l, 2005]. As indicated
above, cholesterol biosynthesis occurs primarily at the ER and within peroxisomes and is
exquisitely regulated at a number of points which sense and respond to prevailing
cholesterol levels. Despite this fact, ER-cholesterol content is relatively low, estimated to
possess only 0.5-1.0% of total cellular cholesterol [Lange et a l, 1999] and endogenously
synthesized cholesterol must leave the ER to exert many of its biological effects.
Following synthesis, cholesterol rapidly distributes throughout the cell in a nonhomogenous manner.

Transport occurs against an increasing cholesterol gradient as

traverses from the ER to the highly enriched plasma membrane gradually increasing in
prevalence from the ER to the cis golgi apparatus [Blanchette-Mackie et al., 2000], from
the cis to the fran.v-golgi compartments and from the trans golgi to the plasma membrane.
The majority of newly synthesized cholesterol is thought be transported from the ER to
the PM by an energy-dependent mechanism [Liscum et al., 1999, Miriam R. Kaplan,
Simoni et al., 1985] involving either sterol-carrier protein-2 (SCP-2) [Puglielli et al.,
1996] or a caveolin complex which bypasses the golgi apparatus [Uittenbogaard et al.,
2000, Smart et al., 1996] with a tm of arrival at the plasma membrane of about 10
minutes [DeGrella et al., 1982]. Alternately, a lesser fraction is thought to follow the
secretory pathway via the trans-golgi network [Maxfield et a l, 2002].
It is estimated that 50-90% of total cellular cholesterol resides in the plasma
membrane [Liscum et al., 1999], and that 30-40% of plasma membrane lipids are
cholesterol [Maxfield et al., 2002]. The influence of cholesterol on the properties of
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cellular membranes is well appreciated in the literature [Pencer et a l, 2005, London et
al., 2002, Niu et al., 2002, Huster et al., 1998, Subczynski et al., 1989] and will be
discussed below.
In addition to de novo synthesis, cellular cholesterol is derived from the uptake
plasma lipoproteins predominately in the form of low-density lipoprotein (LDL).
Lipoproteins are soluble aggregates of protein (apo-lipoprotein) and lipids packaged to
facilitate their systemic transport to and from peripheral tissues.

They are de novo

synthesized in the liver and intestines but can also be formed in peripheral tissues by the
modification of other lipoproteins or from the lipidation of free apo-lipoproteins. Once
formed, lipoproteins are cleared primarily by the liver through receptor-mediated uptake,
but can also be catabolized by peripheral tissues.
Lipoproteins contain various lipid classes including glycerolipids, fatty acids,
phospholipids, lysophospholipids, sphingomyelin, free cholesterol and cholesterol esters.
Lipoproteins are defined on the basis of both their characteristic lipid (triglyceride,
cholesterol and phospolipid) content and hence density, as well as by their association
with a variety of apo-lipoproteins.
Cells derive exogenous cholesterol primarily from LDL-receptor (LDLR)mediated internalization of LDL and respond to its uptake by down-regulating the
expression of the receptor (LDLR). Conversely, cells deprived of exogenous cholesterol
have been reported to increase LDLR expression up to 20-fold [Brown et al., 1981].
LDL taken up by endocytosis is dismantled within the endosomal and lysosomal
compartments and resultant free cholesterol subsequently directed towards either the
plasma membrane in a protein-dependent mechanism in involving the cholesterol-binding
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protein - NPC1 [Wojtanik et al., 2003] or acylated and directed back to the ER [Slotte et
al., 1989],
Conversely, excess cellular cholesterol is effluxed from the cell via the process of
reverse cholesterol transport, in which HDL binds to the cell surface scavenger receptor131 (SRB1) and can act as a cholesterol acceptor, thus facilitating the efflux of cellular
cholesterol [Fielding

et al., 1995, Ji et al., 1997] and its return to the liver for its

excretion as oxysterols. The process of efflux, although known to occur by spontaneous
desorption [Rothblat et al., 1992], is also mediated by the membrane-resident - ATP
binding cassette 1 (ABC1) transporter protein [Wengen et al., 2000], thus delivering
cholesterol to physiological acceptors such as high-density lipoprotein (HDL) or human
serum albumin [Ha et al., 2003].
The field of intracellular cholesterol trafficking is a complex, multi-faceted area,
the progress of which has lagged behind the understanding of cholesterol metabolism.
Here, I have provided only a cursory overview of the various mechanisms responsible for
cholesterol transport within the cell. In the next section I will focus exclusively on the
area of aberrant intracellular cholesterol trafficking mediated by NPC1 and its cellular
consequences.

1.2.4

The Role of NPC1 in cellular cholesterol trafficking and the etiology of
disease
In light of the non-homogenous distribution of cholesterol within the cell and the

critical role that it plays in membrane properties it comes as no surprise that the cell has
evolved a number of mechanisms for sterol trafficking.

Although there still exists

significant ambiguity in the means by which cholesterol is transported throughout the
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cell, studies have provided evidence that this process is mediated by a number of proteins
including caveolin, sterol-carrier protein 2 (SCP2), Niemann-Pick Type C l protein
(NPC1) and steroidogenic acute regulatory protein (StAR) [Schroeder et a l, 2001].
In particular, the role of NPC1 in cholesterol trafficking has been substantially
aided by the study of the genetic disorder that gives rise to molecular defects in the
protein.

This disorder known as Niemann-Pick disease Type C l is an autosomal

recessive, neurodegenerative condition that results in intracellular lipid accumulation.
Discovery of the npcl gene led to the observation that, like both HMG-CoA reductase
and SCAP, NPC1 possessed a sterol-sensing region [Carstea et al., 1997].

Shortly

thereafter reports asserted a putative role for NPC1 in cholesterol transport, confirmed the
role of the sterol-sensing domain in cholesterol binding [Ohgami

et al., 2004] and

localized NPC1 to the membrane of late endosomes and lysosomes [Ko et al., 2001].
It was later noted that mutations in the npcl gene were responsible for the
dysfunctional transport of cholesterol and resultant pathology of Niemann-Pick disease
which manifests clinically as neonatal jaundice, hepatosplenomegaly, vertical gaze palsy,
ataxia, dystonia, and progressive neurodegeneration [Garver et al., 2007ab, Raymond et
al., 2004]. As history shows (and the case of Niemann-Pick disease is no exception), the
study of a disease whose molecular origins are known provides not only valuable insights
into the pathogenesis of disease but also provides clues regarding its function under
normal cicrumstances.
NPC1 is expressed in virtually all tissues of the body, however is most highly
expressed in the liver.

On a molecular level, homozygous npcl deficient (-/-) mice,

exhibit a reported 4-fold accumulation of cholesterol, thought to arise from the
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dysfunctional transport of cholesterol from late endosomes/lysosomes to other cellular
compartments [Garver et al., 2002],

NPC1, normally localized to endosomal bodies is

hypothesized to act in LDL-derived cholesterol trafficking, transporting it from late
endosomes to the plasma membrane.

Thus NPC1-deficient cells instead accumulate

LDL-derived, unesterified cholesterol in the late endosomes and lysosomes [Reid et al.,
2004, Liscum et al., 1989] and are thought to exhibit delayed arrival of LDL-derived
cholesterol at the plasma in comparison to normal cells [Wojtanik et al., 2003].
Several papers have, despite evidence of diminished cholesterol levels in
calveolar structures, reported increased cholesterol / phospholipid ratios and overall
cholesterol levels [Vainio et al., 2005, Koike et al., 1998]. This may be due to increased
non-protein-mediated sterol transfer or spontaneous desorption from cholesterol-enriched
intracellular organelles in close proximity to the plasma membrane [Putney et al., 1999].
Although by no means the only protein which regulates intracellular trafficking of
cholesterol and the content of the cellular plasma membrane, NPC1 apparently fulfills a
critical function in transport, arrival and maintenance of membrane cholesterol levels and
thus membrane properties. As NPC1-deficient cells were used as a model to investigate
the role of lipid accumulation in *NO metabolism and signaling, discussion will be
limited to only this particular trafficking protein.

1.2.5

Role of cholesterol in membrane properties
In recent years, the early concept of the membrane as a homogenous mixture of

lipids and associated proteins, both capable of exhibiting unfettered motion [Singer and
Nicholson] has been challenged by various observations [Simons et al., 1997, Zegers et
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al., 1998].

The model currently under exploration envisions the membrane as an

inhomogeneous mixture in which distinct liquid-ordered (10) microdomains co-exist in
equilibrium with liquid-disordered (la) regions. These ‘rafts’ are hypothesized to act as
triage centres facilitating the interaction of signaling proteins which similarly localize to
these domains for transduction of cellular signals.
Cholesterol, in particular, has been shown to play a major role in membrane
architecture, capable of inducing the formation of 10 domains in model membranes
composed of 1:1 or 2:1 ratios of porcine brain phosphatidylcholine to sphingomyelin
[Crane et al., 2004]. It is the most abundant sterol in eukaryotic plasma membranes,
reported to span 17

A into one leaf of a 60 A thick bilayer [Vanderkooi et al.,

approximately the C9 position along an acyl chain.

1994] or to

Studies on the influence of

cholesterol on the physical structure of lipid bilayers have revealed interesting
observations. Notably, both computational and experimental data suggest that cholesterol
induces an increase in the overall thickness of a bilayer [Mason et al., 2003, Pencer et al.,
2005] expanding it vertically from an average thickness of 52.5

A

to 58

A

[Tulenko et

al., 1998] and concomitantly inducing a decrease in the acyl chain molecular volume
[Greenwood et al., 2006, Coumia et al., 2007].
Cholesterol has also been shown to exert substantial influence over the domain
architecture of cellular membranes inducing the formation of phase-separated domains
[London et al., 2002, Niu et al., 2002, Huster et al., 1998] which exhibit altered physical
properties [Pandit et al., 2007, Henriksen et al., 2006] including changes in fluidity
[Kusumi et al., 1983] and mobility [Pucadyil et al., 2006], hydrophobicity [Subczynski,
et al., 1994], decreased oxygen permeability [Subczynski et al., 1989, Buchwald et al.,
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2000a, Buchwald et al., 2000b], and further, to alter the activity / localization of integral
membrane proteins such as the insulin-receptor [Vanio et al., 2005], Na+-K+ ATPase,
adenylate cyclase, alkaline phosphatase, rhodopsin and transporters for glucose, organic
anions and thymidine [Tabas, et al., 2002]. Importantly, it has been demonstrated that
cholesterol-feeding can induce physical changes in the membranes of arterial smooth
muscle cells derived from rabbit models of atherosclerosis [Tulenko et al, 1998, Chen et
al., 1995a], (consistent with observations from model systems) thus representing an
extension of insights derived from model systems to in vivo systems.

1.2.6

Type II Diabetes, insulin resistance and hypercholesterolemia
The prevalence of diabetes is reaching epidemic proportions in North America

rising in prevalence an average of 6.2% per year between the years of 1995 and 2005 in
Canada alone [Lipscombe et al., 2007]. Ninety percent of diabetes cases are of the Type
2 , characterized by decreasing sensitivity of peripheral tissues to the insulin signal that

normally induces the cellular uptake of glucose thus resulting in elevated blood glucose
levels.

In addition to hyperglycemia, insulin resistance is associated with a host of

metabolic disturbances that manifest as hyperinsulinemia [Olefsky et al., 1981], lipid
abnormalities [Frohlich et al., 2000, Krentz et al., 2003] (including hypertriglyceridemia
decreased HDL levels and increased prevalence of smaller LDL particles), oxidative
stress

[Penckofer et al.,

2002], inflammation

[Dandona et al.,

2002]

and a

hypercoaguable or pro-thrombostic state [Frohlich et al., 2000, Krentz et al., 2003, Grant
et al., 2007].

Long term complications of poorly controlled diabetes include

cardiovascular disorders including atherosclerosis, hypertension and cardiomyopathies,
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often resulting in clinical events such as myocardial infarction, congestive heart failure or
thromboembolic stroke [Carr etal., 2001].
As a key feature of T2D, the causes and consequences of insulin resistance have
been widely investigated.

Insulin is a 5700 Da molecular weight peptide hormone

synthesized in the (3-islet cells of the pancreas as an inactive, single-chain, pre-protein
with an N-terminal signal sequence which directs it towards secretory granules.
Following removal of the signal sequence and introduction of three disulfide bonds,
proinsulin remains stored in granules until blood glucose rises. Spikes in blood glucose
then trigger the proteolytic excision of a peptide producing C-peptide and mature insulin
for export from (3-pancreatic cells into the blood stream where it is estimated to reach
high picomolar to low nanomolar levels [Kiyokawa et al., 1989],
Insulin receptor (IR) is an a 2(32 heterotetramer expressed in a variety of tissues
including liver [Sell et al., 1994], skeletal muscle [Mosthaf et al., 1993], adipocytes
[Marshall et al., 1980] and vascular cells [Rakugi et al., 2002] and upon arrival of the
insulin signal at target tissue, receptor ligation triggers autophosphorylation of cytofacial
Tyr residues in the (3-subunit.

This is the first step in a phosphorylation cascade

propagated from the insulin receptor to various isoforms of insulin receptor substrate
(IRS 1/2/3/4) [Sykiotis et al., 2001]. The kinase activity of IRS activates phosphatidyl
inositol-3-kinase (PI3K) [Asano et al., 2005, Duan et al., 2004] producing (PIP3) and
providing the substrate used by PDK-1/2 to phosphorylate Akt/PKB [Persad et al., 2001].
From this point, Akt/PKB acts to modulate cell-specific signaling cascades that govern
diverse processes including NO production [Zeng et al., 1996], protein synthesis, glucose
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uptake, cholesterol and fatty acid biosynthesis [Porstmann et al., 2005] and cell survival
and apoptosis [Persad et a l, 2001] as illustrated in Figure 1.2.2 below:

Insulin

Insulin receptor
PIP.
Plasma Membrane

IRS
PI3K
Proliferation /
differentiation
lipogenesis

NO synthesis
Akt

PDK

apoptosis /
cell survival
Protein
glucose
uptake
synthesis
glycogen
synthesis

Figure 1.2.2 Role of Akt in insulin signaling events
Image adapted from [Whiteman et al., 2002]
Mechanisms of insulin resistance are thus thought to arise from alterations in
receptor expression [Ondinone et al., 1997], phosphorylation state [Draznin et al., 2006]
and/or kinase activity [Yasukawa

et al., 2005] and can account for many insulin-

resistance phenotypes [Pessin et al., 2000]. Notably there are a number of studies which
suggest that conditions associated with the diabetic milieu, such as hyperglycemia [Oku,
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et a l, 2001] and oxidative [Houstis et al., 2006] and nitrosative [Kaneki et a l, 2007]
stress can contribute to insulin resistance through the aforementioned mechanisms.
Another key feature of T2D is the dysregulation of cholesterol homeostasis which
results in altered lipoprotein levels and properties. Normal total cholesterol levels in the
vasculature are in the range of -200 mg/dl (5mM) and it is estimated that 60-70% of total
cholesterol is derived from apo-B containing LDL and 20-30% is derived from apo-A
containing HDL. Optimum levels are considered to be <100 mg/dL and >50mg/dL for
LDL- and for HDL-derived cholesterol respectively [NIH Publication No. 02-5215,

2002],
Hypercholesterolemia is a known contributor to endothelial and platelet
dysfunction which is characterized by decreased bioavailability of *NO [Warnholtz et
al., 2004], altered expression of cellular adhesion molecules [Sampietro et al., 1997,
Utsumi et al., 2007], generation of reactive oxygen [Stokes et al., 2007 J, Stokes et al.,
2001, Kitayama et al., 2007] and nitrogen species [Forstermann et al., 2006, Pacher ert
al., 2005], and increased secretion of matrix proteins [Fan et al., 2003]. Collectively
these changes influence platelet- and leukocyte-endothelial interactions promoting
adhesion [Stokes et al., 2001] and thrombogenicity [Lacoste et al., 1995, Stokes et al.,
2007, Stokes et a l, 2001], tip vasomotor tone toward constriction [Pratico et al., 2005]
and spur the development of atherosclerosis [Collin et a l, 2007].
Studies have suggested a number of mechanisms by which hypercholesterolemia
limits the bioavailability of »NO including alterations in expression of the »NO target guanylate cyclase [Melichar et a l, 2004], cholesterol-induced increases in generation of
reactive oxygen species resulting in »NO consumption [Stokes et a l, 2002] and resultant
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protein-thiol oxidation [Miersch et al., 2007],

diminished availability of the eNOS

cofactor - tetrahydrobiopterin, [Kawashima et al., 2004] and inhibition of endothelial
nitric oxide synthase (eNOS) due to enhanced inhibitory interaction with caveolin [Feron,
etal., 1999].
However, in light of the ability of increased cholesterol levels to alter the physical
properties of cellular membranes and the generation of reactive oxygen species, primary
questions we asked were 1) whether physical changes in the membrane could contribute
to diminished bioavailability of «NO and 2) whether redox-altered, cell-mediated
liberation of »NO from physiological *NO pools could be restored using cholesterollowering drugs by pleiotropic mechanisms.

1.2.7

Therapeutic Options for Treating Hypercholesterolemia
Recent years have seen the development of a number of approaches to lowering

cholesterol levels. Of course, restricting dietary intake is an obvious means, however
pharmacologic agents provide the clinician with options when altering an individuals diet
proves to be ineffective or infeasible. Each of the available agents marketed to lower
cholesterol does so by interrupting key points of either sterol uptake or biosynthesis.
For instance, a relatively novel drug known as ezetimibe, is capable of lowering
circulating cholesterol levels by 15-20% [Bays et al., 2001, Dujovne et al., 2002] and
does so by interacting with Niemann-Pick C l-like 1 protein, believed to mediate
cholesterol absorption from brush border intestinal epithelial cells [Altmann et al., 2004,
Garcia-Calvo et al., 2005].
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Alternately, bile-acid binding resins (such as cholestyramine) are polymeric resins
which act to sequester bile acids in the gastrointestinal tract thus preventing
reintroduction into enterohepatic circulation [Insull et al., 2006].

They do so by

exchanging anions for negatively charged bile acids forming an insoluble complex that is
subsequently excreted.

Given that bile acids are synthesized from a cholesterol

precursor, these agents show efficacy in lowering circulating cholesterol levels with mean
reductions in LDL up 20% [Aldridge et al., 2001],
Another class of drugs known as statins (HMG-CoA reductase inhibitors), are
perhaps the most widely used hypolipidemic agents on the market today, likely due to
both efficacy in lowering plasma cholesterol levels as well as additional beneficial effects
not fully explained by their lipid lowering capacity.

It is precisely these additional

benefits or ‘pleiotropic effects’ of statins that were the focus of our investigation.
There are a number of statins currently on the market (including lovastatin,
pravastatin, rosuvastatin, simvastatin, atorvastatin and fluvastatin). These drugs share the
common feature of a HMG-like moiety and a bulky, hydrophobic group (illustrated in
Figure 1.2.3) which bind to the HMG-CoA binding site and competitively inhibit
enzymatic activity [Istvan et al., 2002] with inhibition constants in the range of 0.1 - 250
nM [Holdgate et al., 2003, Carbonell et al., 2005, Istvan et al., 2002],
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Figure 1.2.3

Structure of rosuvastatin

Although, statins are well-documented to effectively lower plasma [LDL] [Istvan
et a l, 2002 ], investigators have noted that the beneficial effects of statins are often noted
prior to the observation of the lipid-lowering effects [Tsunekawa et al., 2001, John et
al., 2005] and have led to studies on the pleiotropic effects of statins and their ability to
mitigate vascular dysfunction.
Studies have shown that lipid-lowering therapies are capable of lowering
erythrocyte and platelet membrane cholesterol [Lijnen et al.,

1996], improving

endothelial dysfunction [Davignon et al., 2004], increasing nitric oxide bioavailability
[Feron et al., 2001], exerting antioxidant properties [Aikawa et al., 2002, Thallinger et
al., 2005], inhibiting inflammatory responses [Davignon et al., 2004, Ridker

et al.,

2005], stabilizing atherosclerotic plaques [Fukumoto etal., 2001, Llorente-Cortes etal.,
1998] and more recently restoring platelet function [Miersch et al., 2007, Haramaki et
al., 2007] Although mechanisms for the variety of observed effects are not completely
elucidated, investigations in to the molecular basis for at least one aspect of the
pleiotropic effects of statins reveal that isoprenoid intermediates produced subsequent to
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the reduction of HMG-CoA are critical to the function of a number of Ras family, Gproteins most of which are isoprenylated, including the small GTPase, subunit of
NAD(P)H oxidase - R acl [Di-Poi

et al., 2001],

Studies have shown that R acl

isoprenylation is required for its interaction with Rho-guanosine dissociation inhibitor
(Rho-GDI) [Grizot et al., 2001] and consequently the ability of the Rac-RhoGDI complex
to associate with p67 and activate NAD(P)H oxidase.
NAD(P)H oxidase (NOX) is a membrane-associated, multi-subunit enzyme
complex that catalyzes the one-electron reduction of molecular oxygen forming the more
reactive oxygen species - superoxide (O 2* ). In phagocytes, catalysis is accomplished by
a membrane-resident heterodimer comprised of p22phox and gp91phox which together
form the a - and (1- subunits of the catalytic cytochrome bssg. The catalytic activity is then
regulated by a host of cytosolic proteins including p47 (organizer protein), p67 (activator
protein) and small GTPases - rapl [Quinn et al., 1989] and racl [Miyano et al., 2007]
which are thought to be required for membrane localization and formation of a functional
NAD(P)H complex [Miyano et al., 2007] as shown in Figure 1.2.4.
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Importantly, NAD(P)H oxidase is present in non-phagocytic cells including both
endothelial cells [Li

et al., 2004]

and platelets [Plumb et al., 2005] in which it is

reported to be induced by a hypercholesterolemic milieu [Ohara et al., 1993, Stokes et
al., 2007, Sanguigni et al., 2002].
In light of these findings and that HMG-CoA reductase inhibitors would likely
limit the supply of isoprenoids critical for the formation of a functional oxidase complex,
we hypothesized that the increase in reactive species produced by NAD(P)H oxidase in
platelets and endothelial cells would alter various aspects of platelet function toward a
pro-thrombogenic state and could be remediated by statin treatment.
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1.3

Protein Disulfide Isomerase

1.3.1

Overview
Protein disulfide isomerase is a ubiquitous, 58kDa soluble protein, localized to the

lumen of the endoplasmic reticulum [Luz et al., 1996] where it assists in the oxidative
folding of nascent proteins and the attainment of native disulfide bonding patterns
[Gruber et al., 2006] and stress responses [Uehara et al., 2006, Azfer et al., 2006]. In
addition to its role in protein folding, it is also a subunit of enzyme complexes including
prolyl 4-hydroxylase [Koivunen et al., 2005] and the microsomal triglyceride transfer
protein [Levy et al, 2002].
PDI has been the focus of intense study in light of both its abundance (-0.4% of
total cellular protein [Noiva et al., 1992]) and prevalence in nearly every tissue.
Although it was long considered a strictly ER-resident protein localized by way of its Cterminal KDEL retention signal [Cabrera et al., 2003, Luz J et al., 1996], it has since
come to light that PDI can also be found in several non-ER locations [Essex et al., 1995,
Goplen et al., 2006, Akagi et al., 1988] and in particular on the exofacial surface of a
wide variety of cells [Turano et al., 2002].

This observation suggests that PDI may

possess different physiological functions in the milieu of the cell surface and was thus
both the impetus and a primary focus of the experiments within this thesis.

1.3.2

Domain structure and catalytic activity
PDI possesses four thioredoxin (Trx) folds with an overall domain structure of

a-b-b'-a'-c. For the last ten years, solution NMR structures have been available for
isolated a and b domains of recombinant human PDI [Kemmink et al., 1996, Kemmink
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et al., 1997], a complete crystal structure of the yeast homologue of PDI has now been
determined [Tian et al., 2006] and has shed additional light on the structure-function
relationship of this enzyme. X-ray structures reveal that, as predicted, each of the a and a'
domains bear the structure of the canonical thioredoxin fold with a repeating (3-ot-(3 motif
of the sequence- (3apa|3aPPa. Active site thiols are found toward the N-terminus of the
second alpha helix in the a and a' domains arranged in a thioredoxin consensus sequence CXXC, capable of catalyzing thiol oxidation, reduction and isomerization reactions by
way of the redox active cysteines. In contrast, the thioredoxin modules of the b and b'
domains possess atypical structural features [Tian et al., 2006] and are catalytically
inactive [Kemmink et al., 1997].
Acquisition of the crystal structure also demonstrates that PDI has an overall ‘Ushaped’ structure in which a fold occurs between the b and b' domains such that the a and
a' domains and the enzyme active sites oppose one another separated by a cleft [Fig.
1.3.1] and thus lending credence to evidence of co-operative activity between the two
active sites [Sliskovic etal., 2005, Hawkins etal., 1991].
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Figure 1.3.1 Crystallographic structure of yeast PDI
Permission to use image acquired from corresponding author [Tian et al., 2006].

As stated, the a and a' domains both possess catalytically active vicinal thiols within
the general Cys-XX-Cys motif.

In eukaryotic sources the intervening residues are

glycine and histidine, the latter of which is reported to stabilize the thiolate anion of the
adjacent cysteine residue. It is thus attributed responsibility for the anomalously low Cys
pKa of 4.6 [Lambert et al., 1983] which is thought to confer redox activity to the active
site.
Studies on the role of the b and b ’ domains in protein function support a role in
substrate binding for which the b' domain is considered to be the primary binding site
[Klappa et al., 1998, Pirneskoski et al., 2004, Tian et al., 2006]. Structural studies draw
attention to the significant hydrophobic character along the interior of the U-shaped fold
within the b and b' domains. These patches appear to be contiguous with similar patches
in the a and a' domains are thought to provide an optimal surface to accommodate and
bind substrates [Tian et al., 2006]. Experimental studies further suggest that multiple
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domains (a, b' and a') contribute to its association with other proteins as a subunit of a
functional enzyme [Koivunen et al., 2005].
The c domain possesses both the KDEL-ER retention sequence and a low-affinity,
high-capacity Ca2+-binding site which is reported to affect neither its chaperone nor its
isomerase activity [Koivunen et al., 1999] and whose role in enzyme function is
unknown [Macer et al., 1988], but may be involved in interactions with other proteins or
peptides [Noiva et al., 1993, Klappa et al., 1998].

1.3.3

Redox dependence of PDI catalytic activity
As stated, PDI bears two active sites, one within each of the a and a' domains.

Studies on PDI redox properties show that the reduction potential of PDI active sites
(-175 mV) [Lundstrom et al., 1993] are more oxidizing than those of human thioredoxin
(-270 mV) [Aslund et al., 1997], but less oxidizing than those of the prokaryotic
homologue of PDI - Dsb (-89 mV) [Wunderlich et al., 1993] and that the redox status of
the active site is maintained by a redox buffer such as glutathione and its disulfide
[Walker et al., 1996]. This is an important property of PDI to be considered in assessing
its function at the surface of vascular cells.
PDI is capable of catalyzing reduction, oxidation and isomerization as shown in Fig.
1.3.2 depending upon the oxidation state of its active site thiols [Wilkinson et al., 2004].
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Redox-dependent activities of protein disulfide isomerase

Mechanistically, PDI is thought to initiate nucleophilic attack of a substrate via its
thiolate anion, forming a transient mixed disulfide. Reduced substrate is then released by
formation of the disulfide with the adjacent active-site thiol.
The redox state of PDI is generally maintained by the prevailing [GSH]/[GSSG]
of the compartment in which it is found [Raturi et a l, 2007, Hawkins et al., 1991], but
can also be reduced by thioredoxin reductase [Lundstrom et al., 1990] and perhaps by
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other enzymatic systems.

In the ER the [GSH]/[GSSG] is thought to be -3:1 thus

maintaining PDI a partially oxidized state and is further thought to be oxidized to it
disulfide form by its natural oxidizing agent - E rolp; a flavoenzyme E ro lp that produces
disulfide bonds for oxidative protein folding in the endoplasmic reticulum [Kulp et al.,
2006, Gross et al., 2004].

In contrast, cell surface PDI in the vasculature may be

maintained by both the cysteine and glutathione couples [Go et al., 2005] and also
possibly by a membrane-bound oxidoreductase system that reduces the active site thiols
via the transfer of intracellular reducing equivalents [Berridge et al., 2000, Essex et al.,
2004],
PDI active site thiols have also been shown to be oxidized by auto-oxidation
[Kozarova et al., 2007], reactive oxygen species such as H 2O 2 [Kim et al., 2000, Miersch et
al., 2007], lipid peroxidation products [Carbone et al., 2005] and of course, by oxidized
glutathione [Raturi et al., 2007].
Studies on the isomerization activity of PDI show that substitution of the Nterminal cysteines almost completely abrogates enzyme activity [Walker et al., 1996],
suggesting that the initial step in catalysis is blocked. Alternately, enzyme possessing
serine substituted for the C-terminal cysteine may maintain up to 50% of its isomerase
activity but show less than 5% of its oxidase activity [Walker et al., 1996]. This suggests
1) the C-terminal cysteine provides an escape mechanism that is not absolutely essential
and 2 ) both cysteines are required for oxidation likely by directly oxidizing substrate.
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1.3.4

PDI Denitrosation Activity
An interesting aspect of PDI function is its ability, like that of thioredoxin

[Stoyanovsky et al., 2005, Sengupta et al., 2007], to catalyze the reduction of nitrosated
thiols [Sliskovic et al., 2005].
Although both PDI and thioredoxin require a reduced active site to elicit
denitrosation, the NOx species released as the product of reaction differ between the two
enzymes. Recent characterization of the denitrosation activity of the individual enzymes
have shown that thioredoxin appears to release nitroxyl (NO ) as the product of its
reaction [Stoyanovsky et al., 2005], whereas PDI was shown to release authentic »NO
[Sliskovic et al., 2005].
Mechanistic studies on the catalysis of denitrosation by PDI further suggest that
catalytic denitrosation reactions are initiated by nucleophilic attack of the free thiolate ion
on the »NO moiety of the nitrosothiol resulting in transnitrosation of enzyme thiols,
formation of an enzyme nitroxyl disulfide intermediate and expulsion of nitric oxide
which leaves the active site in an oxidized state [Sliskovic et al., 2005] as shown in Fig
1.3.3. In an alternate possibility the radical disulfide formed in the a domain could either
donate or accept an electron from *NO yielding either 1) nitroxyl (NO ) whose formation
is highly unfavourable [Bartberger et al. 2002] or 2) nitrosonium (NO+) which could
presumably renitrosate formed thiols.

Neverltheless, the demonstation that PDI

denitrosation activity yields radical *NO is an important consideration when evaluating
the role of cell surface PDI and the downstream targets of liberated nitric oxide redox
congeners.
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Figure 1.3.3 Proposed catalytic mechanism for PDI-mediated denitrosation activity
Permission to use image acquired from corresponding author [Sliskovic et al., 2005].
1.3.5

PDI Chaperone Activity
In addition to its ability to assist in forming the native disulfide bonding patterns

in nascent proteins and in liberating »NO from nitrosothiols, PDI also possesses
chaperone activity which is independent of it catalytic activities. Notably, PDI mutants
with no isomerase activity retain full chaperone activity, which is thought to be
maintained by the peptide binding site of PDI [Wang et a l, 1998]. Thus, PDI interacts
with incompletely- or unfolded proteins which expose unstable hydrophobic stretches to
the aqueous environment, which would otherwise aggregate with similarly mis-folded
proteins, thus stabilizing them until refolding takes place. This activity appears to be
important in cell surface-localized PDI as well [Versteeg et al., 2007].
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1.3.6

Identified roles o f cell surface PDI
PDI has been found on the exofacial surface of a variety of cells including

NG108-15cells [Xiao et al., 1999], pancreatic exocrine cells [Yoshimori et al., 1990],
lymphoid cells [Tager et al., 1997, Park I et al., 2006, Barbouche et al., 2005], endothelial
cells [Hotchkiss et al., 1998], hepatocytes [Terada K ert al., 1995] and blood platelets
[Essex etal., 1995].
A number of roles for cell-surface PDI have been identified including
invasiveness of gliomas [Goplen
endothelial cells [Zhang

et al., 2006], transnitrosation of metallothionein in

et al., 2006], promotion of HIV entry into lymphocytes

[Fenouillet et al., 2001], regulation of leukocyte adhesion [Bennett et al., 2000] and in
redox switching of tissue factor [Ahamed et al., 2006].
It has further been demonstrated that cell surface PDI also plays a role in
catalyzing the transfer of NO from exogenous S-nitrosothiols to the intracellular space
[Zai et al., 1999]. These results were subsequently confirmed and extended by showing
that the uptake of NOx from extracellular NO nitrosothiols correlated to the levels of PDI
in HT1080 fibrosarcoma cells in which PDI had been over- and under-expressed.
Importantly, pre-treatment of the cells with lipophilic antioxidant - tocopherol inhibited
the uptake of NOx suggesting the accumulation of N 2O 3 in the membrane [Ramachandran
et al., 2001, Zai et al., 1999]. Studies have shown that incubation of cells with mM
concentrations of the lipophilic antioxidant - a-tocopherol, results in the accumulation of
mM concentrations within cellular membrane compartment [Jiang et al., 2000]. At this
concentration, tocopherol would likely act to quench potent oxidants such as N 2O 3 in the
membrane space.
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A similar role for cell surface PDI has now been demonstrated in platelets in
which it catalyzes not only the known pro-aggregatory, -secretory and -adhesive reactions
in platelets but also an anti-platelet denitrosation activity [Root et al., 2004, Bell et al.,
2007, Shah et al., 2007] and will be discussed further in the next section.
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1.4 Platelets
1.4.1

Introduction
Although the role of platelets in the arrest of bleeding was first noted in the late

1800’s [Bizzozero et al., 1882], interest in their haemostatic function proliferated only in
the mid-1950s. The study of platelets has since become a multi-pronged investigation
revealing the complex signaling pathways which govern the activation, adhesion,
secretion and morphological changes of platelets in both normal vascular response to
injury and in the etiology of thrombotic disorders.
Platelets are small, anucleate, cellular structures less than 1 pm in diameter,
derived from progenitor megakaryocytes via the process of thrombopoiesis. These cells
circulate in the vasculature as discoid cells, numbering ~ 300, 000 / pL for 8 - 1 0 days
before being transported to the spleen where they are dismantled via resident phagocytes.
The primary role of the platelet is in haemostasis, where the activation of platelets
by humoral effectors or exposure to subendothelial proteins results in the execution of an
elaborate array of signals culminating in morphological changes that promote adhesion to
sites of vascular injury. Tethered platelets secrete vasoconstrictors and protein clotting
factors to stem localized blood flow and provide materials that act as the scaffolding for
construction of the platelet plug.

Alternately, platelet dysfunction has been found to

contribute to various pathological conditions which manifest as aberrant adhesion of
platelets to the vessel wall, release of pro-inflammatory substances and thrombotic
disorders resulting in death. Expectedly, contributing factors to mechanisms of platelet
dysfunction have been the subject of intense research. This section will introduce the
basics of platelet aggregation focusing on the link between thrombin-induced stimulation
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of platelets and the role of thiol isomerases in aggregation. It will further discuss the
pathological consequences of hypercholesterolemia and oxidative stress in platelet
physiology.

1.4.2

Platelet structure and function
Although platelets were at one time considered to be mere artifacts formed during

collection, and although lacking certain aspects of their progenitor cell, they have since
been shown to possess specific internal architecture, an active metabolism and various
specialized functions.
Platelets have a unique structure defined as an open-canalicular system [Escolar
et a l, 1991], accessible to the surrounding aqueous environment which serves to increase
their overall surface area facilitating exchange of materials and discharge of internal
vesicles. Platelets contain a variety of intracellular, membrane-bound vesicles including
a granules and dense granules whose contents are released during platelet activation at
sites of vessel wall injury and thus play an important role in haemostasis and wound
repair, as well an inflammation and thrombogenicity [Harrison et al., 1993].
Upon receipt of the appropriate signal a series of signaling events trigger and
elicit drastic morphological changes, mediated by platelet contractile proteins including
actin [Fox et al., 2001] and thrombasthenin which convert the platelet from a discoid- to
a burr-like shape in which numerous extended pseudopods are apparent [Mattson et al.,
1985]. Morphological changes are accompanied by vesicular degranulation [Polasek et
al., 2004], display and activation of membrane receptors [Jurk et al., 2005], shedding of
platelet microparticles [Heijnen et al., 1999, et al., 2007] and metabolic changes [Wee
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et a l, 2006] which mediate vascular adhesion and platelet aggregation. Although these
functions are critical to normal haemostasis, pathological changes in the vasculature are
known to contribute to increased in vivo activation of platelets and shedding of prothrombotic particles [Martinez et al., 2005]. The net result is a tipping of the balance
between readiness and aggregation toward a pro-thrombogenic stance [Bigalke et al.,
2007, Cabeza et al., 2004] which favours adhesion to and infiltration of the vessel wall
and enhances interaction with other platelets.

1.4.3

Platelet agonists
Platelets are capable of responding to a variety of physiological agonists including

thrombin (and other proteases), collagen, adenosine diphosphate, thromboxane A 2,
arachidonic acid, cathepsin G [Selak et al., 1988], antibody-antigen complexes, Ca2+, as
well as non-physiological agonists including the calcium ionophore (A23187) [Geroge et
al., 1985], convulxin [Jandrot-Perruset et al., 1998] and latex particles [Miyamoto et al.,
1989].

In light of the fact that thrombin was throughout our studies, discussion of

agonist-induced activation of platelets will be restricted this protease.

1.4.4

Thrombin-induced signaling and aggregation
Thrombin is a 36 kDa serine protease formed from a 72 kDa pro-thrombin

zymogen following several reactions which occur upon interaction of membrane-bound
tissue factor with circulating Factor Xa and its cofactor Va [Pattersonet et al., 2001].
Proteolytically active thrombin subsequently acts to cleave between Arg 41 and Ser 42 of
protease-activated receptor 1 (PARI) or PAR4 in humans releasing a 6 aa peptide
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(SFLLRN) and exposing a new N-terminus [Coughlin et al., 2000]. This newly exposed
N-terminus exhibits intramolecular affinity for the exofacial body of the receptor and
upon binding triggering conformational changes that promote coupling with and
activation of G12/13, Gq, or Gi G-protein-coupled receptors (GPCR). GPCRs consequently
route a multitude of cellular signals that elicit shape change through phospholipase Cmediated increases in calcium flux [Hubbard et al., 2006] including integrin activation,
metabolic responses, and secretions [Coughline et al., 2000, Shankar et al., 2006] as
summarized in Figure 1.4.1.
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Figure 1.4.1

Signaling of thrombin-induced platelet aggregation - An Overview
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1.4.5

Reactive oxygen species in the vasculature
Vascular cells including leukocytes, endothelial cells and platelets produce a

variety of reactive oxygen species including superoxide (0 2* ) [Cerwinka et al., 2003],
hydrogen peroxide (H 2O 2) [Krotz et al., 2004], hydroxyl radical (*OH) [Caccese et al.,
2000] and hypochlorous acid (HOC1) [Stocker et al., 2004]. Although these species bear
a role in normal cell signaling and physiology, they can also cause oxidative damage to
proteins, lipids and nucleic acids when produced in deleterious quantities [Hawkins et
al., 2003] and thus contribute to the pathology of a variety of disease states including
diabetes [Flora et al., 2007, Ferroni et a l, 2004].
Superoxide is formed by the one-electron reduction of molecular oxygen by a
variety of NAD(P)H oxidase isoforms [Orient et al., 2007], xanthine oxidase [Vorbach,
et al., 2003], Complexes I, II and III of the mitochondrial electron transport chain [AdamVizi et al., 2005], during the uncoupling of NOS [Forstermann et al., 2006] and by
cytochrome P450 enzymes [Coon et al., 1992]. Although superoxide is not itself a
strong oxidant (E°=-0.160 V) [Wood et al., 1987]), it can contribute to the generation of
more potent oxidants such as hydrogen peroxide (via dismutation) [Cai et al., 2000] and
peroxynitrite (via radical-radical reaction with nitric oxide) [Huie et al., 1993].
In addition to its formation by the dismutation of superoxide, hydrogen peroxide
is also generated by a variety of peroxisomal oxidative enzymes during catalysis
[Kunduzova et al., 2002, Schrader et al., 2006]. In platelets especially, cyclooxygenases
and lipoxygenases are also considered be key sources ROS including hydrogen peroxide
[Miller et al., 2006].
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1.4.6

Role of superoxide and peroxide in platelets
Studies have demonstrated the production of superoxide by platelets and

progenitor megakaryocytes, corroborated by the presence of components of a functional
NAD(P)H oxidase [Seno, et al., 2001].
Subsequent efforts have further shown that NAD(P)H oxidase-derived superoxide
is generated in response to both thrombin and collagen agonists and plays a pivotal role
in platelet physiology regulating adhesion [Begonja et al., 2006] (via the allbp3 integrin)
[Begonja et al., 200, Gregg et al., 2004], aggregation [Chlopicki

et al., 2004] and

recruitment [Krotz et al., 2002].
Suggestively, platelets derived from T2D patients are reported not only to produce
increased quantities of H 2O2 [Leoncini et al., 1997] and superoxide [Dixon et al., 2005],
but also exhibit to hyperaggregability [Mandal et al., 1993]. This can be in part,
explained by observations that platelets treated with superoxide or peroxide exhibit
increased intracellular calcium flux [Schaeffer et al., 1999, Redondo et al., 2005].
Undoubtedly, there are additional redox-dependent mechanisms that contribute to
hyperaggregability observed under the conditions of diabetes and associated risk factors
for cardiovascular disease.

1.4.7

Integrin activation and aggregation
Integrin activation is believed to be a key event in the adhesion of platelets to

vascular and extra-vascular proteins such as fibrinogen, von Willebrand factor and
collagen thus contributing to aggregation. Integrin allb p 3 (the fibrinogen receptor) is
perhaps the best-studied integrin to date and is often referred to as the ‘canonical’
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integrin. Although the allb(33 integrin was initially thought to be entirely in the oxidized
state [Calvete et al., 1991], recent studies have shown that it bears not only free thiols
[Yan et al., 2000], but that disruption of disulfide bonds may be involved in conversion to
a high affinity state [Sun et al., 2002, Ruiz et al., 2001].
Activation of allb[33 is known to occur upon agonist-induced stimulation and
involves a conformational change from a low to high affinity state [Shimaoka et al.,
2002] via an inside-out signaling mechanism [Payrastre et al., 2000] initiated via Gprotein coupled receptors [Coughlin et al., 2000, Shankar

et al., 2006]. The allb p 3

integrin cytoplasmic domain is associated with a number of cytoskeletal proteins, adaptor
and signaling proteins, kinases and phosphatases [Ma et al., 2007].

These species

undoubtedly contribute to induction of structural changes in the extracellular region of
the heterodimer that convert it from a compact globular to an extended, ligand-binding
conformation (in what has been referred to as the ‘switchblade’ hypothesis) [Ma et al.,
2007]. Numerous studies have also suggested that platelet exofacial free thiols [Essex et
al., 2004b] and disulfide bond rearrangements [Yan et al., 2000] are intimately involved
in this process and contribute to sustained integrin ligation of both collagen [Essex et al.,
2004b] and fibrinogen [Lahav et al., 2002], ‘irreversible’ platelet aggregation, outside-in
signaling events [Payrastre et al., 2000] and perhaps to activation of the integrin itself
[Chen et al., 1992b]. It is here that PDI is thought to play a primary role in thrombininduced platelet aggregation.
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1.4.8

PDI-mediated aspects of platelet physiology and redox control
Early platelet investigations demonstrated that a variety of both membrane

penetrating and cell-impermeant thiol-modifying agents were capable of potently
inhibiting adhesion [Jocelyn et al., 1968] and aggregation [Aledort et al., 1968, McIntyre,
et al., 1977] of platelets. This work laid the ground for later studies that demonstrated the
presence of protein disulfide isomerase on the surface of platelets [Essex et al., 1995] and
spurred the investigation of exofacial thiol/disulfide-dependent processes in platelet
physiology.

In 1992 it was reported that a PDI activity capable of renaturing scrambled

RNase was observed in supernatants of activated platelets [Chen et al., 1992b] and later
that enzymatically active PDI could be found on the surface of platelets [Essex, et al.,
1995],

This observation undoubtedly led to evidence of a role for PDI in platelet

aggregation and secretion [Essex et al., 1999].
Although it is known that there are at least 17 thiol isomerases in the ER
[Maattanen et al., 2006], evidence for roles in platelet function have only been provided
for PDI [Root et al., 2004], Erp5 [Jordan et al., 2005] and the allb|33 integrin receptor
[O'Neill et al., 2000]
As stated prior, PDI is a redox-sensitive, vicinal thiol-dependent enzyme bearing
reductase, oxidase and isomerase (as well as chaperone and denitrosation) activities
depending upon the prevailing redox environment. Redox balance in the vasculature is
maintained primarily by several thiol-based redox couples including the GSH/GSSG,
Cys/Cys2 and couples that are generally believed to exist at low pM levels and vary from
ratios of -13:1 under normal conditions to -1:1 under conditions of oxidative stress [Go
et al., 2005]. Oxidative stress also manifests as an imbalance between the production of
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ROS, RNS and their neutralization by antioxidants and antioxidant enzymes. The redox
environment established by the interplay between these various species exerts sway over
vascular physiology by altering the functional activity of redox sensitive proteins. Thus,
the central role of platelet surface thiols in aggregation and secretion events have made
readily apparent the redox dependence of platelet physiology, noted by some
investigators [Essex et al., 2003, Raturi et al., 2007]
Notably it has been shown that platelet aggregation is potentiated by the addition
of low (|J.M) quantities of GSH which appears to introduce free thiols in to the p 3 subunit
of the integrin cdlbp 3 subunit [Essex et al.,2003], previously thought to possess no free
thiols.

Although this study confirms a role for PDI by showing inhibition by PDI

antagonists, it however does not directly assess the redox status of PDI or its potential
involvement in directly catalyzing integrin reduction. This study further investigated the
functional role and possible interactions of PDI and the fibrinogen receptor - allb(33
integrin [Essex et al., 2005] using a peptide reported to directly activate the integrin by
inducing a conformational change [Derrick et al., 1997] ostensibly in the absence of any
redox change. Interestingly, aggregation stimulated in this manner could be inhibited by
thiol-blocking agents, but not by inhibitors of PDI, leading authors to conclude that PDI
may be acting upstream of the fibrinogen receptor and supports earlier evidence which
showed that inhibition of PDI was coincident with diminished ‘activated’ allb p 3 as
measured PAC antibody binding (which recognizes only the activated integrin) [Chen et
a l, 1992b],
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1.4.9

Platelet-surface, PDI-mediated denitrosation activity
It is generally recognized that PDI (and possible other thiol-isomerases [Jordan et

al., 2005, Robinson et al., 2006]) mediate integrin-mediated adhesion, events in platelet
adhesion [Lahav et al., 2003.], secretion [Essex et a l, 1999] and aggregation [Lahav et
al., 2000, Lahav et al., 2002, Lahav et al., 2003]
Another equally important aspect of platelet physiology mediated by PDI is
brought to light by a recent in vitro study on the denitrosation activity of PDI [Sliskovic,
et al., 2005]. It was found that isolated PDI was capable of liberating authentic nitric
oxide from S-nitrosoglutathione in a mechanism which invoked a nitroxyl-disulfide
intermediate and co-operative enzyme activity, but required a reduced active site in order
to effectively catalyze the reaction. The ability of •NO to interact with platelet guanylate
cyclase has been recognized for some time [Radomski et al., 1987] thus resulting in the
generation of cGMP which is known to regulate platelet activation [Doni et al., 1991,
Mellion et al., 1983] and adhesion [Radomski et al., 1987]. It was recognized early that
S-nitrosothiols were also capable of activating guanylate cyclase in platelets however the
solution stability of various nitrosothiols did not correlate with their anti-platelet activity,
thus leading authors to believe that platelets must possess some means of active
metabolism [Mathews et al., 1993].

Subsequent studies demonstrated the ability of

platelet-surface PDI to metabolize low-molecular weight S-nitrosothiols and inhibit
platelet aggregation in a guanylate cyclase-dependent fashion [Root et al., 2005, Bell et
al., 2007].
It is apparent that cell surface PDI plays a critical role in both platelet aggregation
events and anti-platelet denitrosation activity however, the influence of PDI redox status
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on these events remains largely uncharacterized. Given the coincidence of lipid disorders
with oxidative stress [Stokes

et al., 2007, Sanguigni

et al., 2002] and platelet

hyperaggregability and in various pathological milieu [Watanabe et al., 1998, Korporaal
et al., 2006] including T2D [Manda et al., 1993, Ferroni et al., 2004] this is presumably a
necessary task.
Work investigating the role of redox environment in pro-atherogenic events and
monocytes adhesion, measured the major thiol-disulfide redox couples in human plasma
and calculated ranges of redox potential (Eh) of -120 to -20 mV for the Cys/Cys 2 couple
and -150 to -50 mV for the GSH/GSSG couple [Go et al., 2005].

Suggestively,

increasing oxidizing environment was associated with increasing adhesion of monocytes
to endothelial cells. In light of these studies, the obvious question is how pathological
changes in redox environment contribute to platelet aggregation and inhibition events
mediated by PDI.
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PART II

CHAPTER 21

ANTI-OXIDANT AND ANTI-PLATELET EFFECTS OF ROSUVASTATIN IN A
HAMSTER MODEL OF PRE-DIABETES

Published as original research as Miersch et al. 2007.
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2.1 Introduction
Elevated reactive oxygen species (ROS) production in diabetes-related cardiovascular
disease has been recognized in both diabetic humans [Spitale et al., 2002] and animal
models of diabetes [Sonta et al., 2004]. ROS have been shown to alter platelet physiology
in a variety of ways [Gregg et al., 2004, Redondo et al., 2005, Walsh et al., 2004,
Chlopicki et al., 2004], thus promoting hyperaggregability. Thrombotic complications in
diabetes remain a leading cause of mortality [Beckman et al., 2002], thus warranting the
investigation and adoption of therapeutic strategies that mitigate this enhanced potential
for thrombogenesis observed in Type II diabetes (T2DM) [Ferroni etal., 2004].
We have recently made the novel and interesting observation that platelets
derived from human Type II diabetics display both elevated NADPH oxidase (N O X )dependent ROS production and a concomitant decrease in platelet-mediated liberation of
nitric oxide from low molecular weight S-nitrosothiols (termed denitrosation) [Miersch,
et a l, manuscript in preparation]. Indeed, we have shown that healthy human platelets
treated with exogenous ROS exhibit a similar loss in ability to metabolize S-nitrosothiols,
as well as an enhanced potential for aggregation. Central to both of these events is the
enzyme protein disulfide isomerase. This enzyme is known to localize to the platelet
surface (psPDI) where it is catalytically active and responsible for both proaggregatory
disulfide exchange reactions [Lahav et al., 2000, Lahav et al., 2002, Lahav et al., 2003]
and antiaggregatory liberation of nitric oxide from low molecular weight S-nitrosothiols
[R ootetal., 2004].
We have thus attributed the observed loss in platelet metabolism of S-nitrosothiols
to the oxidation of psPDI active-site thiols by increased oxidant load and have sought
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Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase

(HMG-CoA reductase) have shown efficacy in lowering circulating lipid levels and in
reducing cardiovascular mortality [Maron et al., 2000]. However, it has recently come to
light that this class of drugs, referred to as statins, may have additional vasculoprotective
benefits that are not derived directly from cholesterol lowering. This assertion stems from
the observations that lower serum cholesterol levels positively correlate with improved
risk of coronary vascular events, but not with risk of stroke [Collins et a l, 2004].
Alternatively, statin treatment has been shown to reduce not only coronary events but
also ischemic stroke [Amarenco et al., 2004].
Investigation of the “pleiotropic effects” of statins is based, in part, on the
hypothesis that they bear antioxidant properties and are capable of inhibiting the
production of reactive oxygen species from enzyme complexes such as NAD(P)H
oxidase.
Other “vascular NOX isozymes” found in endothelial and smooth muscle cells
have been implicated in the promotion of atherogenesis [Laufs et al., 2005] and in animal
models of diabetes [Sonta et al., 2004]. In light of the potential role of NOX in diabetes
and cardiovascular disease, we hypothesized that rosuvastatin would attenuate NOX
activity and perhaps normalize platelet activity by protecting psPDI from excess ROS,
thus providing the impetus for our study of the potential antithrombotic and
antiatherogenic benefits in the vasculature.
We employed the Syrian Golden hamster, which becomes metabolically disturbed
upon fructose feeding for 7 days such that it develops hyperinsulinemia and
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hyperlipidemia in the absence of overt hyperglycemia, thus representing a viable model
of the prediabetic, insulin-resistant state [Taghibiglou et al., 2002]. We observed that
platelets and aortic endothelial cells (AEC) from fructose-fed (FF) animals exhibit
enhanced production of NOX-dependent ROS. Further, platelets showed diminished
psPDI-denitrosation activity and hyperaggregability in comparison to non-fructose-fed
(NFF) control animals. These observations could be mimicked by treatment of platelets
from NFF animals with exogenous ROS.
As expected, rosuvastatin exerts antioxidant properties in both endothelial cells
and platelets derived from fructose-fed animals. Most importantly, we conclude that
rosuvastatin

shows

efficacy

in

reversing

ROS-mediated

inhibition

of platelet

denitrosation activity and hyperaggregability.

2.2

Materials and equipment

2.2.1

Materials
Ellman's reagent (DTNB), glutathione (GSH), sodium nitrite, trisodium citrate

dihydrate, citric acid monohydrate, dextrose, apyrase, sodium chloride (NaCl), dibasic
sodium phosphate (Na2HP 0 4 ), dibasic potassium phosphate (KH 2PO 4), potassium
chloride (KC1), sodium bicarbonate (NaHCOa), magnesium chloride hexahydrate
(MgCl2-6 H 20), calcium chloride hexahydrate (CaCl2-6 H 20 ), fructose, BSA, F12K media,
endothelial cell growth supplement (ECGS), porcine heparin, xanthine, xanthine oxidase,
thrombin, diphenyleneiodonium chloride (DPI), and mevalonate were purchased from
Sigma-Aldrich Canada (Oakville, ON). Isofluorane was purchased from the Leamington
Animal Clinic (Leamington, ON). Medical grade oxygen was purchased from BOC
Gases

(Windsor,

ON).

10-Acetyl-3,7-dihydroxyphenoxazine

(Amplex

red)

and
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horseradish peroxidase (HRP) were obtained from Molecular Probes (Eugene, OR).
Mn(III)tetrakis(l-methyl-4-pyridyl)porphyrin

pentachloride

(Mn(III)TMPyP)

was

obtained from Cedarlane Labs (Hornby, Ontario). Matrigel was purchased from BD
Biosciences (Mississauga, ON). Rosuvastatin was provided by AstraZeneca (UK).

2.2.2

Equipment

Tech3 Isoflurane Key-Fill Vaporizer, Harvard Appartus, Holliston, MA
EBA 12 Desktop Centrifuge, Fisher Sceintific, Mississauga, ON
Popper 3” Curved Feeding Needles, Fisher Scientific, Mississauga, ON
Agilent 8453 UV-VIS Spectrophotometer; Agilent Technologies Canada Inc.,
Mississauga, ON
Apollo 4000 Free Radical Analyzer; World Precision Instruments USA, Sarasota, FL
Biotek Ex808 UV/Vis Plate Reader, Biotek Instruments, Inc., Winooski, VT
Haemocytometer; Reichert Co, Buffalo, NY
ISO-NOPF200 200 jxM Flex NO Sensor; World Precision Instruments USA, Sarasota, FL
Jouan CR3i Centrifuge, Jouan Inc., Winchester, Virgnia
Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON
Microtitre 96-well Solid Plate, Thermo Electron Corp., Canada, Burlington, ON
NUAIRE Biological Safety Cabinet Class II Type A/B3; Thermo Electron Corp. Canada,
Burlington, ON
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON
Tissue Culture Flask, T-75, Sardstedt Inc., Montreal, PQ
Wallac 1420 Victor3 Fluorescent Plate Reader, Perkin Elmer, Woodbridge, ON
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2.3

Methods

2.3.1

Synthesis of GSNO
S-nitrosoglutathione was prepared as previously described [Root et al., 2004],

Briefly, GSH [free thiol] content was determined with DTNB [Riddles et al., 1983].
Acidified N aN 0 2 was added to GSH solution in a stoichiometric amount and reacted for
30 min at 4°C. The final pH of the solution was adjusted to 7.4. GSNO was further
recrystallized by the slow addition of ice-cold acetone and resuspended in the appropriate
buffer.

2.3.2

Animal care
All experimental procedures performed on the Syrian hamsters were approved by

the University of Windsor Research Ethics and Animal Care Committees and in
accordance with the CCAC Guide to the Care and Use o f Experimental Animals. Syrian
Golden hamsters were obtained from Charles River Canada (Montreal, PQ). Animals
were housed one per cage and given free access to food and water. Animals were divided
into two groups: water feeding (control) and 10% fructose feeding. After 2 weeks of
fructose feeding, animals were subdivided into four groups as follows: control with no
rosuvastatin, control with 10 mg/kg rosuvastatin, fructose-fed with no rosuvastatin, and
fructose-fed with 10 mg/kg rosuvastatin. Rosuvastatin was prepared in water and
administered daily to animals by oral gavage for 7 days.
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2.3.3

Determination o f rosuvastatin pharmacokinetics
Plasma concentration (Cp) of rosuvastatin was determined by collecting 200-jiL

samples of blood from non-fructose-fed animals only at 1-h intervals post-oral gavage for
24 h. These samples were analyzed for their rosuvastatin content by reverse-phase HPLC
with electrospray ionization tandem mass spectrometric detection at AstraZeneca
(Wilmington, DE). Primary cultures of endothelial cell explants were cultivated in the
presence of a range of rosuvastatin concentrations comparable to the Cp max values in
order to simulate in vivo exposure to the drug.

2.3.4

Isolation of whole blood and tissues from hamsters
Hamsters were anesthetized using isoflurane delivered with 1% oxygen through

an isoflurane vaporizer in an induction chamber and then transferred to a heating pad in
the supine position and fitted with a rodent circuit. The thorax and abdomen were then
rinsed with 70% isopropanol and hamsters were euthanized by exsanguination. Blood
was removed from the inferior vena cava using a 25 3/8 gauge syringe needle and mixed
with ACD in a 9:1 ratio. The heart was then removed by severing the aorta just below the
iliac bifurcation. It was flushed with PBS and an approximately 3-mm section of aorta
excised from just above the left ventricle. This was placed in F12K media warmed to
37°C.

2.3.5

Isolation and primary culture o f aortic endothelial cells
Aortic segments were cleaned of remaining adventitial tissue, cut into 2 x 2-mm

squares, and placed endothelium down on Matrigel-coated petri dishes in a similar

81

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

manner to previously described methods [Suh et al., 1999]. Cultivation in F12K media at
37 °C in 5% carbon dioxide, with or without rosuvastatin, resulted in growth of
endothelial cells outward from the aortic square which continued to proliferate after
removal of the fragment. Cells were grown to 85% confluence and used within three
passages. Adherent endothelial cells were washed twice with ice-cold PBS, pH 7.4, then
gently scraped off using a rubber cell scraper and collected for experimentation by
centrifugation at 100 g.

2.3.6

Isolation and preparation of platelets from whole blood
Washed Syrian hamster platelets were obtained by centrifuging whole blood for

15 min at 190 g at 37°C, to yield platelet-rich plasma (PRP). Platelets were obtained from
PRP and washed three times in Tyrodes-albumin solution by successive rounds of
centrifugation for 15 min at 900 g and 37°C. The first wash was supplemented with
2 U/mL heparin and 1 U/mL apyrase, the second with 1 U/mL apyrase and the third wash
contained Tyrodes-albumin solution only without heparin or apyrase. Platelet count was
performed using a hemocytometer. Suspensions of washed Syrian hamster platelets were
kept in the incubator at 37°C and used within 4 h of isolation.

2.3.7

Analysis of platelet aggregation
Aggregations were performed in triplicate and monitored spectrophotometrically

as the rate of turbidity clearance at 630 nm following initiation of aggregation by the
addition of 0.5 U thrombin. This was the amount of thrombin determined by titration to
yield maximal rates of initial aggregation. Reactions were followed for 15 min at 37°C
and initial rates of aggregation compared to a blank prepared without thrombin.

82

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2.3.8

Analysis of platelet denitrosation
An aliquot of platelet suspension was added to a stirred cuvette containing

100 mM phosphate buffer, pH 7.2, with 1 mM EDTA and 100 pM GSNO in the presence
or absence of 50 pM of the cell-permeant superoxide dismutase mimetic, Mn(III)TMPyP.
Prior studies have shown that platelet-mediated consumption of GSNO can be blocked by
anti-PDI antibodies [Root et al., 2005] and although the [GSNO] used is 1-2 orders of
magnitude larger than found physiologically, this is ~2 times the Km determined for PDI
in in vitro studies [Sliskovic et al., 2006].

Evolution of nitric oxide was monitored

amperometrically using a Clark-type electrode (ISO-NOP, World Precision Instruments,
Sarasota, FL) interfaced with the Apollo 400 free radical analyzer (WPI, Sarasota, FL).
Signal was measured following addition of platelets as the change in current and [NO]
released interpolated from a standard curve. Platelet denitrosation activity was assessed
by monitoring the platelet-mediated release of •NO from a solution of 100 pM GSNO.

2.3.9

Determination of cellular NAD(P)H oxidase-derived ROS
Cells were split into equal portions and ROS measured in the presence and

absence of 40 pM of the flavoprotein inhibitor, diphenyleneiodonium [O'Donnell et al.,
1993] using 15 pM 10-acetyl-3,7-dihydroxyphenoxazine and 1 U/mL horseradish
peroxidase as a reporter system for hydrogen peroxide (H 2O2) and ROS which ultimately
form peroxide [Zhou et al., 1997]. NOX generates superoxide, which is rapidly dismuted
to hydrogen peroxide [Cai et al., 2005]. Fluorescence in the assay is generated through
oxidation of the substrate to the highly fluorescent resorufin by H 2O 2 in a horseradishperoxidase (HRP) -coupled reaction. Signal was obtained on a Spectramax Gemini XS
fluorescent

microplate

reader

(Molecular

Devices,

Sunnyvale,

CA)

using
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excitation/emission of 544/590 nm over 60 min at 37°C. DPI-inhibitable ROS-dependent
signal was calculated by the subtraction of total ROS minus ROS generated in the
presence of DPI, thus yielding the contribution of ROS derived from NOX.

2.3.10 Superoxide treatment of ex vivo platelets
Platelets were isolated as indicated and treated with a range of xanthine
concentrations and 1.5 mU/mL xanthine oxidase or xanthine alone for 30 min. The
reaction proceeded until completion (-3 0 min as confirmed by Amplex assay) and 108
platelets were suspended for use in aggregation and denitrosation experiments

2.3.11 Statistical analysis
Error bars represent standard deviation of the mean. Statistical analysis was
performed using ANOVA with readings deemed to be significant at the 95% confidence
interval and determined by pairwise comparison using Tukey's post hoc test.
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2.4 Results
2.4.1

Pharmacokinetics
A time-course of Cp for rosuvastatin revealed that a maximum of about 20 nM

was reached at 4-6 h following oral gavage and increased to ~30 nM at 24-h, potentially
due to re-ingestion of drug by coprophagia (Fig 2.1).

2.4.2

Platelet generation of reactive oxygen species
Upon fructose feeding, platelet ROS generation increased by ~ 1.5-fold (Fig. 2.2)

in comparison to controls.

Daily administration of 10 mg/kg of rosuvastatin to FF

hamsters for one week normalized production of ROS to levels similar to that of NFF
control animal levels.

Rosuvastatin treatment did not affect the ROS production of

platelets derived from NFF animals in a statistically significant manner.

2.4.3

Platelet surface PDI denitrosation activity

psPDI •NO-releasing activity was - 45 % lower in platelets from FF hamsters when
compared to those from NFF hamsters (Fig. 2.3).

psPDI NO-releasing activity of FF

animals was restored almost to control levels by rosuvastatin. Surprisingly, rosuvastatin
administration to NFF hamsters decreased platelet-mediated denitrosation by -15% and
may reflect the role of hydrophobic interactions in PDI-platelet surface binding.
Importantly, platelet denitrosation was measured in the presence of the superoxide
dismutase mimetic, Mn(III)TMPyP. Comparison of the results ± superoxide dismutase
(SOD) mimetic show little difference in denitrosation activity, suggesting that the
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observed loss in denitrosation activity is not simply due to scavenging of liberated »NO
by elevated levels of superoxide, but to a diminished capacity to metabolize nitrosothiol.
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Figure 2.1

Monitoring pharmacokinetics of rosuvastatin in Syrian hamsters

Rosuvastatin concentrations in plasma were determined by taking 200 pL of blood at
time intervals over 24 hours from the initial drug administration. Plasma concentrations
of rosuvastatin were analyzed by reverse-phase HPLC with electrospray ionization
tandem mass spectrometric detection.
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Monitoring platelet
rosuvastatin fed Syrian hamsters

NFF+R

FF

ROS-generating

FF+R

activity

in

fructose

and

Platelets from both control and fructose fed hamsters, with and without 10 mg/kg of
rosuvastatin, were collected and prepared as described in Materials and Methods. DPIinhibitable ROS production was monitored in the presence of 15 pM 10-acetyl-3,7dihydroxyphenoxazine (Amplex Red) and 1 U/mL horseradish peroxidase.

The

formation of resorufin, indicative of reactive oxygen species production, was monitored
as the increase in fluorescence at 590 nm Data shown represent percent difference in
DPI-inhibitable ROS with respect to control, with n=13 study samples taken from 13
animals for each group of NFF and FF, with and without drug, run in triplicate. P<0.05, *
with respect to NFF control, ** with respect to FF untreated with drug.
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Figure 2.3
PDI denitrosation activity o f platelets from fructose fed and non
fructose fed Syrian hamsters
Platelets from both control and fructose fed hamsters, with and without lOmg/kg of
rosuvastatin, were collected and prepared as described in Materials and Methods. PDI
denitrosation activity was monitored amperometrically immediately following injection
of the platelet suspension in to a solution of 100 |iM GSNO in the absence (B) or
presence of 50 pM Mn(III)TMPyP (A). Data shown represent the percent difference in
absolute amounts of *NO released per 108 platelets, for n=6 study samples taken from 6
animals for each group of NFF and FF, with and without drug, run in triplicate. P<0.05,
* with respect to control, ** with respect to FF untreated with drug. Platelets injected as
blank into solution in the absence of GSNO and buffer injected into GSNO exhibited no
measurable evolution of »NO.
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2.4.4

Platelet aggregation
Representative examples of the aggregation profiles are shown in Fig. 2.4 and

compiled aggregation data is presented in the inset (n=13, per group). As expected, the
initial rates of thrombin-induced aggregation in FF animals were ~ 1.5-fold larger than
controls (inset). Rosuvastatin decreased the initial rates of aggregation in NFF platelets
by ~20%.

In the case of FF animals receiving rosuvastatin, the initial rates of

aggregation normalized returning to near those observed for NFF hamsters receiving
rosuvastatin.

2.4.5

Effect of fructose feeding on GSNO inhibition of platelet aggregation
To assess the implications of lost denitrosation activity, we further monitored the

ability of GSNO to inhibit platelet aggregation at time points prior to and following
commencement of fructose feeding. Results indicate a progressively diminished ability of
GSNO to inhibit thrombin-induced aggregation of washed platelets with the duration of
fructose feeding. Figs. 2.5A and B show representative aggregation plots in the absence
(o) or presence (•) of 12.5 pM GSNO compared to unstimulated platelets (▼) at 0 and 2
weeks of fructose feeding. Observations are summarized as percent inhibition of initial
rates of with GNSO in Fig. 2.5C and reveal a -15% loss in inhibition at the second week.
Treatment of platelets from NFF animals with increasing amounts of X/XO show a
similar decline, up to -20% inhibition of platelet aggregation induced by GSNO (Fig.
2.5D) at 10 pM xanthine, suggesting that the loss of GSNO anti-platelet effects with
fructose feeding may be due to ROS-induced changes in PDI-mediated liberation of *NO.
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Figure 2.4
Effects of fructose feeding and rosuvastatin administration on
aggregation rates of Syrian hamster platelets
Platelets from four study groups of hamsters were collected and prepared as outlined in
Materials and Methods. Aggregation of platelets in Tyrodes-albumin solution (108) was
monitored at 630 nm after stimulation with 0.5 U/mL thrombin over a 10-minute time
period.

Representative traces are shown for platelet aggregation profiles from NFF

animals ( • ) , NFF animals treated with lOmg/kg rosuvastatin (V), FF animals (■ ) and FF
animals treated with lOmg/kg rosuvastatin (0). Unstimulated platelets ( A) are shown as
blank. Inset data shown represent percent difference in aggregation rates with respect to
control. n=13 study samples taken from 13 animals for each group of NFF and FF, with
and without drug, run in triplicate, P<0.05, * with respect to thrombin-stimulated NFF
control, and ** with respect to thrombin-stimulated FF hamster platelets.
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Effect of fructose feeding on GSNO inhibition of platelet aggregation

Platelets from hamsters were collected and prepared as outlined under Materials and
Methods at 0, 1, and 2 weeks of fructose feeding. Aggregation of platelets in Tyrodesalbumin solution was monitored at 630 nm after stimulation with 0.5 U/mL thrombin in
the presence or absence of 12.5 pM GSNO over a 10-min time period. Representative
traces are shown for platelet aggregation profiles from NFF animals in the presence (• )
and absence (o) of the indicated [GSNO]. Unstimulated platelets (▼) are shown as blank.
Percentage inhibition of aggregation was calculated as the ratio of the GSNO-inhibited to
uninhibited initial rate of aggregation and summarized in panel C at Weeks 0, 1, and 2. n
= 6 study samples taken at each time point and run in triplicate, p < 0.05, * with respect
to thrombin-stimulated NFF control. Similarly, platelets isolated from NFF-fed animals
were suspended in Tyrodes-albumin solution and exposed to a transient (30 min) flux of
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superoxide generated from 0 to 10 pM xanthine and 1.5 mU/mL xanthine oxidase,
verified to be complete within the allotted time by the Amplex assay. Aggregation of
platelets was then monitored at 630 nm after stimulation with 0.5 U/mL thrombin in the
presence or absence of 12.5 pM GSNO over a 10-min time period. Percent inhibition of
aggregation was calculated the same as above.
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2.4.6

The effects of X/XO-generated superoxide on NFF platelet function
The question arises as to whether the observed attenuation of the ‘NO-releasing

activity of psPDI and potentiation of the initial rates of aggregation could be the result of
increased ROS production observed in FF hamsters.

In order to test this hypothesis,

platelets isolated from control (NFF) hamsters were exposed to a combination of X and
XO.

Xanthine oxidase is known to generate O2*' and H 2O 2 through the enzymatic

transfer of electrons from xanthine to molecular oxygen [Vorbach et al., 2003] and
subsequent spontaneous dismutation of O 2*' to H 2O 2. In these experiments, generation of
ROS was controlled to ensure completion of the reaction within 30 min as assessed by
the Amplex assay.

The platelets were then probed for psPDI denitrosation activity and

thrombin-induced aggregation in vitro.

2.4.7

Effect of ROS on psPDI denitrosation activity from NFF animals
Platelets from NFF animals were treated with X and XO to mimic the effects of

excess vascular ROS derived from superoxide and then assessed for psPDI denitrosation
activity. The initial rate of psPDI-catalyzed GSNO denitrosation was measured as the
current evolved from a «NO-specific electrode (Fig 2.6) in a solution of buffered GSNO
into which a suspension of ROS-treated platelets from NFF animals was injected.
Results revealed dose-dependent inhibition following treatment with

increasing

concentrations of X in the presence of XO versus both controls with X (in the absence of
XO) and in the absence of X. It was observed that pre-treatment of platelet from NFF
animals with ROS generated from 25 pM X and 1.5 mU/mL XO resulted in 60 ± 11.2%
inhibition of denitrosation activity.
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Notably, ROS generation from the X/XO system was verified to have ceased prior
to assessment of denitrosation. Catalytically-formed superoxide can react with liberated
•NO during denitrosation experiments, thus appearing to inhibit denitrosation. Thus, this
was a necessary control to show that diminished denitrosation activity was not due
merely to consumption of released *NO by reaction with platelet superoxide, but instead
due to a loss in the enzymatic liberation of *NO from S-nitrosoglutathione. Given that
platelets from NFF animals produce normal levels of ROS, but displayed inhibition of
denitrosation activity upon treatment with exogenous ROS, this confirms the loss of
psPDI-mediated activity.
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Figure 2.6
Effect o f transient platelet exposure to superoxide on psPDI
denitrosation activity
Washed platelets were obtained from NFF hamsters by centrifugation and then exposed
to a transient (30 min) flux of superoxide generated from 25 pM xanthine and 1.5
mU/mL xanthine oxidase, verified to be complete by Amplex assay before assessment of
the denitrosation activity. Release of «NO was measured amperometrically following
injection of treated platelets into a stirred cuvette containing 1 mM EDTA and 100 pM
GSNO. Data shown represent the absolute amount of *NO released per minute for each of
n = 4 study samples with standard deviation and indicate an IC 50 of -25 pM xanthine.
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2.4.8

The effects of ROS on NFF platelet aggregation
The initial rates of thrombin-induced aggregation of NFF animal platelets with

( # ,) or without (O,) 25 pM xanthine exposure (30 min) were nearly identical (-0.022
± -0.002 /min) as shown in Fig 2.7. Upon exposure to 25 pM X plus 1.5 mU/mL XO (30
min) the initial rates increased by ~1.4-fold (-0.032 + -0 .0 0 3 /min) (A , Fig. 5B) versus
those treated with X alone ( • ) . Unstimulated platelets are shown as control (V).

2.4.9

NOX activity in 1° culture of hamster AEC
Recent evidence points also to the constitutive expression of NOX in endothelial

cells resulting in the generation of low levels of superoxide [Li et a l, 2004]. Elevations
in NOX activity have been observed in the pathophysiology of vascular diseases
including diabetes [Beckman et al., 2002], hypertension [Paravicini et al., 2004] and
atherosclerosis [Rueckschloss et al., 2003, Laufs et al., 2005].

In these series of

experiments, aortic endothelial cell explants taken from NFF and FF animals were
exposed to 0 to 100 nM concentrations of rosuvastatin in culture (Fig 2.8).

The FF

group had -1.6 fold larger NOX activity than NFF. The exposure of the NFF group to
increasing concentrations of rosuvastatin had no statistically significant effect on the
basal NOX activity. However, elevated NOX activity of endothelial cells derived from
FF animals decreased in a rosuvastatin-dose dependent manner and was statistically
identical to the basal NFF-NOX activity in the presence of 50 nM rosuvastatin. This is
very significant as 50 nM is in range of the in vivo Cp (-30 nM) of the drug determined in
this study.

Further, in the presence of 200 pM mevalonate, the anti-oxidant effects of
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100 nM rosuvastatin were partially lost suggesting that restoration of isoprenoid
biosynthesis was associated with restoration of NOX function.
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aggregation

Effect of transient platelet exposure to superoxide on platelet

Washed platelets were obtained from NFF hamsters by centrifugation and then exposed
to a transient (30 minute) flux of superoxide generated from 25 jiM xanthine and 1.5
mU/mL xanthine oxidase. Platelets (108) were suspended in Tyrodes-albumin buffer in
triplicate and aggregation initiated by the addition of 0.5 U/mL thrombin. Traces are
representative of the initial aggregation in triplicate run in triplicate from n = 4
experiments and show that platelets treated with X/XO ( T ) exhibit an approximately 1.4fold increase in the initial rates of aggregation versus either untreated platelets (o) or
platelets treated with xanthine alone (• ) all compared to unstimulated platelets (y). p <
0.05, * with respect to thrombin-stimulated control treated with 25 pM xanthine alone.
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Effect of varying rosuvastatin on primary hamster AEC

Hamster aortas were collected as indicated from FF and NFF hamsters. Primary AEC
were cultivated until 85% confluent in the presence of varying levels of drug for one
week at which time they were harvested for measurement of DPI-inhibitable reactive
oxygen species.

Data shown represent the % difference in DPI-inhibitable ROS

produced in one hour as measured by Amplex fluorescence emission at 590 nm. n = 6
study samples derived from 6 animals for each group of NFF and FF, with and without
drug and run in triplicate. P <0.05 * with respect to NFF controls without drug and **
with respect to FF without drug and *** with respect to FF treated with 100 nM
rosuvastatin.
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2.5 Discussion
The present study was initiated by our observations that both in humans with
T2DM and in an animal model of pre-diabetic insulin resistance, elevated platelet
production of ROS is observed concomitantly with a decrease in psPDI denitrosation
activity and enhanced aggregatory potential. Studies within our lab suggest that elevated
vascular ROS oxidize active-site thiols of psPDI, thus contributing to both inhibition of
the anti-aggregatory nitric oxide liberating activity and an increased potential for
aggregation. The hypothetical mechanism of ROS-mediated inhibition of psPDI RSNOdenitrosation activity is thought to be as follows: ROS is produced by enzymes such as
NOX or other ROS-producing enzymes and is rapidly converted to H 2O 2 by extracellular
superoxide dismutase (SOD) or by spontaneous dismutation.

H 2O2 readily oxidizes

vicinal dithiols [Conway et a l, 2002, Kim et al., 2000], such as those found at the active
site of PDI, thus inactivating the RSNO-denitrosation activity of PDI and contributing to
enhanced potential for aggregation through provision of oxidative equivalents.
Bolstering this hypothesis is the recent report indicating that psPDI and NOX are in close
spatial contact in the platelet PM [Janiszewski et al., 2004],
Another crucial piece of evidence supporting our hypothesis is our recent
demonstration [Root et al., 2004] that the RSNO-denitrosation activity of psPDI inhibits
platelet aggregation by two routes: first, PDI denitrosates RSNOs, releasing *NO that
attenuates platelet activation via the guanylate cyclase/G-kinase route; secondly, RSNOs
are denitrosated at the same PDI-active site that catalyses the disulphide bond formation
between integrins and their ligands [Lahav et al., 2000, Lahav et al., 2002, Lahav et al.,
2003], thereby attenuating irreversible aggregation. In addition to the demonstration that
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inhibitors of platelet PDI inhibit the consumption of S-nitrosoglutathione [Root et al.,
2004], others have shown that inhibition of platelet PDI also impedes the accumulation of
cGMP and intracellular reaction of delivered nitric oxide equivalents with DAF [Bell et
al., 2007].

In contrast, inhibitors of other putative nitrosothiol-degrading enzymes

(glutathione peroxidase) or nitrosothiol transporter (L-amino acid transporter) were found
to exert only a minimal effect on •NO-signaling [Bell et al., 2007], suggesting that psPDI
may be the most physiologically relevant system for delivering *NO-equivalents into
platelets.
In the past five years several isozymes of NOX have been identified in nonphagocytic cells like platelets [Krotz et al., 2002], smooth muscle cells [Hilenski et a l,
2004), neurons [Hilburger et al., 2005], endothelial cells, [Griendling et al., 2000] and
fibroblasts [Griendling et a l, 2000].

In platelets, NOX is believed to be plasma-

membrane associated [Krotz et al., 2004], however, in endothelial cells the NOX subunits
are largely assembled and found associated with the intracellular cytoskeleton and
distributed perinuclearly [Li et al., 2002]. Vascular NOX isoforms display low (nM)
constitutive 0 2*~ generation and this basal activity is reported to be potentiated by a
variety of stimuli common to type II diabetes pathology, including increased insulin
[Kashiwagi et a l, 1999], glucose [Inoguchi et al., 2000], oxidized LDL [Rueckschloss et
al., 2001] and hyperlipidemia [Li e ta i, 2003].
NADPH oxidases (NOX) catalyze the one electron reduction of molecular oxygen
to yield superoxide anion (02*~). NOX, initially identified in neutrophils, is a multimeric
protein composed of plasma membrane (PM) catalytic subunits p22phox and p91phox
containing cytochrome b558, cytosolic regulatory subunits p47phox, p40phox p67phox and the
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small G-protein R acl or Rac2, which translocate to the PM to activate the catalytic
subunits . Assembly of a functional enzyme complex requires association of Rac GTPase
and this association appears to be regulated by its carboxyterminal geranylgeranylation
(isoprenylation) [Ando et al., 1992]. Biosynthesis of isoprenoids, as well as cholesterol
requires mevalonate, thus NOX activity can be attenuated with HMG-CoA inhibitors
[Bandoh et al., 2003, Takayama et a l, 2004] like rosuvastatin which inhibit the ratelimiting conversion of hydroxymethylglutaryl CoA to mevalonate.
Therefore, the first aim of this study was to determine the effects of rosuvastatin
on platelet PDI and NOX activities and on in vitro platelet aggregation in the animal
model of pre-diabetes - the Syrian Golden hamster. Previous studies have demonstrated
that fructose feeding of hamsters for 2-3 weeks induces insulin resistance, as confirmed
by in vivo euglycemic hyperinsulinemic clamp studies [Taghibiglou et al., 2002].
Fructose

feeding

is

associated

with

hyperinsulinemia,

hyperlipidemia

but

a

normoglycemic state, suggesting the development of a pre-diabetic, insulin resistant state.
Although the mechanism by which hamsters develop insulin resistance and resultant
dyslipidemia is not known, several groups have noted this phenomenon and use this
model to investigate carbohydrate-induced chages in lipid metabolism [Remillard et al.,
2001, Kasim-Karakas et al., 1996]
Fructose feeding of hamsters resulted in a -60% increase in platelet ROS
production in comparison to NFF controls (Fig. 2.2) a concomitant -4 2 % reduction in
psPDI RSNO-denitrosation activity (Fig. 2.3) and thrombin-induced aggregation rates
(Fig. 4) that were on average - 1.5-fold larger than platelets from NFF hamsters. Fructose
feeding of hamsters was also found to result in a progressive loss in inhibition of platelet

103

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

aggregation mediated by GSNO that varied with the duration of feeding (Fig. 2.5C) to a
maximum of <15% loss at the second week. Similar results were obtained in platelets
from NFF animals treated with X/XO revealing a <20% loss in GSNO-mediated platelet
inhibition at 10 pM xanthine (Fig. 2.5D), further supporting our hypothesis that ROS
readily oxidizes the active-site vicinal dithiols of PDI, blocking denitrosation activity and
thus limiting the anti-platelet effects of GSNO.
The second aim of the study was to determine whether the observed attenuation of
the ‘NO-releasing activity of psPDI and potentiation of the initial rates of aggregation
could be the result of increased NOX activity, i.e. superoxide overproduction, observed in
platelets of FF hamsters. To test this, we exposed platelets from NFF animals to the
xanthine / xanthine oxidase superoxide-generating system and in support of our
hypothesis, platelets exposed to a range of xanthine concentrations and 1.5 mU/mL
xanthine oxidase over 30 min 1) inhibited the psPDI-dependent RSNO denitrosation
activity by -50% at 25 JJ.M xanthine (Fig. 2.6) and 2) potentiated the initial rates of
thrombin-induced aggregation by - 1.4-fold (Fig. 2.7). These effects are very similar to
the FF platelet results lending credence to our hypothesis.
The third aim was to determine the effects of short-term rosuvastatin treatment on
the platelet-parameters tested here. Rosuvastatin had no statistically significant effect on
the platelet ROS production by NFF hamsters.

However, drug administered to FF

animals attenuated the generation of ROS to control levels (Fig.2.2).

In the case of

psPDI, rosuvastatin decreased the NFF-psPDI denitrosation activity by -20% (Fig 2.3).
Although PDI is generally considered to bind to the plasma membrane through
electrostatic interactions, we have recently investigated and provided evidence that
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interaction with the platelet plasma membrane is mediated, in part, by hydrophobic
interactions (Raturi, manuscript submitted). It is then possible that cholesterol lowering
induced by rosuvastatin in NFF animals alters the hydrophobic character of the platelet
plasma membrane potentially diminishing the bound enzyme and accounting for this
-20% loss in denitrosation activity.
Alternately, exposure of FF animals to rosuvastatin resulted in the restoration of
the psPDI activity to near control levels. These results suggest that rosuvastatin at nM Cp
is effective in blunting the production of ROS by platelets, and thus permitting psPDIcatalyzed release of sufficient »NO from RSNOs to inhibit platelets. This was borne out
in the aggregation studies in which rosuvastatin treatment slightly decreased (-20% ) the
initial rates of aggregation in NFF animals and significantly decreased (-50% ) the initial
rates in FF animals (Fig. 2.4). Results obtained from the aggregation study suggest that
rosuvastatin treatment of FF animals, not only contributes to the normalization of platelet
ROS production and psPDI activities, but also restores normal platelet aggregability.
Numerous studies have established links between an elevated pathologic
endothelial NOX activity and atherogenesis [Cai et a l, 2005, Li et al., 2004, Redondo et
al., 2005, Spitaler et a l, 2002], thus the fourth aim of this study was to examine the effect
of rosuvastatin on NFF and FF hamster aortic endothelial cell NOX activity (Fig. 2.8).
To this end, aortic explants from NFF and FF animals were grown in primary culture and
exposed to varying nM concentrations of rosuvastatin.
insensitive to in vitro rosuvastatin exposure.

NFF NOX-activity was

In contrast, FF animals displayed aortic

endothelial NOX activity that was on average - 1.8-fold larger than controls and could be
attenuated to near control levels by 50 nM drug. At 100 nM rosuvastatin, FF-NOX-
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dependent ROS production was -40% less than NFF controls, an effect which could be
partially reversed by the addition of 200 |iM mevalonate. That ROS production was not
fully reversed by mevalonate, suggests that other sources may also contribute to DPIinhibitable ROS. Diphenyleneiodonium is a flavoprotein inhibitor and will inhibit other
enzymes such as nitric oxide synthase which has been shown to produce superoxide in
platelets of patients with coexisting hypertension and diabetes [Dixon et al., 2005].
However, that mevalonate could in part reverse the anti-oxidant effects of rosuvastatin in
AEC, corroborates the assertion that drug effects are possibly elicited by the inhibition of
isoprenoid formation.
The relative insensitivity of AECs derived from NFF animals compared to the
mitigation of ROS production in those derived from FF animals at the same level of drug
suggests that perhaps a different NOX isozyme is being induced in the animal model of
pre-diabetes. It can be postulated that the rosuvastatin insensitive NFF-isoform of NOX
possesses a higher affinity for geranylgeranylate or the geranylgeranyl transferase in
comparison to the FF-isoform of NOX. The net result would be that NFF-NOX would
remain active even if rosuvastatin attenuated geranylgeranylation, whereas the activity of
the FF-NOX would diminish with decreasing levels of geranylgeranylate.
In summary, this study elaborates on the novel finding that increased ROS
production in animal models of diabetes is accompanied by an attenuation of psPDI
denitrosation activity that likely contributes

to platelet hyperaggregability and

thrombogenesis. Treatment of hamsters with 10 mg / kg rosuvastatin shows efficacy in
normalizing both of these activities in this animal model of pre-diabetes.

Further

investigation of ROS generated from primary endothelial cells similarly shows a
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significant increase in fructose-fed versus non fructose-fed hamsters that would perturb
normal intracellular signaling and contribute to endothelial dysfunction. Treatment of
primary endothelial cells with levels of rosuvastatin in the range of those found in vivo
results in a restoration of ROS production to control levels.
Based on the demonstrated efficacy of rosuvastatin to restore platelet and
endothelial ROS levels, as well as normalizing platelet aggregation and PDI-denitrosation
activity in models of pre-diabetes, broadening of the pathological states to which this
drug

is utilized

may be beneficial

in preventing

secondary

atherothrombotic

complications associated with non-insulin dependent diabetes mellitus.
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PART II

CHAPTER 32

NITRIC OXIDE SIGNALING IS AFFECTED BY VARIATIONS IN
THE CHOLESTEROL CONTENT OF THE PLASMA MEMBRANE

'Submitted for publication to the Proceedings o f the National Academy o f Sciences, Sept. 2007.
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3.1

Introduction
Nitric oxide signaling is a complex process governed by numerous factors

including its partitioning into hydrophobic cellular environments [Liu et al., 1998a], its
diffusional path from a point of generation [Lancaster et al., 2000, Wood et al., 1994,
Philippides et al., 2004] and reaction with oxygen [Caccia et al., 1999, Lewis et al.,
1994], other radicals [Kissner et al., 1998, Lima et al., 2003] and metal centres [Chiang
et al., 2006, Mason et al., 2006], all of which will contribute to its spatial heterogeneity
of biological activity.

Although there are a number of explanations for the general

decline in »NO bioavailability under conditions of hypercholesterolemia [Stokes et al.,
2002, Munzel et al., 2005], there have been relatively few papers that have sought to
question the role of cellular cholesterol in altering the diffusional properties of *NO
[Subczynski, et al., 1998], despite 1) prompts to do so from researchers in the literature
[Denicola et al., 1996b], 2) evidence of the critical role of lipids in determining the
lifetime and reactivity of *NO [Liu et al., 1998a] and 3) reports noting the role of cellular
lipids in defining the diffusional field of »NO [Porterfield et al., 2001].
Nevertheless, there exists a growing appreciation of cholesterol (Choi) as a major
determinant of membrane properties and architecture (Subczynski
Nedeianu et al., 2004,

Pucadyil

et al., 1996,

et al., 2006] and as a contributing factor to

pathophysiological changes [Hao et al., 2001, Rukmini et al., 2001, Preston et al., 2003,
Chen et al., 1995a, Qin et al., 2006].
Experiments conducted in liposomal and bilayer lipid membrane model systems
to evaluate the contribution of changes in the diffusional properties of *NO demonstrate
the existence of cholesterol-dependent changes in membrane transit times and suggest
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significance to overall cellular metabolism. This may be of particular importance in »NO
-responsive cells exhibiting lipid disorders such as Niemann-Pick disease and cells such
as RBCs and platelets in which membrane cholesterol is believed to vary passively
[Cazzola et al., 2004],
Niemann-Pick type C l (NPC1) disease is a fatal neural disorder whose molecular
origins are believed to result from mutations in an intracellular sterol transporter (NPC1
and 2) that manifest as the accumulation of unesterified Choi, glycosphingolipids,
sphingomyelin in late endosomal and lysosomal compartments and progresses towards
neurodegeneration and loss of neural cells [Patterson et a l, 1991]. Investigations of the
cellular consequences of aberrant lipid trafficking have found disturbances in both
intracellular and plasma membrane Choi distribution that affect cellular function and
contribute to the pathogenesis of disease.

Several studies have shown that despite

bearing diminished Choi within caveolar structures [Garver et al., 2002], NPC1-deficient
cells exhibit a marked increase in the plasma membrane Choi content that alters
membrane bilayer properties and fluidity [Vainio et al., 2005, Koike et a., 1998] as well
as functional signaling [Vainio et al., 2005].
In this study, we sought to evaluate the influence of cholesterol on the cellular
metabolism of »NO in NPC1-deficient fibroblasts in which the levels and distribution of
cholesterol are known to be altered in comparison to normal (NPC+/+) human
fibroblasts. Our study demonstrates a clear and significant role for cellular cholesterol in
altering both guanylate cyclase-mediated »NO -dependent generation of cGMP and the
modulation of reactions capable of nitrosating nucleophilic species such as amines, thiols
and hydroxyl residues [Espey et al., 2001]. To assess the generality of our observations,
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•NO metabolism was similarly monitored and confirmed to show cholesterol-dependence
in platelets, RBCs and MCF-7 cells.
In concert, these observations raise the possibility that pathological alterations in
levels and distribution of cellular cholesterol constitute a common, but as yet under
investigated mechanism of errant •NO-signaling.
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3.2

Materials and equipment

3.2.1

Materials
Tris-Base,

EDTA,

PMSF,

NG-monomethyl-L-arginine

(L-NMMA),

diaminofluorescein diacetate, dimyristoylphosphatidyl choline, dipalmitoylphosphatidyl
choline, Choi, Dulbecco’s modified eagle’s media (DMEM), diethylaminetriamine
pentaacetic acid (DTPA), hemoglobin, sodium dithionite, malachite green, ammonium
molybdate and performic acid was obtained from Sigma, Mississauga, ON. Alexa 532
succinimidyl ester was obtained from In vitro gen, Burlington, ON. l-hexadecanoyl-2-(lpyrenedecanoyl)-

.vn-glycero-3-phosphocholine

(p-py-Cio-HPC)

from

Cayman

Chemicals, Ann Arbor, MI. Mn(III)tetrakis(l-methyl-4-pyridyl) porphyrin pentachloride
(Mn(III)TMPyP) from Cedarlane Labs, Hornby, ON. cGMP enzyme immunoassay kit
was from Amersham Biosciences,

Baie d'Urfe, Quebec. *NO(g), 10% with argon

balance (BOC gases, Mississauga Ontario), was purified by bubbling though 1M KOH
solution and used directly for experiments or dissolved in deoxygenated PBS with 500
pM DTPA and quantified spectrophotometrically by hemoglobin assay as previously
described (Sliskovic, I., Raturi, A. & Mutus, B. (2005) J Biol Chem 280, 8733-41.).
Normal human fibroblasts (HFF-1) were obtained from ATCC and NPC1 fibroblasts
(GM17923) from the Coriell Cell Repository and maintained in Dulbecco’s minimal
essential medium (DMEM) supplemented with 10% fetal calf serum and cultivated at
37°C under an atmosphere of 5% CO 2.

3.2.2

Equipment

Agilent 8453 UV-VIS Spectrophotometer; Agilent Technologies Canada Inc.,
Mississauga, ON
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Apollo 4000 Free Radical Analyzer; World Precision Instruments USA, Sarasota, FL
BBA-01A BLM amplifier; Eastern Scientific LLC, Rockville MD, USA.
BBS-100 Basic BLM setup; Eastern Scientific LLC, Rockville MD, USA. (See Figure
3.1
Haemocytometer; Reichert Co, Buffalo, NY
ISO-NOPF200 200 pM Flex NO Sensor; World Precision Instruments USA, Sarasota, FL
Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON
MB-1 BLM testing circuit; Eastern Scientific LLC, Rockville MD, USA.
Northern Eclipse 6.0 Imaging Software; Empix Imaging Inc., Mississauga, ON
NUAIRE Biological Safety Cabinet Class II Type A/B3; Thermo Electron Corp. Canada,
Burlington, ON
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON
Varian Eclipse Fluorescence Spectrophotometer, Varian Canada, Mississauga, ON
Wallac 1420 Victor3 Fluorescent Plate Reader, Perkin Elmer, Woodbridge, ON
Zeiss Axiovert 200 Inverted Fluorescence Microscope, Empix Imaging Inc., Mississauga,
ON
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Figure 3.1

Experimental setup of the bilayer lipid membrane chamber

A teflon divider separates the right and left sides of the chamber. Clear plastic windows
allow real-time visualization and monitoring of bilayer integrity. On the right side of the
chamber, a temperature probe monitors temperature at 37°C. On the left side, a 0.7 mm
nitric oxide probe monitors nitric oxide which traverses the bilayer, which is delivered
from a tank of 1% nitric oxide in argon by a high-accuracy, low flow gas regulator.
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3.3

METHODS

3.3.1

Quantification of NO diffusion by pyrene quenching
The interaction of excited-state pyrene moieties with paramagnetic species such

as NO and O2 are diffusion controlled processes [Birks et al., 1970] and have previously
been used to monitor the diffusion of nitric oxide in hydrophobic environments allowing
determination of apparent diffusion coefficients [Denicola et al., 1996b, Denicola et al.,
2002,

Moller et al., 2005].

We thus prepared liposomes of either dimyristoyl- or

dipalmitoyl-phosphatidylcholine in the presence or absence of 33 mol % cholesterol
doped with l-hexadecanoyl-2-(l-pyrenedecanoyl)-sn-glycero-3-phosphocholine ((3-pyC 10-HPC) as previously described. Briefly, KOH-scrubbed nitric oxide from a 10% gas
mixture (balance argon) was bubbled into oxygen-free liposome samples in sealed
cuvettes equilibrated to 37°C while monitoring fluorescence quenching (7.ex 337 nm, Xem
= 376 nm) in a Cary Eclipse fluorescence spectrometer (Varian, Cary, Mississauga). 10
pL aliquots were removed with a gastight syringe and »NO determined by a *NO-specific
electrode and comparison to a standard curve. Stem-Volmer plots were constructed by
plotting the fractional quenching observed against the measured [*NO] for not less than 5
replicate runs each with a coefficient of linearity >0.95. Quenching constants (kq) were
then determined from the slope using previously published fluorescence lifetimes (x0) of
178 and 194 ns for DMPC and DMPC:Chol and 163 ns in DPPC and 178 ns in
DPPC:Chol [Fischkoff et al., 1975].

Diffusion coefficients were calculated from the

Einstein-Smoluchowski equation (D=p*kT/e) [Denicola et al., 1996b] and subsequently
used to calculate membrane transit times using the equation <x> = 2Dt [Einstein et al.
1905].
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3.3.2

Measurement of NO diffusion across synthetic BLMs
The BLM chamber was purchased from Eastern Scientific, Rockville MD. The

desired ratios of chol:phospholipids were prepared in decane in a vial sealed with a
septum and purged with N 2(g). A 5 pL aliquot of this solution was withdrawn and placed
on the 1 mm hole in the Teflon divider in the BLM chamber. The both sides of the
chamber were then filled with PBS at a rate of 500 |iL/ min. The entire BLM chamber
was maintained at 37°C and both sides of the chamber were stirred with the aid of micro
stir-bars.

The formation of the lipid bilayer was monitored by the saturation of the

capacitance and by visual inspection. A constant amount of *NO(g) (ultrapure 1%, 99%
argon) 200 jiL/ min was metered out with a Matheson gas regulator (FM-1050) and
introduced to one side of the chamber. The amount of *NO(aq) diffusing through the BLM
was measured with Clark-type NO electrode (WPI, Inc) as a function of time and
recorded digitally via D uo-18 software (WPI, Inc).

3.3.3

Synthesis, purification and Alexa 532-labeling of PFO-D4
Plasmid pRTIO containing the perfringolysin O gene (pfoA) was used to

construct the pfoA derivative D4 encoding the C-terminal region of the toxin. The DNA
fragment containing the D4 (K391-N500) - encoding region was PCR amplified using
pRTIO plasmid as the PCR template and ligated into the pTrcHisB expression vector
inserting it between the BamHI and KpNI restriction sites on the 3’ end of the sequence
encoding the His-tag site. The polymerase chain reaction primers used were:
forward primer 5'- CCCGGATCCGTCTACAGAGTATTCTAAGG -3' and
reverse primer 5'- CCCGGT ACCGGATTGT A AGT A AT ACT AG AT CC-3'.
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His-tagged PF0-D 4 was isolated on a Ni2+ affinity column after successive washes
totaling 8 column volumes with 30 mM imidazole in 100 mM Tris buffer pH 8.0. PFOD4 was eluted with 100 mM imidazole in pH 8.0 100 mM Tris buffer, concentrated and
purity demonstrated to be >95% pure by image analysis on a 15% SDS-PAGE

gel.

Isolated PFO-D4 extensively dialyzed and labeled over night with a five fold molar
excess of Alexa 532 succinimidyl ester (epsilon = 81000 L mol 'cm '1) at 4°C, separated
from unreacted dye on a Sepahdex-G25 column and extent of labeling calculated as the
molar ratio of dye to protein.

3.3.4

Preparation o f Chol-loaded cyclodextrins
Cyclodextrin was charged with cholesterol as per previously described methods

[Christian et al., 1997].

3.3.5

Cellular membrane cholesterol labeling by Alexa532-PFO-D4
Cells were fixed for 15 minutes at room temperature with 4% paraformaldehyde

in HEPES buffer, washed 3 times and stained with 400 nM Alexa 532-labeled D4 for 30
minutes with gentle shaking. Cells were washed again 3 times and imaged on an Axiovert
epifluorescence microscope with 535 nm/550 nm excitation/emission under identical
exposure conditions.

Images were pseudo-coloured red using Northern Eclipse 6.0

imaging software and the average intensity per unit cell area measured for 50-80 cells
from a number of separate images.
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3.3.6

Isolation of fibroblast plasma membranes
The cells of 3 T75 flasks of either normal or NPC-1 deficient fibroblasts at -85%

confluency were trypsinized, washed once with 100 mM IX Tris buffer pH 7.4 and then
once with 10 mM hypotonic Tris buffer pH 7.4 containing 2mM EDTA and 1 mg PMSF.
A 1 mL suspension was then homogenized by 50 strokes in a Dounce.

Mechanical

disruption was verified by microscopic inspection and the homogenate was spun at 190g
for ten minutes.

Subsequent isolation of plasma membrane lipids was performed as

previously described [Vainio et al., 2005].

Lipid suspension isolated in buffer was

extracted 2X with 200 pL 1:1 MeOH/CHCl3, back-extracted once with 1M NaCl and the
solvent evaporated in a glass tube under a gentle stream of nitrogen.

3.3.7

Determination of plasma membrane cholesterol and phospholipid content

3.3.7.1 Phospholipid Analysis
Lipid film was dissolved in 200 pL HCIO 3, and digested for 60 minutes at 180°C.
Aliquots of the acidified digest mixed with Malachite Green and ammonium molybdate
and the absorbance measured at 630 nm as per previously published methods [Zhou et
al., 1992].

Phosphorous concentration was interpolated from a standard curve.

Phospholipid content was estimated by multiplying by 25 the moles of phosphorous and
expressed as pmol PL / 106 cells.

118

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

3.3.7.2 Cholesterol Analysis
Lipid film was sonicated in 200 pL CHAPS:Triton:NaCholate buffer and Choi
quantified using a Choi oxidase enzymatic assay (Invitrogen) and interpolation from a
standard curve and expressed as pmol PL / 106 cells.

3.3.8

Cellular NO responsiveness by cGMP determination
Cells

were

cultivated

to

approximately

85%

confluency,

collected

by

trypsinization and washed once with PBS containing 500 pM DTPA. Cells counts were
adjusted, treated with bolus authentic nitric oxide from a gastight syringe in the presence
of 50 pM Mn(III)TMPyP and incubated for 2 minutes at 37°C. Cells were immediately
spun down and lysed with lysis buffer (containing phosphodiesterase inhibitors) and
lysates prepared as per cGMP EIA kit (Amersham Biosciences) instructions.

3.3.9

Measurement of NOx-mediated extracellular nitrosation by cell impermeant
DAF
•NO uptake and metabolism to species capable of nitrosating DAF was also

monitored by the reaction of extracellular DAF-2 with *NO supplied by exogenous »NO donor in the presence of intact cells. Cells are capable of acting as ‘NO sinks’ and will
take up a portion of «NO from an extracellular donor, altering subsequent reactions with a
NOx sensitive fluorophore, such as DAF-2. This approach has the additional benefit of
circumventing potential intracellular interferences which can contribute to artifactual
DAF-2T signals [Zhang et al., 2002, Espey et al., 2002 et al., Jourd'heuil D et al., 2002].
Adherent NHF and NPC1-deficient fibroblasts and MCF-7 cells were trypsinized,
collected, washed once with and suspended in PBS containing 500 pM DTPA (used
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throughout DAF experiments). Human RBCs and platelets were isolated from whole
blood by differential centrifugation, washed with 200 volumes of buffer and resuspended.
Membrane cholesterol was then augmented or depleted using increasing concentrations
of the cholesterol-loaded adduct of M(3CD (Choi: MPCD) or MpCD (or cholesterol
oxidase) alone with gentle nutation for one hour.

Cells were removed from excess

cholesterol adduct, cyclodextrin or enzyme by centrifugation, washed once and
suspended in a 10 pM DAF solution in PBS containing 0.5 mM DTPA. Cells counts
were optimized to consume approximately 50% of delivered «NO.and then treated with
the NO donor (either DEA/NO or Proli/NO) for monitoring of evolved fluorescence over
time. Cell viability was measured by Trypan blue exclusion to be greater than 90% in all
cases following treatment.
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3.4

RESULTS

3.4.1

Choi attenuates NO-induced pyrene quenching in liposomes
Incorporation of cholesterol into DPPC and DMPC liposomes induced a -14%

and -30% decrease respectively in the slopes of the Stern-Volmer plot indicating a
decrease in the frequency of quenching interactions between excited-state pyrene and
•NO (Fig, 3.2A, 3.2B, repectively). The bimolecular quenching constant

(k q )

for each

liposome preparation was then determined (kq=Ksv/x0) from the slope (Ksv) of the StemYolmer plot for each experiment using previously published fluorescence lifetimes for
each in the various lipid mixtures (see Materials and Methods). Apparent diffusion
coefficients were then estimated from the Einstein-Smoluchowski equation

(k q

=

47tRDN) [Fischkoff et al., 1975]. These calculations indicate that the presence of Choi in
DPPC and DMPC liposomes decreases the diffusion coefficients measured at
approximately the C9 position of acyl chains in the membrane by -27% and -29%
respectively, suggesting a substantial influence of cholesterol over the diffusion of nitric
oxide in a lipid environment. Assuming a membrane thickness of 10 nm, transit times
were calculated using the measured diffusion coefficients using the equation <x> = 2Dt
[Einstein et al., 1905] and are shown in Table 1.

3.4.2

The diffusion of NO across bilayer lipid membranes decreases as a function
of increasing Choi

In these studies, the 1mm diameter hole of the BLM chamber (Fig. 3.1) was “painted”
with either dipalmitoylphosphatidylcholine (DPPC) or to varying Choi to DDPC
mixtures. Authentic •NO(g>was bubbled at a rate of 200 pL of 1% *NO in argon/min on
one side of the chamber with stirring and the arrival of »NO that had crossed the
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membrane bilayer measured with a »NO-electrode was placed in the trans chamber.
Rates were calculated as the initial rate of increase in [*N0] measured by the electrode
during the approach to steady state. The average diffusion rate of •NO across the DPPC
bilayers decreased by -4 8 % upon introduction of 17.3 mol% Choi and 67 % to 75 %
when cholesterol levels were increased to -3 0 mol% and -3 7 mol%, respectively (Fig.
3.3).

These results illustrate the dramatic manner in which Choi modulates »NO -

diffusion in the model bilayer employed here.

Although the changes in transit time

calculated in the pyrene quenching experiments are substantial, in order to account for
experimental observations, the increase in membrane residence time would have to alter
the net diffusion time required to reach the electrode.

Alternately, if the changes in

membrane properties and resultant changes in •NO diffusion altered the potential for
reaction within the membrane, this may account for observed differences in rates of
arrival at the electrode.
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Figure 3.2 Quenching o f pyrene phospholipids in liposomes
Stem-Volmer plots were obtained for deoxygenated suspensions of both DPPC (A) and
DMPC (B) liposomes doped with 0.02 mol% P-py-Cio-HPC in the presence (filled
squares) and absence (hollow squares) of 33 mol% cholesterol containing 1.35 pmol total
lipid. Experiments were conducted at 37°C in PBS with 500 pM DTPA and illustrate the
fractional quenching of the excited state pyrene moiety at various [«NO] in the presence
and absence of cholesterol.
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Table 1
Measured diffusion coefficients and membrane transit times for liposomes
of determined cholesterol :phospholipid composition by pyrene quenching

DPPC
DPPC + 30% Choi
DMPC
DMPC + 30% Choi

kQ (M'V1)

D(quencher) cm2 s"1

3.07E+09
2.25E+09
5.06E+09
3.61E+09

6.76E-06
4.95E-06
1.11E-05
7.95E-06

transit time
(jiseconds)
1.48
2.02
0.89
1.25
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Rates of »NO diffusion across the BLM as a function of BLM-Chol composition (mol%)
(n=12, p<0.05 Tukey’s post hoc test).
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3.4.3

Quantitation of NPC1 and normal human fibroblast plasma membrane (PM)
cholesterol content
Studies have shown that despite bearing diminished Choi within caveolar

structures [Garver et al., 2002], NPC1-deficient fibroblasts exhibit a marked increase in
plasma membrane (PM) Choi content [Vainio et al., 2005] and exhibit a concomitant
decrease in membrane fluidity [Vainio et al., 2005, Koike et al., 1998].

To verify

previous assertions, the PM-Chol content of both cell lines was determined and compared
by two independent methods: i) direct analyses of phospholipid and Choi content of
isolated plasma membranes and ii) by probing intact cells with a fluorescent-labeled
(Alexa 532) perfringolysin domain 4 (PFO-D4), a PM-directed, cholesterol-rich domainspecific probe [Shimada et al., 2002, Waheed et al., 2001].
When intact cells were fixed and exposed to Alexa532-PFO-D4, the labeling of
the NHFs was not uniform but punctate in appearance (Fig. 3.4A). In contrast, the NPC1
fibroblasts were labeled more uniformly across the surface of the cellular membrane (Fig.
3.4C).

In order to confirm the cholesterol-specific binding of the Alexa532-PFO-D4

probe, NHFs were incubated with cholesterol-loaded MpCD to augment PM-Chol
[Christian et al., 1997]. Upon Chol-loading, the Alexa532-PFO-D4 labeling increased in
uniformity (Fig. 3.4B) resembling the staining pattern of NPC1 cells (Fig 3.4C).

In

addition, raft-associated Choi was depleted from the PM of NPC1 cells by exposure to
MpCD [Christian et al., 1997] (Fig. 3.4D), resulting in loss of the uniform labeling
pattern and development of a staining pattern resembling that of Alexa532-PFO-D4labelled NHFs (Fig. 3.4A). In the case of NPC1 fibroblasts, incubation of the cells with
MpCD resulted in a -2.7 fold decrease in staining intensity. In a further experiment to
confirm the specificity of PFO-D4, the NPC1 cells were first incubated with unlabelled
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PF0-D4, washed, fixed then exposed to Alexa532-PFO-D4. Under these conditions the
amount of cell surface-bound label decreased to levels obtained with NPC1 cells treated
with 2 mM M(3CD (Fig. 3.4E, right most bar). Image density plots of the data (Fig. 3.4E;
summary of n = 9 experiments) revealed that NPC1 fibroblasts stained ~3.7-fold more
intensely upon staining with 400 nM Alexa532-PFO-D4 label than NHFs and that upon
enhancement of the NHF-PM with Chol-loaded MpCD (100 pM), cholesterol-specific
labeling increased by -2.5 fold.
In agreement with previous reports, plasma membranes isolated from NHF and
NPC1 fibroblasts were positive for PM-resident proteins (data not shown), had similar
phospholipid content (Fig 3.5) but exhibited ~2-fold higher total Choi content in the PM
of NPC1-deficient versus NHFs (Fig. 3.5). The difference in relative cholesterol levels
between methodologies (~2-fold by cholesterol isolation vs -3.7 by D4-labeling of fixed
cells) may reflect the previously reported ability of cell fixation to increase cholesterol
accessibility [Lange et al., 1983], however these experiments clearly illustrate that NPC1deificient fibroblasts contain PM-Chol than their normal counterparts.
Noting the importance of hydrophobic environments in »NO signaling we
questioned whether cholesterol, as a critically important and abundant component of the
plasma membrane, was capable of influencing *NO diffusion and reactivity and resultant
NO-signaling (i.e. cGMP production and nitrosation).
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Figure 3.4 PM cholesterol of NHF vs NPC1 fibroblasts by fluorescent imaging of
D4-labeling
Fixed normal (A) and NPC1-deficient fibroblasts (C) stained with 400 nM Alexa 532labeled D4 and imaged under identical exposure conditions exhibited cholesteroldependent fluorescence. Normal human fibroblasts repeatedly stained less intensely than
their NPC1-deficient counterpart.

Importantly, treatment of NHFs with 100 pM

cholesterol-loaded M|3CD was associated with an increase in cellular staining (B) and
staining observed in NPC1-deficient cells could be largely abrogated by treatment with
10 mM MpCD prior to fixation (D). Data taken from multiple images in nine separate
experiments are summarized numerically from average intensities per cell for not less
than 50 cells (E).

Errors represent standard deviation from the mean.

*P < 0.005

compared to NHF. **P < 0.001 compared to NPC1.
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Figure 3.5 PM cholesterol:phospholipid of NHF vs NPC1 fibroblasts by analysis of
lipid isolates
Cholesterol and phospholipid levels were determined from plasma membrane isolates
obtained by sucrose gradient ultracentrifugation and are representative of two separate
experiments with error shown as the standard deviation of the mean.
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3.4.4 Responsiveness of NPCl-deficient and NHFs to bolus «NO by cGMP
response
NPCl-deficient and normal human fibroblasts were used as a model to compare
whether variations in the cellular cholesterol content and localization affected NOdependent reactions in intact cells.
We first determined whether NO-signaling, as assessed by • NO-mediated cGMP
production, was altered in NPCl-deficient cells versus NHFs. •NO-dependent cGMP
generation in NPC1 fibroblasts was 44.6±5.3% (n=3 experiments, ***p<0.005) of that
accumulated in NHFs in response to 3 pM of extracellular NO (Fig. 3.6A). NHF cGMP
production could be brought to near NPC 1-levels by exposing the cells to 100 pM Cholloaded MpCD (Fig. 3.6B). The lower response in NPC1 fibroblasts was not due to lower
guanylate cyclase activity as lysates derived from equivalent numbers of both NPC1 and
NHF cells produced nearly identical amounts of cGMP when stimulated with bolus »NO
following, rather than prior to cell lysis (Fig. 3.6C).
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Figure 3.6 Comparison of the NHF vs NPC1 cGMP response mediated by bolus »NO
Cyclic guanosine monophosphate was measured by enzyme immunoassay following
stimulation of normalized cell counts of both NHF and NPCl-deficient fibroblasts with
identical concentrations of bolus authentic nitric oxide and compared in (A). ***P<0.005
versus NHFs at the same [*NO], n = 3 experiments. Normal human fibroblasts were then
treated with 100 pM cholesterol-loaded MPCD to increase PM cholesterol and similarly
stimulated with »NO prior to measurement of cGMP for comparison to NHFs bearing
normal PM cholesterol (B) **P<0.05 versus untreated NHFs at the same [•NO], n = 3
experiments. As a control, cGMP was measured following «NO treatment of lysates of
both normal human and NPCl-deficient fibroblasts and found not to be statistically
different in n = 2 experiments (C).
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3.4.5

Influence of cholesterol on the nitrosation of extracellular DAF in the
presence o f either NPC1-deficient or NHFs
Several papers have noted drawbacks in the imaging of intracellular *NO

reactions in DAF-loaded cells [Zhang et al., 2002, Espey et al., 2002, Jourd'heuil D et al.,
2002]. Alternately, extracellular DAF (DAF-2) will compete for nitrosating equivalents
with intact cells delivered from physiological fluxes of •NO generated upon
decomposition of DEA/NO [Espey et al., 2001]. W ith this experimental design, we were
able to obtain insight into the factors influencing the cellular metabolism of »NO and
resultant extracellular nitrosative reactions while circumventing noted interferences.
In extension to the observed cholesterol-dependence of »NO-induced cGMP
accumulation, 5 X 105 NPC1 -deficient fibroblasts/mL exhibited ~3-fold larger nitrosative
response when treated with 250 nM DEA/NO in the presence of cell-impermeant 10 pM
DAF-2 versus an identical suspension of NHFs (Fig. 3.7A) in n = 3 experiments. Error
bars are expressed as the standard error of mean naphthatriazole accumulation for
quadruplicate samples following completion of decomposition (n = 3 experiments, p <
.001) in the presence of NHFs vs N PC ls in all three experiments. Upon inspection of the
fluorescence traces of naphthatriazole (DAF-2T) accumulation in the presence and
absence of cells, one notes that in the initial stages of NO flux, that the rate of DAF-2T
formation is unity in the presence or absence of cells. Only after the initial flux of *NO
has been delivered, are the divergent rates observable. Higher fluxes of NO achieved
during early time points promotes nitrosative reactions and only after the slowing of NO
delivery do differences in competing processes manifest. Results thus more likely reflect
variation in the net cellular metabolism of *NO arising from differences in sterol levels or
localization.

132

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Further, it was observed that a one hour treatment with 0.2 units/mL cholesterol
oxidase resulted in diminished DAF nitrosation in the presence of either NHF (86.5 ±
4.0%, n=3, p<0.05) or NPC1-deficient fibroblasts (74.9 ± 14.2%, p<0.05) versus buffertreated controls (Fig. 3.7B). Measurement of membrane cholesterol by enzymatic assay
confirmed a 47.6±7.3% and 33.2±1.4% decrease in membrane cholesterol NHF and
NPC1 cells, respectively.

Alternately, treatment of each cell type with 100 pM

MpCD:cholesterol adduct for one hour enhanced membrane cholesterol 4.25±.25 fold in
NHFs and 2.39±. 19-fold in NPC1-deficient cells and resulted in modest increases in DAF
nitrosation in the case of NHFs (12.9± 7.1%, n=3, p<0.05) that were, however, not
statistically significant in the presence of NPC1-deficient cells (10.8±7.9%, n=3, p>0.5)
versus buffer-treated controls (Fig. 3.7B).

Taken together these observations are

consistent with the hypothesis that membrane cholesterol is capable of modulating
nitrosation reactions in the presence of nanomolar to micromolar fluxes of »NO.
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Figure 3.7
DAF nitrosation is altered in the presence of NHF vs NPC1 fibroblasts
upon modulation of plasma membrane cholesterol
Cell suspensions containing 5 X 105cells/mL with 10 jxM DAF were treated with 250 nM
DEA/NO in quadruplicate in a microwell plate and the evolved fluorescence intermittently
monitored with shaking over the course of DEA/NO decomposition at 37°C. Shown are
representative traces from n = 3 experiments with errors bars calculated as the standard
error of n = 4 samples and p < 0.001 comparing the extent of nitrosation in the presence of
NPC1 versus normal human fibroblasts (A) following the completion of *NO delivery.
Collected results from experiments in which the membrane cholesterol was either
enhanced (with 100 pM MpCD:Chol) or depleted (with 0.2 U/mL cholesterol oxidase) in
both NHF (black bars) and NPC1-deficient cells (white bars). Shown are collected results
from n = 3 experiments with errors bars calculated as the standard error accumulated
naphthatriazole of n = 12 samples and *P < 0.05 versus buffer-treated controls (grey bars).
Note that **P > 0.05 in the case of cholesterol-enhanced NPC1 cells (B). Experiments
performed in the presence of the superoxide dismutase mimetic Mn(III)TmPyp were
nearly identical (data not shown).
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3.4.6

Comparison o f the superoxide-independent effects of cholesterol modulation
on extracellular DAF nitrosation in platelets, erythrocytes and MCF-7 cells
In order to test the generality of our observation, several cell types were treated to

deplete/enhance membrane cholesterol and assessed for their ability to modulate DAFnitrosation. Experiments were performed in the presence of the SOD-mimetic
Mn(III)TMPyP to exclude potential changes in superoxide production upon depletion or
enhancement of cholesterol that could alter nitrosative potential. In all three cell types
tested, modulation of plasma membrane cholesterol induced similar patterns of DAFnitrosation upon treatment with »NO donor in the presence of 5 |lM Mn(III)TMPyP.
Depletion of membrane cholesterol in the various cells impeded DAF-nitrosation
between 10 and 33% in comparison to cells in which membrane cholesterol was enriched
(Table 2).

Collectively, these data are in accord with the notion that increased that

cholesterol is capable of shifting the chemical equilibrium of NO towards formation of
nitrosating species such as N 2O 3.
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Table 1.2
Comparison of the superoxide-independent effects of
cholesterol on DAF-nitrosation in the presence in various cells
150 X 105/ mL
erythrocyte

1 X 10b/m L
MCF-7 adenocarcinoma

5 X 105 / mL
platelets

% nitrosation - cholesterol depleted vs cholesterol enhanced cells
81.1%
n=3

±16.9%
p = 0.052

90.0
n=4

±6.3%
p = 0.0129

67.6
n=3

±17.5%
p < 0.005
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3.5

Discussion
Although recent claims may challenge this long-standing axiom of nitric oxide

behaviour [Herrera et al., 2006], •NO is generally held to traverse the membrane freely
[Subczynski et al., 1996].

Oddly, although *NO and O2 are similarly paramagnetic,

lipophilic and low in molecular weight, membrane cholesterol is reported to act as a
barrier to oxygen in model systems [Subczynski et al., 1989] and as a determinant in
oxygen gradients and uptake in cellular systems [Khan et al., 2003], but is reported to
have no effect on »NO permeation [Subczynski et al., 1996]. The basis for this difference
is, at this point, unknown but may reflect inadvertent differences in model membrane
structure that arise as a result the domain-forming, lateral associations of cholesterol
[Veatch et al., 2003].
We thus investigated the effects of membrane cholesterol on *NO diffusion in
artificial liposomal membranes doped with P-py-Cio-HPC. Preparation of either DPPC
or DMPC liposomes bearing 30% cholesterol decreased the rate of transbilayer diffusion
-30% in comparison to liposome comprised of phospholipid alone, mirrors previous
results obtained using oxygen [Fischkoff et al., 1975]. These studies revealed that O 2
diffusion rates, like the rates measured for nitric oxide, were inversely related to
cholesterol content. Suggestively, in the study by Denicola, diffusion coefficients for
•NO in liposomes derived from erythrocyte plasma membranes were 13 - 70% less than
those determined in liposomes comprised of egg phosphatidyl choline alone [Denicola et
al., 1996b].
Cholesterol is known to induce the ‘condensation’ of phospholipids acyl chains
[Radhakrishnan et al., 2005] and thus our observations are thought to result from lower
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diffusivity of *NO through the more tightly packed bilayer. Similar results were obtained
using planar bilayers, in which as little as 17 mol% Choi inhibited the transbilayer
diffusion rates of »NO as much as 50% and increasing the Choi fraction to 37mol%
resulted in a 75% decrease in diffusion rates (Fig. 7). These data show that manipulation
of cholesterol levels can have a significant impact on transbilayer diffusion of *NO,
altering the membrane transit time and possible intra-membrane reactivity.
In an attempt to assess the role of membrane lipids in modulating *NO and NOx
signals, we used human fibroblasts which bear a molecular defect in the sterol trafficking
protein - NPC1. These cells consequently accumulate cholesterol in comparison to
normal fibroblasts and have been previously reported to contain increased levels of PM
Choi. Consistent with previous reports it was determined that NPC1-deficient fibroblasts
exhibited ~2-fold greater [Chol]/[phospholipid] in plasma membrane isolates [Vainio et
al., 2005], but further exhibited ~3-fold higher content of cholesterol-rich lipid raft in
their PM than in intact NHFs (as determined by the specific labeling of the fluorophoretagged cholesterol-binding domain of PFO) [Ohno-Iwashita et al., 2004].
Our experiments show that plasma membrane cholesterol exerts influence over
both the cellular generation of cGMP induced by bolus authentic »NO as well as the
cellular metabolism of *NO supplied from synthetic *NO donors as measured by
extracellular DAF nitrosation.

Inclusion of a SOD-mimetic would presumably

circumvent changes in nitrosylation and nitrosation patterns that arise from reaction of
NO with O2' , thus suggesting that results obtained may reflect physical differences or the
formation of reactive intermediates that depend upon cholesterol.
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More specifically, NPC1-deficient cells bearing high levels of plasma membrane
cholesterol exhibited diminished cGMP accumulation, but enhanced extracellular DAF
nitrosation versus their normal counterparts.

Both cGMP accumulation and DAF-

nitrosation could be modulated by altering plasma membrane cholesterol levels. These
results extended to other cell types including platelets, erythrocytes and MCF-7 cells
which showed varying degrees of change in DAF nitrosation in response to alterations in
membrane cholesterol, thus emphasizing the generality of our observations.
Since guanylate cyclase and DAF undergo reaction with distinct »NO species
(•NO vs N 2O 3 / «N0 2 respectively), any explanation of the apparent relationship between
plasma membrane cholesterol and *NO signaling requires consideration of the identity of
the nitrosating / nitrosylating species.

Attempts were made to distinguish between

observed effects arising from nitrosation versus those arising from the reaction of NO
with superoxide by inclusion of a SOD mimetic.

Although this would presumably

obviate ( V ’-mediated changes in DAF nitrosation, it certainly does not exclude
alterations in *NO metabolism that arise from other radicals that could facilitate
nitrosation reactions and thus must be considered in any explanation of our observations.
DAF nitrosation is not directly mediated by authentic »NO, but by ‘activated’
redox congeners of •NO including N 2O 3 and «N02. These reactions occur by
fundamentally

different

mechanisms

(nitrosation

versus

oxidation

followed

by

nitrosylation as shown in Figure 1.1.5A and 1.1.5B) and thus, alterations in DAF
nitrosation induced by a cellular system must be preceded by reactions which form one of
these nitrosating species. Importantly, these experiments were also conducted in the
presence of a superoxide oxide dismutase mimetic - Mn(III)TmPyP to prevent the
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diffusion-limited reaction of »NO with the radical anion - superoxide. Consumption of
•NO by 0 2*" (when contemporaneously produced) yields OONO which is capable of
reacting with DAF by oxidative nitrosylation forming the fluorescent DAF-2T [Espey
MG et al., 2002].

In excluding reaction with superoxide, observed changes in DAF

nitrosation must be attributed to other causes.
Indeed it has been shown that cholesterol reduces the permeability of oxygen to
model bilayer membranes by a factor of 5 [Subczynski et al., 1989], substantially affects
oxygen uptake in RBC [Buchwald

et al., 2000a, Buchwald et a l, 2000b] and is an

important factor in determining the magnitude of oxygen gradients observed across the
cell membrane [Khan et al., 2003], In these studies, incorporation of cholesterol into the
plasma membrane was shown to increase the magnitude of the oxygen gradient.
Conversely, transmembrane gradients were diminished upon depletion of plasma
membrane cholesterol by resultant increases in intracellular oxygen levels.
We thus propose, in accord with our observations, that spatial control exerted by
membrane cholesterol over •NO shifts the balance of «NO reactivity from intracellular
nitrosylation of haem targets such as guanylate cyclase to extracellular nitrosation of
nucleophiles potentially via cholesterol-dependent changes in membrane structure /
properties which affect the apparent reactivity of nitric oxide. This is consistent with our
results which show that upon depletion of plasma membrane cholesterol in both NPC1deficient and NHFs that nitrosation of extracellular DAF is diminished.

In addition,

loading of cellular plasma membranes was found to enhance nitrosation of extracellular
DAF consistent with the notion that by increasing membrane transit times, membrane
cholesterol appears to alter subsequent reactions of NO promote formation of nitrosating
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and modification of extracellular targets perhaps through enhanced reactivity with
oxygen. At this time however, there is no evidence to suggest that the changes in transit
times are rate-limiting and thus other mechanisms cannot be excluded.
In terms of the physiological significance of these studies, alterations in *NO mediated accumulation of cGMP observed between normal and diseased states in human
[Aydin et al., 2001, Lucotti et al., 2006] are in the range of those observed within this
study and are thus believed to be of physiological significance. Further, altered *NOdiffusion and signaling may contribute to the etiology of Niemann-Pick disease. Recent
studies have provided evidence that NPC1 cells exhibit defective «NO-dependent
deamination

of glypican-1

heparin

sulphate which may

arise

from

restricted

import/export of nitric oxide [Mani et al., 2006].
The current dogma is that cellular PM-lipid composition is tightly controlled and
need not be considered in altered nitric oxide signaling. However, both the existence of
diseases of cholesterol metabolism and trafficking and experimental evidence that
suggests that elevated serum cholesterol levels may alter the plasma membrane content of
critical cells [Kim et al., 1991] reconsideration of this assumption may be warranted. The
studies herein suggest that PM cholesterol levels as well as lipid composition can affect
the transbilayer diffusion rates of »NO and therefore *NO-mediated intracellular
signaling. In light of reports of similar findings for cellular oxygen levels [Khan et al.,
2003] a re-examination of the relationship between vascular disease, cholesterol and fatty
acid composition of plasma membranes and their effect on the bioavailability of not only
•NO, but also O 2 needs to be addressed.
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PART II

CHAPTER 4

PLATELET SURFACE PDI REDOX STATUS
AND PLATELET EVENTS IN DIABETES
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4.1

Introduction
A number of studies now published emphasize the importance of platelet surface

thiol isomerases in redox-dependent platelet events [Lahav et al., 2003, Jordan et al.,
2005, O'Neill et al., 2000]. Thiol isomerases are structurally-related members of the PDI
family of proteins which possess both redox-dependent activity (attributed to the
common thioredoxin consensus sequence - CXXC), as well as chaperone activity
[Versteeg et al., 2007], Vicinal thiols within the CXXC motif exist in equilibrium with
the disulfide form and depending upon the status of the active site can catalyze reduction,
oxidation or isomerization [Wilkinson et al., 2004].

Although the necessity of a

particular redox potential in platelet aggregation has been noted [Essex et al., 2003], little
has been done to directly explore specifically the role of thiol isomerase redox status and
its influence on platelet physiology.
The best studied member of this family is the 56 kDa protein disulfide isomerase
which has been localized to the surface of platelets where it is catalytically active and
critically involved not only in aggregation, adhesion, and secretion, but also in inhibition
of these events [Root et al., 2005, Miersch et al., 2007]. Notably, monoclonal antibodies
to PDI have been shown to inhibit thrombin-stimulated activation of the allbfl3 integrin
(measured by PAC-1 binding) [Essex et al., 1999], adhesion to fibrinogen [Lahav et al.,
2000] and aggregation [Lahav et al., 2002] in comparison to treatment with non-specific
immunoglobulins.
Although there have been numerous studies into the redox-dependent behaviour
of PDI, its influence in the context of platelet function requires characterization.
Although it is generally held that free thiols are required for platelet aggregation [Lahav
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et a l, 2002], these assertions 1) are based upon experiments in which all free thiols were
irreversibly blocked, 2) do not consider the possibility of reversible oxidation to the
disulfide and 3) require more detailed interpretation in the context of the both redox
dependence of aggregation and pathological changes in the vasculature.
PDI active site thiols are susceptible to oxidation by hydrogen peroxide [Kim et
al., 2000, Miersch et al., 2007], oxidized glutathione [Raturi

et al., 2007] and S-

nitrosothiols (with concomitant release of nitric oxide) [Root et al., 2005, Raturi et al.,
2007]. We have recently shown that in animal models of pre-diabetes that a diet-induced
increase in platelet and endothelial ROS production resulted in enhanced initial rates of
aggregation and diminished platelet metabolism of S-nitrosoglutathione [Miersch et al.,
2007],

Importantly, these characteristics could be normalized by treatment with the

HMG-CoA reductase inhibitor - rosuvastatin.
We now extend these studies comparing various characteristics of platelets from
human normal and diabetic subjects. Further in vitro experiments were conducted to gain
insight into the influence of human platelet-surface PDI (psPDI) redox status.
We have found, in agreement with others [Signorello, et al., 2007] that platelets
from diabetic subjects exhibited significantly elevated production of ROS compared to
those from normal human subjects. Suggestively, they also exhibited diminished psPDImediated denitrosation and disulfide reductase activities but enhanced aggregation
potential.
In vitro experimentation show that the oxidation of psPDI active site thiols using
either H 2O2 or decreasing ratios of GSH/GSSG results in 1) loss of platelet denitrosation
activity 2) loss of disulfide reductase activity and 3) enhanced rates of initial aggregation.
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Under these conditions we demonstrate the specific loss of psPDI thiols by maleimide
labeling. However, our attempts to investigate specifically the role of psPDI-redox status
on platelet aggregation, demonstrate that inhibition of aggregation associated with the
loss of psPDI can be restored with exogenous enzyme, however, in a redox-insensitive
manner. Consequently, increased rates of platelet aggregation observed under oxidizing
conditions must be attributed to factors other than redox-dependent changes in psPDI.
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4.2

Materials and equipment

4.2.1

Materials
Glutathione (GSH), oxidized glutathione (GSSG), dithiothreitol (DTT), EDTA,

PMSF,trisodium citrate dihydrate, citric acid monohydrate, dextrose, NaCl, Na 2HP 0 4 ,
KH2

P 0 4,

KC1,

N aH C 03,

MgClr 6H20,

CaCl2-6H20,

4-(2-hydroxyethyl)-l-

piperazineethanesulfonic acid (HEPES), Sephadex G-10 and G-100, apocynin, 4,5diaminofluorescein (DAF-2), eosin isothiocyanate, bacitracin, thrombin and horseradish
peroxidase (HRP) were purchased from Sigma-Aldrich Canada (Oakville, ON).
Prostaglandin Ei was obtained from Avanti Polar Lipids (Alabaster, AL). 10-acetyl-3,7dihydroxyphenoxazine (Amplex Red) and Alexa 532 succinimidyl ester were obtained
from

Invitrogen

(Burlington,

ON).

Mn(III)tetrakis(l-methyl-4-pyridyl)

porphyrin

pentachloride (Mn(III)TMPyP) from Cedarlane Labs (Hornby, ON). RL90 anti-PDI
mouse

monoclonal

antibodies

were

obtained

from

Abeam

(Cambridge,

MA).

Immobilized Protein G agarose beads were obtained from Pierce Biotechnology,
(Rockford, IL).

4.2.2

Equipment

Agilent 8453 UV-VIS Spectrophotometer; Agilent Technologies Canada Inc.,
Mississauga, ON
Apollo 4000 Free Radical Analyzer; World Precision Instruments USA, Sarasota, FL
Ex808 Biotek Absorbance Microplate Reader, Biotek Instrument Inc., Winooski, VT
Haemocytometer; Reichert Co, Buffalo, NY
ISO-NOPF200 200 pM Flex NO Sensor; W orld Precision Instruments USA, Sarasota, FL
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Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON
Varian Eclipse Fluorescence Spectrophotometer, Varian Canada, Mississauga, ON
'j

Wallac 1420 Victor Fluorescent Plate Reader, Perkin Elmer, Woodbridge, ON

4.3

METHODS

4.3.1

Platelet isolation from whole blood
Whole blood was collected from the antecubital vein of healthy donors into ACD

collection tubes. PRP was collected from whole blood after centrifugation at 900 g and
treated with 1 pM prostaglandin Ei to inhibit platelet activation.

4.3.2

Purification of recombinant human protein disulfide isomerase
PDI was expressed as the entire human sequence fused to an N-terminal His6 tag

in Escherichia coli strain BL21(DE3) using a pET-28a vector and isolated according to
previously published methods [Sliskovic, et al., 2005]. PDI was either fully oxidized or
reduced by incubation with 20 mM GSSG or 20 mM DTT respectively for 2 hours at
room temperature, purified over a G-25 column and stored at -80°C until use.

Fully

reduced enyme was further blocked by treatment with 20 mM iodoacetamide at pH 8.5
for 4 hrs at room temperature.

Unreacted iodoacetamide was removed over a G-25

column and concentrated in a centrifugal concentrator. Enzyme redox status was verified
by monitoring the disulfide reductase activity as indicated below following separation
from reductant/oxidant/alkylating agent and immediately prior to use.
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4.3.3

Preparation of S-nitrosoglutathione

S-nitrosoglutathione was synthesized according to previously published methods [Root et
a l, 2005].

4.3.4

Preparation of di-eosin GSSG

Di-eosin GSSG was synthesized according to previously published methods [Raturi et
a l, 2007],

4.3.5

Diabetic Inclusion Criteria
Healthy human subjects, ages 35-70 years were chosen to participate in the study

only if they showed no overt symptoms of disease and were taking no medication.
Diabetic human subjects, ages 35-70 were chosen to fulfill the criteria of the Expert
Committee on the Diagnosis and Classification of Diabetes Mellitus [Meltzer et al.,
1998].

Patients on diet treatment alone or diet treatment in combination with oral

hypoglycemic agents were included in the study, however, subjects taking investigational
agents, insulin or that were pregnant were excluded from the study. The experimental
protocol was approved by the University of Windsor Research Ethics Board.

4.3.6

Platelet aggregation
Platelets from PRP centrifuged at 1500 g and washed 2X in HEPESrACD pH 6

and exposed to either a range of [peroxide] or a decreasing ratios of GSH/GSSG for 30
minutes. Aggregation was stimulated by treatment with 0.5 U/mL thrombin under the
indicated redox conditions and aggregation monitored as the decrease in OD at 630 nm.
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4.3.7

Measurement of platelet NAD(P)H-derived ROS
Platelets were washed and suspended in 100 mM phosphate buffer pH 7.2

containing 2 mM EDTA and split into equal portions. ROS was then measured in the
presence and absence of 100 (lM of the NAD(P)H oxidase inhibitor, apocynin [Manning
et a l, 2003] using 15 pM Amplex Red and 1 U/mL HRP as a reporter system [Zhou et
al., 1997] on a Spectramax Gemini XS Fluorescent Microplate Reader (Molecular
Devices, Sunnyvale, CA) using excitation / emission of 544 / 590 nm over 60 minutes at
37°C. Thus, apocynin-inhibitable ROS was calculated by subtraction of total ROS minus
ROS generated in the presence of apocynin, yielding the contribution of ROS derived
from NAD(P)H oxidase.

4.3.8

Analysis of platelet denitrosation by •NO -electrode
An aliquot of platelet suspension was added to a stirred cuvette containing

100 mM phosphate buffer, pH 7.2, with 1 mM EDTA, 100 pM GSNO and 50 pM
Mn(III)TmPyP. Evolution of nitric oxide was monitored amperometrically using a Clarktype electrode (ISO-NOP, W orld Precision Instruments, Sarasota, FL) interfaced with the
Apollo 400 free radical analyzer (WPI, Sarasota, FL). Signal was measured following
addition of platelets as the change in current and [»NO] released interpolated from a
standard curve.

4.3.9

Platelet disulfide reductase activity
Platelets were isolated from PRP and treated exactly as above.

Disulfide

reductase activity was monitored using a novel probe (N, N ’,-dieosin-GSSG) designed
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within our lab and synthesized according to previously published methods [Raturi et a l,
2007] and capable of detecting platelet disulfide reductase activity in the absence of
exogenous reducing agent.

Platelets were suspended under the indicated redox

conditions in the presence of 150 nM N, N ’,-dieosin-GSSG with the appropriate blanks
and the increase in fluorescence indicative of disulfide bond reduction was monitored
using a 525 / 545 excitation / emission couple.

4.3.10 Redox modulation of platelets
Several papers have noted the redox dependency of events during platelet
aggregation [Essex et al., 2003, Gregg et al., 2004], To better understand specifically the
role of PDI redox status in platelet physiology we assessed several platelet PDIdependent activities including 1) aggregation by turbidimetry, 2) disulfide reductase
activity using a novel fluorescent probe and 3) denitrosation activity each under varying
redox conditions by the methods indicated above. To corroborate observations, the redox
status of platelet PDI was further investigated by 1) labeling of active site thiols with a
thiol-directed biotinylating agent, 2) assessing the effect isopropanol-assisted removal of
psPDI on aggregation and 3) replacing liberated psPDI with exogenous PDI of known
redox status and evaluating its influence on aggregation.

4.3.11 Measurement o f platelet-mediated GSNO consumption with DAF
Isolated platelets were incubated with varying [H2O 2] ± bacitracin for one hour,
washed and suspended in 10 pM GSNO for 15 minutes along with a GSNO control.
Platelets were then removed by centrifugation at 900 g for 5 minutes and remaining
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supernatant GSNO solution added to wells of a microplate containing 10 pM DAF and 25
pM CuCl2, resulting in Cu2+-mediated decomposition of GSNO and DAF-nitrosation
[Cook et al., 1996].

4.3.12 Labeling of platelet surface PDI with biotin-PE 0 4 maleimide
Unwashed platelet pellet was suspended in HEPES:ACD buffer pH 6.5 containing
3 mM biotin-PE 04 maleimide and gently nutated for 90 minutes. Platelet-surface PDI
was then liberated from the cell surface by suspending in HEPES:ACD containing 5%
isopropanol and gentle vortexing for one minute.

Labeled, liberated PDI was then

immunoprecipitated using Protein G beads covalently coupled to RL90 anti-PDI
antibodies for 24 hours at 4°C. Beads were washed 2X with TBS and protein eluted by
boiling in IX loading dye containing 20 mM DTT for separation by SDS-PAGE.
Separated proteins were transferred to a PVDF membrane and blotted with both RL90
anti-PDI antibodies and streptavidin-HRP. Thiol-specificity of platelet labeling was
demonstrated by pre-incubating platelets with 1 mM DTNB for 10 minutes.

This

treatment abolished subsequent labeling according to the above procedure (data not
shown).

Further, analysis of platelet washes in the absence of labeling revealed

endogenous biotinylation of several proteins at >150 kDa, however no interferences in
the size range of PDI (data not shown).

4.3.13 Removal and replacement o f platelet surface PDI
Platelet surface PDI was removed from 108 platelets by treatment with
HEPES:ACD containing 5% isopropanol (IP) for one minute with gentle vortexing.
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Platelets were then centrifuged for 5 minutes at 500 g and the supernatant removed after
which platelets were washed once and resuspended in HEPES:ACD alone for
aggregation studies. PDI was replaced by the addition of either 1 |iM oxidized or reduced
PDI or an equimolar mixture of the two to the reaction mixture prior to addition of
thrombin and monitoring of OD.
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4.4

RESULTS

4.4.1

Effects of RL90 anti-PDI antibodies versus non-specific antibodies on
platelet disulfide reductase activity aggregation
Washed platelets were incubated with 5 pg/mL of RL90 anti-PDI antibodies (in

ascites fluid) or an equivalent amount of non-specific, reagent grade IgG at 37°C for 10
minutes.

In assessing the enzymatic source of platelet surface disulfide reductase

activity, 107 platelets per mL were suspended in HEPES buffer in individual wells of a
black fluorescent microplate. A final concentration of 150 nM dieosin-GSSG was added
to the wells with platelets in triplicate (in the absence of any exogenous reducing agent),
and the evolution of fluorescence monitored with intermittent shaking at 37°C using an
excitation / emission couple of 525 / 545 nm. Results representative of n = 3 experiments
show that probe reduction is substantially inhibited upon antibody-mediated blockade of
platelet surface PDI in comparison to treatment with non-specific antibodies.

For

aggregation studies 108 platelets/mL in individual wells of a 96-well microplate were
stimulated with 0.5U thrombin in the presence of immunoglobulin and the optical density
read in a UV/VIS microplate reader at 630 nm at 37°C with shaking. Readings were
performed in triplicate with results shown representative of n = 3 experiments and show
that antibody-mediated blockade of PDI results in marked inhibition of both the initial
rates and extent of aggregation.
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Figure 4.1
Effects of RL90 anti-PDI antibodies versus non-specific antibodies on
platelet disulfide reductase activity and thrombin-stimulated aggregation
Fluorescence signal generated by platelet-mediated reduction of dieosin-GSSG was
monitored in triplicate wells of a microplate following a brief incubation of platelets with
anti-PDI antibodies (•) or an equivalent concentration of non-specific IgG (o)(left). The
marked inhibition of disulfide reductase activity by anti-PDI mediated blockade suggests
a central role for PDI in reducing disulfides at the platelets cell surface. As expected,
anti-PDI antibodies also caused a significant decline in both the initial rates and overall
extent of thrombin-stimulated aggregation (0) in comparison to non-specific antibodies
(♦). Controls run without thrombin stimulation (T ) confirm that the loss in OD is due to
agonist-induced aggregation of platelet suspensions (right).
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4.4.2

Platelets from diabetic subjects exhibit enhanced ROS production and
aggregation but diminished disulfide reductase and denitrosation activity
Platelet NAD(P)H oxidase-derived ROS were measured by fluorometric assay.

Platelet ROS generation was inhibited by apocynin [Manning RD Jr et al., 2003] and the
apocynin-inhibitable signal was subtracted from the total ROS signal, to obtain NAD(P)H
oxidase-derived ROS. Results shown on left side of Fig. 4.1 were collected from n = 10
samples for both normal and T2D samples and indicate that platelets from T2D patients
exhibited a 7-fold increase in ROS generation versus normal platelets (P<0.005).

In

contrast, results on the right show that psPDI on platelets derived from n=10 T2D
patients released on average ~30% of the *NO release catalyzed by platelets derived from
n=10 normal patients (P<0.002).

As necessary controls, platelets injected into buffer

alone or injection of buffer into a solution of 100 pM GSNO resulted in no significant
generation of signal, confirming that in all cases we were observing platelet-mediated
liberation of »NO.

Previously, GSNO denitrosation by platelets was shown to be

inhibited to >90% by anti-PDI antibodies and by the vicinal thiol blocker phenylarsine
oxide (PAO) [Root et al., 2005]
Aggregation profiles were also compared for n = 12 samples of normalized counts
of platelets from both normal and diabetic subjects in Fig. 4.2 (left) and show a 35±8.2%
(P<0.05) increase in initial rates of thrombin-induced aggregation of diabetic platelets
confirming expectations.

In contrast, comparison of the disulfide reductase activity for

the same samples reveals a 42±9.3% decrease in psPDI-mediated activity in platelets
derived from diabetic samples (P<0.01) as shown in Fig. 4.2 (right). In all cases error
bars were calculated as the standard error of the mean and statistical analysis was
performed using a paired t-test.
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Figure 4.2
Comparison of platelet ROS and psPDI-mediated denitrosation
activity of human normal versus diabetic platelets

NAD(P)H oxidase activity was measured using oxidation of the fluorophore, 10-acetyl3,7-dihydroxyphenoxazine-HRP system as a reporter of ROS in the presence and absence
of apocynin.

NAD(P)H oxidase activity is shown on the left as the difference in

fluorescence generated in the presence and absence of apocynin for n = 10 normal and n
= 10 T2D platelet samples (P< 0.005 versus normal). In contrast, platelet PDI-mediated
denitrosation activity in the presence of 50 |jM Mn(III)TmPyP was measured
amperometrically as the amount of *NO evolved per 109 platelets for both n = 10 normal
and n = 10 T2D samples (P< 0.002 versus normal).
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Figure 4.3
Comparison of the initial rates of aggregation and psPDI-mediated
disulfide reductase activity in human normal vs diabetic platelets

Platelets were isolated from whole blood of diabetic and non-diabetic patients as
indicated then suspended in HEPES buffer (pH 7.2). Triplicate platelet samples in
microplate wells at a final concentration of 108/mL were stimulated with 0.5
thrombin/mL and aggregation monitored as the loss in OD at 630nm. Plots shown are
average initial rates of aggregation measured for n = 12 diabetic and non-diabetic
platelets with error bars representing the standard deviation of the mean (P<0.05) (left).
Alternately, triplicate samples were suspended in HEPES buffer (pH 7.2) containing 150
nM dieosin GSSG in fluorescence microplate wells at a final concentration of 107
platelets/mL.

The increase in fluorescence, indicative of intrinsic platelet disulfide

reductase activity, was monitored using an excitation / emission couple of 525 / 545 nm
in a fluorescence microplate reader. Plots shown are average initial rates of disulfide
reduction measured for n = 12 diabetic and non-diabetic platelets with error bars
representing the standard deviation of the mean (P<0.01) (right).
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4.4.3

Platelet psPDI-mediated disulfide reductase activity is inhibited by
decreasing GSH/GSSG and by increasing H 2O 2
Platelet disulfide reductase can be inhibited by the addition of anti-PDI antibodies

(Figure 4.1).

Although PDI is known to be susceptible to alterations in redox

environment we sought to confirm this on the platelet cell surface. Treatment of platelets
with either decreasing GSH/GSSG or with increasing H 2O2 resulted in a dose-dependent
inhibition of disulfide reductase activity measured by the reduction of dieosin-GSSG
probe, likely due to oxidation of psPDI active-site thiols. In our studies, it is assumed that
in light of the relatively low extracellular concentrations of GSH and GSSG (<200 pM
total) and the brief incubation period (<5 min) that its effect on the intracellular
GSH/GSSG ratio would be minimal. Importantly, treatment of 107 platelets / mL with
equimolar GSH and GSSG (100 pM each) resulted in -80% inhibition of platelet
disulfide reductase activity (Fig 4.4A). This result is of physiological significance given
that the thiol:disulfide ratio of low molecular weight plasma thiols is thought to vary
between -13:1 and -1:1 depending on prevailing conditions [Go et al., 2005].
Further, platelet disulfide reductase activity could be inhibited by increasing
[H2O2] to a maximum of -75% at 100 pM H 2O 2 (Fig 4.4B) suggesting that inhibition
occurs through oxidation of the active site thiols of psPDI.
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Figure 4.4
In Vitro effects of varying redox conditions on psPDI-mediated
disulfide reductase activity

Washed platelets were suspended at a density of 107/mL in HEPES buffer (pH 7.2) in the
presence of 150 nM dieosin-GSSG and the indicated concentration (or ratio) of reduced
and oxidized glutathione (A) or hydrogen peroxide (B).

Intrinsic platelet reductase

activity was measured as the increase in fluorescence that occurs upon reduction of the
probe in the presence of oxidant. Shown in both plots are values representing the initial
rates of fluorescence increase for triplicate samples representing the results of n = 3
experiments. Error bars were calculated as the standard deviation of the mean. As a
control, the fluorescence of reduced probe was monitored in the presence of the highest
[oxidant] used and showed no evidence of quenching that would indicate oxidation of the
probe back to the disulfide form.
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4.4.4

Biphasic response of thrombin-stimulated platelet aggregation under
conditions of decreasing GSH/GSSG correlates to oxidation of psPDI
In order to determine how the observed inhibition of platelet disulfide reductase

activity under conditions of decreasing GSH/GSSG correlates with its influence on rates
of platelet aggregation, washed platelet were suspended in identical ratios of glutathione
and

its

oxidized

disulfide

for

measurement

of thrombin-induced

aggregation.

Interestingly, results shown in Fig. 4.4A demonstrate that initial rates of aggregation are
maximal at both the highest and lowest ratios of GSH/GSSG. These results are in accord
with reported observations in which aggregation could be potentiated by both the addition
of low concentrations of either GSH or GSSG [Essex et al., 2003].

However, this

provides an alternate explanation for observations focused instead on the redox status of
psPDI. Labeling of PDI thiols on the surface of intact platelets using a biotinylatedmaleimide reagent (shown in Fig. 4.4B) confirms the oxidation of PDI on the platelet
surface as suggested by the inhibition of disulfide reductase activity.

This further

suggests that the loss of psPDI-mediated disulfide reductase and denitrosation activity
exhibited by platelets obtained from diabetic patients versus their normal counterparts
could also be caused by ROS-dependent changes in the plasma thiol-disulfide balance.
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Figure 4.5 In vitro effects of varying redox conditions on psPDI-mediated
aggregation events and redox status of psPDI

(A)

Washed platelets were suspended in the wells of a microplate containing the

indicated GSH/GSSG at a constant [GSH] of 100 pM in triplicate and stimulated with 0.5
U/mL thrombin. Plots shown are representative of n=5 experiments, calculated as the
average initial rates of aggregation with error bars calculated as the standard error of the
mean of three replicates. (B) Platelets were labeled with PECL-biotin maleimide at pH
6.5 for one hour at 37°C under the indicated GSH/GSSG. Platelets were then washed
once with 100 pL of 5% IP as indicated and PDI immunoprecipitated from the
supernatant using RL90 anti-PDI antibodies covalently bound to Protein G-Sepharose.
Liberated PDI was run on an SDS-PAGE and transferred to a solid support for probing
with both strepavadin-HRP and anti-PDI antibodies.
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4.4.5

Bacitracin protects platelets from the ability o f H^C^-treatment to potentiate
thrombin-induced aggregation
Washed platelets exposed to increasing concentrations of H 2O 2 exhibit a

progressive increase in the initial rates of thrombin-induced aggregation to -2-fold
increase at 25 pM H 2O 2 as observed in representative aggregation profiles shown in Fig.
4.5A.

In order to implicate PDI in events contributing to the potentiated rates of

aggregation, platelets were subsequently treated with 25 pM H 2O 2 in the presence or
absence of the thiol-isomerase-specific inhibitor - bacitracin at a concentration known to
inhibit platelet aggregation [Lahav et al., 2002].

Although the mechanism by which

bacitracin is capable of inhibiting thiol-isomerases is unknown, it is thought to inhibit
multiple isomerases on the platelet cell surface [Robinson et al., 2006]. Nevertheless, the
rationale for this experiment predicted that if bacitracin is capable of inhibiting the thiolisomerase activity of psPDI, that it could also protect active site thiols from oxidation by
blocking access to the active site. By washing and diluting platelets following oxidant
treatment in the presence or absence of bacitracin, excess bacitracin could be diluted to a
level at which it would no longer inhibit platelet activity. This proved to be the case in
that platelets treated with peroxide exhibited ~2-fold increase in initial rates of
aggregation versus untreated controls. In the presence of bacitracin and 25 pM H 2O 2,
rates of aggregation were restored to rates similar to untreated controls as shown in Fig.
4.5B. Importantly, this was not simply due to inhibition of potentiated rates given that
platelets treated with bacitracin alone showed no evidence of inhibition compared to
untreated controls, suggesting that the platelet wash step and dilution was effective in
removing residual inhibitor.
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Figure 4.6
Bacitracin protects platelets from the ability of H 2O 2 treatment to
potentiate thrombin-induced aggregation

Thrombin-induced platelet aggregation can be potentiated by treatment with H 2O 2.
Representative aggregation traces are for experiments ran in triplicate are shown in (A)
for platelets treated with 0 (0), 1 (A), 10 (+) and 25 [iM (□) H 2O2 and stimulated by 0.5
U/mL thrombin versus unstimulated control platelets (o). Alternately, platelets suspended
in HEPES:ACD buffer were incubated with the 25 (iM H 2O 2 for 60 minutes in the
presence or absence of 2 mM purified bacitracin. The platelet suspension was spun at
500 g for 5 minutes, the supernatant removed and platelets washed IX with 20 volumes
of HEPES :ACD buffer. Resuspended platelets were diluted 10X in HEPES buffer (pH
7.2) to a final concentration of 108/mL and stimulated with 0.5 U thrombin/mL. Change
in OD was monitored at 630 nm for platelet samples run in triplicate for n = 3
experiments and shown as a representative plot of average initial rates of aggregation in
(B). Error bars represent standard deviation of the mean for initial rates.
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4.4.6

Bacitracin protects platelets from H202-mediated inhibition of psPDImediated denitrosation of S-nitrosoglutathione
We have shown previously that treatment of platelets with superoxide delivered

from xanthine/xanthine oxidase effectively inhibited the ability of psPDI to liberate «NO
from S-nitrosoglutathione [Miersch et al., 2007].

Using human platelets we have

similarly investigated the ability of H 2O 2 to inhibit metabolism of S-nitrosoglutathione.
Incubation of platelets with increasing [H2O2] resulted in the progressive loss of GSNO
consumption measured by the decomposition of residual GSNO by CuCl2 in the presence
of the NOx-sensitive fluorophore - 4,5-diaminonaphthalene (DAF-2).

Following

treatment of platelets with the indicated [H2O 2], platelets were washed once and
resuspended in 10 fiM GSNO for 15 minutes.

Platelets were then removed by

centrifugation and aliquots of supernatant containing GSNO reacted in the presence 25
|iM Cu2+ and 10 |iM DAF and residual GSNO and the evolved fluorescence compared to
aliquots of an identical [GNSO] in the absence of platelets [Cook et al., 1996], Results
shown in Fig. 4.6 demonstrate that as [H2O2] increases, platelet consumption of GSNO
declines to near control levels at 100 pM H 2O 2. In order to further implicate psPDI in
this activity, platelets were again treated with oxidant in the presence of 2 mM bacitracin.
In similar fashion to results discussed in section 4.4.9, bacitracin protected denitrosation
activity from the inhibitory effects of H 2O2 bolstering evidence implicating psPDI as
primarily responsible for platelet-mediated metabolism of GSNO.

Importantly,

bacitracin treatment in the absence of H 2O 2 did not affect platelet denitrosation activity
confirming the effective removal of the inhibitor.
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Figure 4.7
Bacitracin protects platelets from the ability o f H 2O 2 treatment to
inhibit psPDI-mediated denitrosation of S-nitrosoglutathione

Platelets suspended in HEPES:ACD buffer were incubated with the indicated [H202] for
60 minutes in the presence or absence of 2 mM purified bacitracin.

The platelet

suspension was spun at 500 g for 5 minutes, the supernatant removed and platelets
washed IX with 20 volumes of HEPES :ACD buffer.

Platelets treated with peroxide

and/or bacitracin as above, were resuspended in 10 |lM GSNO and incubated for 15
minutes for comparison to GSNO alone (blank without platelets).

To measure

consumption of GSNO, platelets were removed by centrifugation at 500 g for 5 minutes.
20 jjL aliquots of supernatant GSNO were decomposed by the addition of 25 mM Cu2+ in
the presence of 10 pM DAF and evolved fluorescence measured in a microplate using
525 / 545 excitation / emission. Samples were run in triplicate and results shown are
representative of three separate experiments.
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4.4.7

Modulation of psPDI redox status by removal and replacement of cell
surface enzyme - effects on aggregation
Studies have suggested that surface-bound PDI may interact with the cell exterior

through electrostatic interactions [Terada et al., 1995], Alternately, it has been shown
within our lab that brief, gentle washing of platelets with concentrations of isopropanol
between 1 and 5% in HEPES:ACD result in an efficient, dose-dependent liberation of
exofacial-bound platelet PDI by western blot (data not shown). We have exploited this
observation to investigate specifically the role of PDI redox status in platelet aggregation.
Platelets were washed as indicated to effect removal of psPDI.

Following

isopropanol treatment platelets were separated by centrifugation, washed once with 20
volumes of HEPES :ACD and resuspended in wells of a microplate in quadruplicate. PDI
(with the indicated redox status) was added to a total final concentration of 1 pM enzyme
and platelets stimulated with 0.5 U/mL thrombin. Aggregation profiles representative of
those obtained from 3 separate experiments are shown in Fig. 4.7A. Collected results
with in Fig. 4.7B illustrate -60% inhibition of aggregation which results with the loss of
psPDI.

It further illustrates the restoration of the initial rates of aggregation by

replacement of liberated PDI with exogenous PDI, irregardless of the redox status of the
enzyme, or even whether free thiols were present. This suggests that, although PDI
contributes positively to platelet aggregation, it does so independently of its thiol
isomerase activity. These results are not in conflict with aggregation experiments in
which rates of aggregation could be potentiated by either reducing or oxidizing ratios of
physiologica [GSH]/[GSSG], Undoubtedly, other platelet-surface species are susceptible
to redox modification and could be responsible for observed changes in aggregation rates.
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Figure 4.8
Removal and replacement of psPDI with PDI o f defined redox status effect on initial rates of aggregation

Platelets were washed with 5% isopropanol (IP) in HEPES:ACD pH 6.5 for 1 minute
(▼) with gentle vortexing to assist removal of psPDI and initial rates of aggregation
compared to platelets washed with buffer alone (•) and compared to unstimulated
controls (o). Traces representative of n = 3 experiments are shown in (A). IP-washed
platelets consistently exhibit a -5 0 - 70% decrease in rates of aggregation versus buffer
washed platelets (p<0.05).

Initial rates of aggregation of IP-washed platelets can be

restored by the addition of 1 |lM of either fully oxidized or reduced recombinant PDI as
well as by equimolar mixtures of the two and with PDI in which the active site is
irreversibly blocked by alkylation.

Collected data showing the average initial rates of

aggregation for quadruplicate samples are shown in (B) with the error bars calculated as
the standard error of the mean, representative of n = 3 experiments.
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4.5

Discussion
In this study we found that ROS production from platelets of human T2D subjects

was ~5-fold greater than their normal counterparts (Fig. 4.2). Measurement of plateletsurface PDI-dependent activities that require reduced active site thiols (namely
denitrosation and disulfide reduction) revealed that both activities were 60%-70% lower
in T2D platelets than controls indicating that psPDI was more oxidized in T2D (Fig. 4.2,
4.3). Similar to our earlier animal studies [Miersch et al., 2007], platelets from T2D
subjects aggregated with average initial rates that were ~1.4-fold faster than controls (Fig.
4.3). Although these observations strongly suggest oxidation of psPDI active site thiols,
the question of whether psPDI oxidation state plays any significant role in potentiation of
aggregation rates remained.
We attempted to test this by exposing control platelets to varying ratios of
GSH/GSSG or to H 2O 2; a product of 0 2’ dismutation in the cellular milieu.

As one

would expect, psPDI disulfide reductase and denitrosation activities were inhibited by
increasing oxidative potential as shown in Fig. 4.4A/B and 4.7.
It is commonly accepted that aggregation is influenced by dynamic shuffling of
thiol and disulfide bonds at the platelet surface [Essex et al., 2004b, Robinson et al.,
2006] and that psPDI plays a critical role in these events [Lahav et al., 2002]. Although
it is known that PDI exhibits redox-dependence [Wilkinson et al., 2004] and that redox
conditions within the vasculature are known to fluctuate [Go et al., 2005], there have
been no reports that systematically evaluate the role of psPDI-redox status under varying
conditions. These studies are likely hampered by the use of conventional aggregometers
in which the number of samples that can be simultaneously measured is limited.
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Thus, we assessed the initial rates of platelet aggregation in the presence of either
100 pM GSH or GSSG and varying ratios of the two similar to that found under normal
and pathological conditions. Aggregation of platelet samples was monitored by optical
density at 630 nm in a microplate reader. This method has been validated in comparison
to aggregation by convential aggregometers [Krause et a l, 2001] and has the advantage
of being able to run a number of replicates simultaneously. Using this methodology we
observed, as seen in Fig. 4.5A, that under varying ratios of GSH/GSSG that initial rates
of aggregation were maximal under both the most reducing and most oxidizing
conditions used and a minimum at ~2:1 ratio of GSH/GSSG. Importantly, these results
are in general accord with prior observations that platelet aggregation is potentiated by
the addition of either GSH [Essex et al., 2003] or GSSG [Essex et al., 2004a] suggesting,
in an alternate but not exclusive interpretation, that aggregation at either extreme is
potentiated in a PDI-dependent fashion. Further, we confirm under these conditions that
the redox status of the PDI active site is altered and that enzyme thiols are progressively
lost with increasing oxidative potential as seen in Fig. 4.5B.
In order to further demonstrate that the observed changes in psPDI-dependent
activities in diabetics were the result of the action of H 2O2 on PDI thiols, we performed in
vitro experiments in the presence and absence of purified PDI inhibitor - bacitracin
[Robinson et al., 2006, Mandel et al., 1993]. When platelets were exposed to H 2O 2 in
the presence of purified bacitracin, no substantial effect on psPDI activities or on
aggregation profiles was observed (Fig. 4.6B, 4.7), an indication that bacitracin blocked
access to the PDI active site thiols. In the absence of bacitracin, treatment of platelets
with 25 juM H 2O 2, inhibited PDI denitrosation activity by -35% and potentiated initial
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rates of aggregation by ~2-fold (Fig. 4.6B, 4.7).

Importantly, platelets treated with

bacitracin alone showed no evidence of inhibition of either aggregation or denitrosation,
suggesting that wash and dilution steps were effective in removing inhibitor.
Lastly, we attempted to directly assess the role of PDI redox status by
isopropanol-assisted removal and replacement of psPDI. Western blots of platelets have
shown that PDI is liberated from the cell-surface in an isopropanol-dependent manner
with 1-5% alcohol versus buffer alone (data not shown). Platelets washed in this manner
exhibit substantially inhibited initial rates of aggregation presumably due to the loss of
psPDI that can be restored by the addition of purified enzyme to the reaction mixture
(Fig. 4.8). Although it is likely that platelets washed with isopropanol also release other
proteins, the restoration of aggregation by exogenous PDI suggests that PDI is perhaps
one of the most critical components lost from the cell surface.
Surprisingly though, our experiments demonstrate that aggregation is restored, not
only as expected with reduced and oxidized PDI, but also in the presence of either a 1:1
mixture of reduced:oxidized enzyme (attempting to mimic the Vi oxidized state) or
enzyme in which all thiols had been covalently blocked by iodoacetamide.

These

studies indicate our hypothesis, that elevated NOX activity in T2D oxidizes psPDI active
site thiols, thereby giving rise to elevated rates of aggregation, may be, only in part,
correct.
PDI has two active sites in its a and a’ domains which face each other in the
recently solved crystal structure [Tian et al., 2006]. These two active sites can be in one
of 3 redox forms reduced, Vi-reduced and oxidized as seen in Scheme I:
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PDI is thought to be involved in mixed disulfide formation between fibrinogen (or
collagen) and their specific free thiol-containing integrins [Lahav et al., 2003, Essex et
al., 2003] as shown in Scheme I:

Platelet-integrin S-H + fibrinogen S-S
—>platelet-integrin-S-S-fibrinogen

(aggregation)

Scheme I

A reduced and V2 reduced PDI active site may catalyze both the reduction of the
fibrinogen disulfide, as well as the integrin-fibrinogen mixed disulfide and the formation
of integrin-fibrinogen mixed disulfide.

However, we suggest that a quiescent, fully

oxidized PDI can essentially act as a chaperone facilitating the formation of the integrinfibrinogen mixed disulfide by simply binding the fibrinogen in the right conformation for
nucleophilic attack of the integrin-SH thus permitting the facile one step formation of the
integrin-fibrinogen mixed disulfide (Scheme II).
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Scheme II
In light of these observations, oxidation of psPDI active site thiols certainly
impedes the reduction of S-nitrosothiols and disulfides however; the ability of PDI to
restore platelet aggregation, independent of its oxidoreductase activity, suggests that its
chaperone activity may instead be responsible for its role in assisting in integrin-ligand
disulfide bond formation. Indeed, investigations have shown 1) that the allb(13 integrin
bears intrinsic thiol-isomerase [O’Neill, et al., 2000] and 2) that the ability of PDI to
potentiate tissue factor coagulant function is also independent of its oxidoreductase
activity [Versteeg et al., 2007].
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5.1

Conclusion
Understanding platelet function and dynamics under the spectrum of vascular

conditions to which they are exposed bears significant importance in mitigating
thrombotic

disorders

which

pre-dispose

individuals

to

risks

associated

with

cardiovascular dysfunction.
This thesis has examined the role of protein disulfide isomerase at the exofacial
surface of the platelet plasma membrane, as well as features of vascular relevance which
influence its activity in animal models bearing characteristics of a pre-diabetic state,
human normal and diabetic subjects and in vitro. The findings herein, show that the
thiol-disulfide status of platelet-surface PDI is susceptible to changes in vascular redox
and contributes to a pro-aggregatory state, in which platelets lose their ability to
metabolize S-nitrosothiols required for generation of platelet anti-aggregant cGMP.
Importantly, lost denitrosative activity and platelet hyperaggregability could be restored
in animal models by treatment with statins which are thought to inhibit the excessive
generation of NAD(P)H oxidase-derived ROS from various vascular sources, including
platelets and endothelial cells, via a pleiotropic mechanism. Interestingly, despite several
lines of evidence which implicate PDI both as critical in platelet-surface, thiol-disulfide
dynamics and as a target of oxidant species, we have shown that, although PDI
contributes positively to platelet aggregation, that it does so independently of its
oxidoreductase activity.
This thesis further examined the dynamics of nitric oxide to gain insight into
factors which influence its signaling properties. As a unique bioactive radical, signals
transduced by nitric oxide are governed by localized generation, diffusion and reactivity
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rather than interaction with cell-surface receptors. We have questioned the assumption
that nitric oxide diffuses freely through biological membranes, irregardless of structure or
composition, thus bearing no significant impact on its subsequent signaling properties.
Indeed we have found that cholesterol incorporated into model bilayers
substantially alters the diffusion of nitric oxide. In cellular systems, it was further found
that cholesterol alters the equilibrium of *NO-signaling, measured either by its interaction
with guanylate cyclase or through subsequent nitrosative reactions measured by DAF-2T
fluorescence.

Thus it appears that the ordering effect of cholesterol in biological

membranes may fine-tune the spatial reactivity of nitric oxide and subsequent signaling
targets such that the reactive equilibrium of *NO is shifted from intracellular nitrosylation
of haem targets such as guanylate cyclase to the nitrosation of extracellular nucleophiles.
This represents a novel observation and paradigm that may have relevance to
pathological conditions in which cholesterol metabolism is disturbed.

W hether these

observations are directly due to changes in diffusion, altered reactivity, physical
interactions or a combination therein remains open to debate.
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